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ABSTRACT  
   
Whole genome sequencing (WGS) and whole exome sequencing (WES) are two 
comprehensive genomic tests which use next-generation sequencing technology to 
sequence most of the 3.2 billion base pairs in a human genome (WGS) or many of the 
estimated 22,000 protein-coding genes in the genome (WES). The promises offered from 
WGS/WES are: to identify suspected yet unidentified genetic diseases, to characterize the 
genomic mutations in a tumor to identify targeted therapeutic agents and, to predict future 
diseases with the hope of promoting disease prevention strategies and/or offering early 
treatment. Promises notwithstanding, sequencing a human genome presents several 
interrelated challenges: how to adequately analyze, interpret, store, reanalyze and apply 
an unprecedented amount of genomic data (with uncertain clinical utility) to patient care? 
In addition, genomic data has the potential to become integral for improving the medical 
care of an individual and their family, years after a genome is sequenced. Current 
informed consent protocols do not adequately address the unique challenges and 
complexities inherent to the process of WGS/WES.  
This dissertation constructs a novel informed consent process for individuals 
considering WGS/WES, capable of fulfilling both legal and ethical requirements of 
medical consent while addressing the intricacies of WGS/WES, ultimately resulting in a 
more effective consenting experience. To better understand components of an effective 
consenting experience, the first part of this dissertation traces the historical origin of the 
informed consent process to identify the motivations, rationales and institutional 
commitments that sustain our current consenting protocols for genetic testing. After 
understanding the underlying commitments that shape our current informed consent 
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protocols, I discuss the effectiveness of the informed consent process from an ethical and 
legal standpoint. I illustrate how WGS/WES introduces new complexities to the informed 
consent process and assess whether informed consent protocols proposed for WGS/WES 
address these complexities. The last section of this dissertation describes a novel 
informed consent process for WGS/WES, constructed from the original ethical intent of 
informed consent, analysis of existing informed consent protocols, and my own 
observations as a genetic counselor for what constitutes an effective consenting 
experience. 
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CHAPTER 1 
INTRODUCTION 
Bill Miller is a 28-year-old science reporter working on an article about the implications 
of whole genome/exome sequencing on the Affordable Care Act. He works at The 
Washington Post, and has been with the newspaper for about a year. He owes over 
$75,000 in student debt incurred while earning his master’s degree in journalism from 
Northwestern University. He recently married his college girlfriend, Melinda. Melinda is 
25 years old and works part-time as a freelance photographer. She brings $25,000 in 
student debt to the marriage. The couple has been married for eight months. They are 
considering starting a family in a little over a year so that they can take some time to pay 
off their student debts. 
 Through his research on whole genome/exome sequencing, Bill becomes 
intrigued with the technology and the implications of this technology on personal health 
care. His fascination reaches the point where he decides that he must learn about his 
genetic make-up and he persuades his editor to extend the deadline for his article to allow 
him to write about his own experience undergoing whole genome sequencing as part of 
his article. Bill even persuades Melinda to undergo sequencing as well, not as part of his 
article for the newspaper, but simply because he knows that she is concerned about her 
own health risks based on her family history, and he believes the sequencing would 
provide her with information and possible reassurance for future health risks. In addition, 
he argues they would learn information about any possible risks for genetic conditions 
that might affect their future offspring.  
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 Genome sequencing is a new technology designed to analyze most of a human 
genome in order to identify genetic alterations. A human genome is the complete set of 
DNA inside our cells. DNA is made up of four bases: adenine (A), thymine (T), guanine 
(G), and cytosine (C) (Strachan & Read, 1999). These bases are paired together on the 
DNA molecule. The process of sequencing an entire genome involves scanning and 
identifying the exact order of the approximate 3.2 billion base pairs in a human genome 
(Nussbaum, McInnes, & Willard, 2001). Whole genome sequencing (WGS) sequences 
the entire genome (all the bases) and whole exome sequencing (WES) sequences the 
genes that express proteins (known as exons). A gene is a section of DNA bases. A 
human genome contains approximately 22,000 genes (E. Green, 2013).  
 WGS and WES were introduced into clinical medicine around the year 2010 
(Lifton, 2010) (Ashley et al., 2010) and sequencing was initially used to help medical 
oncologists identify more targeted chemotherapy agents for patients with advanced 
cancers that no longer respond to traditional chemotherapy drugs (Diamandis, White, & 
Yousef, 2010). The process of WGS and WES in oncology care involves sequencing a 
tumor genome and comparing the DNA sequence of the tumor to the corresponding DNA 
sequence of the individual’s hereditary genome, to better understand the genetic changes 
that cause a cancer to continue growing despite multiple treatments (Plon, 2011). Whole 
genome sequencing is also used in clinical medicine to assist physicians with obtaining a 
better understanding of a complex disease which is likely hereditary, but for which 
single-gene testing has been unable to identify the underlying genetic mutation (Lupski et 
al., 2010). At this time, only a small percentage of healthy individuals seek out 
WGS/WES to learn about possible disease susceptibilities.   
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 After Melinda agrees to undergo genomic sequencing, Bill contacts a clinical 
laboratory to inquire about their whole-genome sequencing services. He finds a company 
that offers a preventative genome analysis for adults, designed to identify specific 
disorders commonly screened for in newborn and carrier testing as well as a 
predisposition test evaluating risk factors for a number of known and well described 
hereditary conditions. The company agrees to sequence the couple’s DNA and produce a 
report for each of them. The fee for the sequencing one individual is $9,500, but the cost 
was reduced for Bill and Melinda because the company knew they would gain some 
publicity from the story. The Washington Post paid for the balance of the total fee. The 
genomic testing protocol requires that a licensed physician discuss the consequences of 
genomic testing with interested individuals and order a sample collection kit so the blood 
sample can be collected at a physician’s office. A physician signature is required on the 
test requisition form and results are released only to the ordering physician.  
 Bill contacts his brother-in-law (his sister’s husband) who is a plastic surgeon, 
and asks if he would order the test for both him and Melinda. His brother-in-law agrees 
and arranges to have the sample collection kits sent to his office. Bill and Melinda go to 
the office together to have their blood drawn and sign a three-page consent form. Bill 
carefully reads the consent form but feels that the form did not contain any new 
information. Because of the research he has done for his article about the implications of 
undergoing WGS, he believes he is prepared to learn about his genomic make-up. 
Melinda accompanied Bill somewhat reluctantly to the office and signs the form without 
reading it completely because she was late meeting a potential client. 
  4 
 Bill and Melinda’s results were delayed by two months (results are typically 
available in 90 days) due to issues with processing the samples in the laboratory, but after 
about five months, Bill receives a phone call from his brother-in-law’s office that the 
results are back. The receptionist in his brother-in-law’s office emails Bill a copy of both 
his and Melinda’s results. The couple decides to look at the information together on a 
Sunday afternoon when they are both home and know they would not be interrupted.  
 The process of sequencing a human genome takes more than three months on 
average to complete because, instead of searching for only one genetic alteration in one 
gene (known as single gene testing), WGS and WES search for thousands of possible 
alterations amongst the 3.2 billion base pairs in a genome. Researchers who are working 
to understand the implications of the process predict individuals will carry between 
20,000-40,000 possible structural variants in one genome (Chen et al., 2012) (The 1000 
Genomes Project Consortium, 2010). What is important to understand about these 
20,000-40,000 variants is that many of them are not always related to a disease, but 
instead may be part of the normal variations found between all people: Other variants are 
themselves not enough to cause a particular disease, but are only one of multiple variants 
necessary for the disease to occur. In addition, some variants require environmental 
insults to trigger the cascade of events that lead to the beginning of a disease process 
(Mueller & Young, 2001) (Cirulli & Goldstein, 2010). At this time, the implications for 
possible disease risks are not well understood for many variants identified through 
genome sequencing, but researchers believe that someday many, if not all of these 
variants will be better understood (E. Green & Guyer, 2011).  
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 In the meantime, the dilemma for laboratories performing genomic sequencing is 
whether to report uncertain variants uncovered in sequencing a genome, and if so, which 
variants should be reported: those with a possible association for increased risks for a 
particular disease or only the variants with a known risk for a particular disease? The 
variants, which have been confirmed to have a known link to a described hereditary 
disease, I will refer to throughout the remainder of this document as deleterious 
mutations. Because many variants, with an unknown disease association, may be 
associated with a disease at some point in the future, how will an individual who was 
found to carry the variant before it was fully understood, be re-contacted with the updated 
information and if they are re-contacted, who is responsible for re-contacting the 
individual? The other question to ask: should the individual be re-contacted at all?  
 Beyond the issue of identifying thousands of variants with unknown associated 
disease risk factors is the fact that there are currently over 4,000 described hereditary 
conditions (McKusick, 2013). When an individual elects to undergo WGS or WES, it is 
not known how many variants or deleterious mutations and corresponding genetic 
conditions each person will be identified with at the conclusion of the sequencing 
process. Several major academic centers have reported their experiences with sequencing 
over several hundred individuals and predict that on average, most individuals will carry 
at least one hundred deleterious mutations (Ormond, Wheeler, Hudgins, Klein, & Butte, 
2010). Without a specific clinical indication of a possible hereditary condition based on 
medical history or family history suggestive of a hereditary condition, it is unknown 
which of the 4,000 hereditary disorders each individual undergoing sequencing will be 
diagnosed with at the completion of genome sequencing.  
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 Because Bill and Melinda submitted their samples as a couple, the laboratory 
created a report combining the first set of results. The first set of results is categorized as 
carrier testing and report mutations for any autosomal recessive conditions they might 
pass along to their offspring. The term autosomal recessive refers to the fact that an 
individual who is a carrier of the disease is typically not going to be affected with 
symptoms of the condition, but if their partner is a carrier of the same disease, their 
children have a 25% chance to be affected (Nussbaum et al., 2001). Melinda was found to 
be heterozygous (defined as carrying only one mutation) for three different genetic 
conditions: Tay-sachs disease, Gaucher’s disease and cystic fibrosis. Tay-sachs disease 
and Gaucher’s disease are both genetic conditions more commonly diagnosed in the 
Ashkenazi Jewish population (Mueller & Young, 2001). Melinda was raised Catholic and 
her family always believed that her ancestors were from France and England. Sharing the 
fact that her family might have Jewish heritage would be difficult for Melinda, given her 
family’s strong Catholic faith. Melinda is torn about whether she should reveal this 
information to her parents fearing the information will cause family tension.  
 Bill also tested positive for a mutation for cystic fibrosis. Because Melinda and 
Bill both carry one mutation for the same condition, they learn that with every future 
pregnancy, there is a 25% chance they will have a child born with cystic fibrosis. Carriers 
of a CF mutation are also predicted to have between a 2% to a 23% chance to develop 
symptoms of chronic pancreatitis. Pancreatitis is inflammation in the pancreas and 
symptoms of chronic pancreatitis include upper abdominal pain, indigestion, and weight 
loss (Behrman & Fowler, 2007).  
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 The next set of results was compiled separately from the carrier screening results 
and summarizes their individual genome sequencing findings. Melinda tested positive for 
a mutation for familial amyloidosis, a multi-system adult-onset, autosomal dominant 
disorder. The symptoms of amyloidosis differ according to the specific mutation 
identified in a family but typically include carpal tunnel syndrome, neuropathy, 
gastrointestinal issues (alternating bouts of constipation with diarrhea) and progressive 
heart failure (Sekijima, Yoshida, & Tokuda, 2012). The only viable treatment option for 
some patients with familial amyloidosis is a liver transplant, but not all forms of this 
genetic disease will respond to a liver transplant (Sekijima et al., 2012). Melinda’s father 
died young, at age 52. In the years before his death, he suffered a variety of health issues 
and complained of pain and numbness in his extremities, lost over 25 pounds and 
ultimately died from heart failure. While the cause of his symptoms were never 
determined, Melinda now suspects that her father died from amyloidosis as his symptoms 
match the description of this condition. She becomes concerned she is destined to suffer 
the same fate as her father.  
 Melinda’s genomic analysis also included pharmacogenomics results. 
Pharmacogenetic testing predicts individual variation in drug response based on specific 
genomic markers (Mills, Voora, Peyser, & Haga, 2013). Melinda’s pharmacogenomics 
analysis reveals she carries a variant in the genes that control the production of the 
CYP2D6 enzymes. CYP2D6 enzymes are responsible for metabolizing approximately 
25% of all medications, including many of the common antidepressant medications 
(Hicks et al., 2013). Melinda’s specific variant leads to an over production of enzyme 
resulting in a rapid breakdown of the medications metabolized by the CYP2D6 enzymes. 
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Therefore she is predicted to respond poorly to normal doses of medications metabolized 
by these enzymes. This information is very useful to Melinda because she has tried 
several different types of antidepressants over the last several years, none of which were 
effective in treating her depression.  
 Melinda has a strong family history of cardiovascular disease and was hoping to 
learn about her genetic risk factors for heart disease. The report from the laboratory stated 
her risk for cardiovascular disease was no greater than the general population risk. 
Melinda did not find this information very helpful because she was unclear what a 
person’s general population risk is and how this risk relates to her strong family history 
of heart disease. Melinda is uncertain whether the laboratory knew about her family 
history of heart disease and thought that perhaps without her family history information, 
her genetic test results would not be accurate. She feels frustrated that she did not have a 
better understanding of how the genomic test determined her disease risks. Specifically, 
she did not understand what type of health information genome sequencing could provide 
versus what type of information it could not provide? She began to question the accuracy 
of her results as well as the validity of the company.  
 Bill’s individual genome results report he is positive for variants known as SNPs 
(single nucleotide polymorphisms) that might increase his background risk for prostate 
cancer. Bill’s father and his maternal grandfather were diagnosed with prostate cancer 
later in life. The type of genetic variants Bill was found to carry were identified through 
genome wide association studies (GWAS). GWAS look at common variants associated 
with hundreds of diseases and traits. When a specific variant is found to occur 
repetitively in hundreds to thousands of individuals with the same disease, then it is more 
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likely to be associated with that disease. There is great skepticism amongst genetic 
researchers about the validity of the association of SNPs to common diseases, as most 
scientists believe that the SNPs are not enough by themselves to cause a disease, because 
environmental exposures also significantly contribute to the manifestation of a disease 
(Offit, 2008). Recent findings suggest that less commonly identified rare variants are 
more likely to be linked to common diseases providing conflicting information on the 
role SNPs play in complex disease processes (Cirulli & Goldstein, 2010). Because the 
findings from genome-wide-association studies are continuously being revalidated, the 
laboratory commented in their report that the information regarding Bill’s prostate cancer 
SNPs will be updated in the future and it is Bill’s responsibility to contact his physician 
to learn about any changes to the data available about the risk factors from carrying this 
variant.  
 Bill was hoping to learn whether he was at an increased risk for a hereditary 
neurological condition known as Huntington’s disease. He became worried about being 
affected with this condition while writing an article about the financial burden of 
incurable diseases for The Washington Post. His research for this article included 
spending several days with a woman who was taking care of her husband in the late 
stages of Huntington’s disease. Bill learned first hand what a devastating disease this 
was, with profound psychological, neurological and physical symptoms. Even more 
shocking to him was the fact that the average age of onset of symptoms was between 35 
and 44 years, with an average lifespan of only fifteen years once the symptoms of the 
disease begin (Warby, Graham, & Hayden, 2010). Bill also witnessed the tremendous 
financial and emotional toll of this disease on the entire family, and learned about the 
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tragic fate of this gentleman’s two children, who were also found to carry the same 
genetic mutation for Huntington’s disease. Both children were predicted to experience the 
same symptoms as their father. Bill’s genomic report did not include information about 
Huntington’s disease, yet he was concerned enough about his potential risk for this 
disease that he planned to contact the company and ask if they were certain he does not 
carry the mutation for Huntington’s disease.  
 While WGS and WES are capable of sequencing many of the known important 
genes in our genomes and capable of identifying many of the known mutations for a large 
majority of hereditary diseases currently defined, neither test is capable of identifying all 
the known mutations and therefore identifying all the genetic diseases currently described 
(Ormond et al., 2010). Most laboratories offering WGS and WES report they are able to 
sequence approximately 97% of the genes with known functions (exons) in our genome. 
The ability to find a variant and/or mutation in the exons is estimated to be 90% (Bick, 
Chao, Cho, & Cohen, 2013). In other words, not all of the exons in a genome can be 
sequenced and approximately 10% of the time, the sequencing technology will not be 
able to identify a specific variant and/or mutation present within the exons. There are 
areas of the genome where WGS and WES cannot identify known mutations for well 
described hereditary conditions: there are also many unknown hereditary conditions for 
which WGS and WES will not be able to identify the causative mutation, since the 
disorder and corresponding genetic mutation for the disorder have not been well defined 
at this point (Feero, Guttmacher, & Collins, 2008).   
 The same week the couple received their results Melinda learned that she was 12 
weeks pregnant. Because Melinda is a freelance photographer she does not carry any 
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health insurance. After the couple got married, Bill had intended to add Melinda to his 
insurance policy at work, but never got around to it. Bill has no life insurance policy yet. 
Given his young age and the fact he and Melinda had no children, he figured he had more 
time to look into his options for life insurance policies. Bill is now wondering if their 
genome results will make it difficult for Melinda to obtain health insurance and whether 
his genomic test results must be reported on a life insurance application and if so, how 
this will affect his premiums? Melinda and Bill need to quickly figure out how to obtain 
health insurance for Melinda so she can establish care with an obstetrician.  
 After reviewing their results together, Melinda becomes very emotional and is 
angry with Bill for talking her into participating in one of his projects for work. The joy 
she hoped to experience during her first pregnancy is overshadowed by her fear that the 
baby she is carrying could be affected with cystic fibrosis and potentially, also affected 
with the same condition she tested positive for, familial amyloidosis. She searches 
frantically online for doctors’ offices where she can discuss prenatal testing options. She 
wants to determine if her baby will be born with either of these conditions. After reading 
about the various options for prenatal diagnosis, she quickly becomes distraught again 
when she learns that prenatal testing could result in the loss of her pregnancy. Melinda 
and Bill do not know whom to contact to ask for help with the overwhelming amount of 
information about their individual genomes that was suddenly thrust upon them, in the 
midst of learning about Melinda’s pregnancy.  
 Could Bill and Melinda have been better prepared for their genomic information? 
How could this scenario played out differently? Should it have played out any 
differently? Were Bill and Melinda harmed in any way? If so, who is at fault for not 
  12 
providing more information to Bill and Melinda about the consequences of their 
sequencing? Should the blame to be placed on Bill’s brother-in-law for not fulfilling his 
legal and ethical obligations as a physician to ensure Bill and Melinda were properly 
informed? Was it the laboratory’s responsibility to better inform the couple about what to 
expect and ensure the couple was more prepared for the information before undergoing 
sequencing? Should the onus be placed on Bill for not taking the time to better 
understand some of the consequences of whole genome sequencing? Bill is a science 
reporter, who has been researching the technology of genome sequencing and therefore, 
one could assume that he would have understood the potential implications for 
undergoing genome sequencing including better understanding the consequences of 
learning about disease they may or may not exhibit symptoms for in the future. He should 
have conceivably understood the potential for health insurance discrimination after 
genetic testing as well as the possibility that life insurance or long-term care insurance 
would also be affected by a positive genetic test result.    
 Perhaps it would be unfair to fault this couple for not understanding the possible 
emotional responses they experienced when reviewing their results, if neither one fully 
comprehended what kind of information the test would reveal. Who could or should be 
responsible for informing the couple on how to prepare themselves psychologically and 
financially, for the type of genomic information they could expect from genome 
sequencing? Do the Millers have a strong enough legal argument to successfully file a 
lawsuit against the laboratory for failure to warn them about the financial and 
psychological harm that resulted from undergoing whole genome sequencing? 
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 How can medical providers adequately prepare individuals for all the possible 
type of results available after undergoing WGS or WES, as well as discuss the possible 
medical, psychological, and psychosocial implications of learning information about an 
unknown number of genetic risk factors?  
 The traditional practice of informed consent is the point in clinical care when 
individuals are informed of all the possible implications from undergoing a specific test, 
diagnostic procedure or medical treatment. Informed consent is obtained before the 
recommended test, procedure or treatment is ordered or initiated. Along with providing 
information about a specific test to individuals during the consent process, the consent 
process was designed to allow time for individuals to ask questions or request additional 
clarification about the information provided to them, to be sure they fully comprehend the 
implications to their own health, and in the case of genomic testing, the implications to 
family members. The third component of the traditional informed consent process is for 
the individual to be given an opportunity to decline the test recommended by their 
physician. Although informed consent is an institutional requirement at all hospitals and 
medical clinics across the United States, and a requirement for all medical research 
studies in the world, the process itself may not fulfill the underlying ethical obligations it 
was designed to achieve.  
 Informed consent practices in medical research and clinical care evolved from the 
same ethical principle of autonomy; and one intent of informed consent is to fulfill ethical 
obligations of fully informing, respecting and engaging individuals in medical decisions 
about their own health, and the decision to participate in a clinical trial. The 
implementation of informed consent into clinical care and medical research, historically 
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occurred at the same time, but the practices of informed consent differ due to underlying 
differences in the legal objectives between the two consent protocols. The legal emphasis 
of informed consent practices in clinical care is to inform individuals of the underlying 
risks, benefits and limitations of a recommended test/procedure/treatment. The legal 
emphasis of informed consent practices in medical research is to ensure research 
participants know they are “research subjects”. Chapter two describes the divergence of 
these two practices and explores the similar reason both practices do not always fulfill the 
underlying ethical obligations. The complexities of undergoing genome sequencing have 
challenged the informed consent practices and in chapter four I discuss how this 
technology blurs the distinction between clinical informed consent and research informed 
consent practices.  
There is considerable focus at this time in medicine (both in clinical care and 
medical research) on how to obtain informed consent for WGS/WES. The informed 
consent process for WGS/WES is burdened by the vast amount of potential genomic 
information generated from sequencing, as well as the large degree of uncertainty 
surrounding the potential medical implications of the results from WGS/WES. The 
informed consent process is also burdened by unknown utility for how or whether 
genomic information should be used in the medical care of individuals undergoing 
sequencing; and unknown implications for the relatives of individuals undergoing 
sequencing. These are the issues researchers and clinicians are discussing while working 
to create informed consent protocols for individuals seeking WGS/WES (van El et al., 
2013). The fact that current informed consent protocols do not fulfill the ethical 
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obligations of the informed consent process is an issue that is not being considered in the 
design of new informed consent protocols for WGS/WES.  
 As a genetic counselor, I have been privileged to work with individuals and 
families, like Bill and Melinda, who are considering genetic and genomic testing. My 
experiences in the field of genetics for over 18 years inspired me to pursue further 
research and study in the area of medical informed consent to find ways to improve upon 
the informed consent process. I have witnessed the failures of informed consent in 
medical care through many of my interactions with individuals undergoing genetic and 
genomic testing and these experiences motivate me to deepen my understanding of the 
intent of informed consent in an effort to develop methods to improve informed consent 
practices, especially now, as the field of medical genetics is grappling with the 
complexities of whole genome and whole exome sequencing.  
 The goal of this dissertation is to describe the rationale and ongoing motivations 
for sustaining traditional models of informed consent for genetic testing; to analyze the 
effectiveness of these traditional models and the applicability of the traditional models to 
WGS/WES, in order to better understand how to create a more effective informed 
consent process for individuals considering WGS/WES. This dissertation culminates with 
a novel proposal of an informed consent process for WGS/WES designed to fulfill the 
ethical obligations of informed consent and respond to the complexities of WGS/WES, 
resulting in a more effective consenting experience for individuals undergoing 
WGS/WES and the medical professionals obtaining consent.  
 The original contribution achieved from this project is to provide the medical 
professionals and scientists who are currently enmeshed in the process of sorting through 
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the complexities of how to adequately consent individuals considering WGS/WES a new 
perspective for how to think about the informed consent process. It is my hope that by 
thinking about informed consent differently, a new approach towards the informed 
consent process can be achieved for WGS/WES, which will result in a more effective 
informed consent process for both patients and the medical providers who are consenting 
individuals. A secondary contribution achieved from this project is to present a novel 
method for obtaining informed consent for WGS/WES which both improves upon 
existing informed consent protocols and provides opportunities to integrate the 
technology of WGS/WES into our current health care model.  
 This dissertation begins with an ethnographic review of the practices and 
effectiveness of informed consent in clinical medicine and informed consent practices for 
genetic testing. The next chapter (chapter two) begins with a historical review of the legal 
rulings and the corresponding ethical obligations that provide the rational for informed 
consent mandates in medical research and clinical care. The historical review of the legal 
incorporation of informed consent into clinical care is drawn from the accounts of the 
legal proceedings published in textbooks and journal articles. The review of the ethical 
evolution of informed consent is drawn from accounts in bioethics textbooks and journal 
articles describing the failure of medical research studies to protect and respect the rights 
of medical research subjects. In chapter two I describe the motivations for creating 
informed consent practices in medicine, to better understand the fundamental intent of 
informed consent from both a practical and ethical standpoint.  
 The subsequent chapter (chapter three) continues the exploration of the rationale 
for informed consent practices in medical care as it relates specifically to genetic testing. 
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To illustrate the evolution of informed consent practices, I review components of genetic 
testing protocols (defined in professional genetics literature) to demonstrate the ways 
genetic testing challenged existing informed consent protocols and restructured these 
early informed consent practices. After establishing the foundation for the rationale, 
integration and perpetuation of informed consent practices for genetic testing, chapter 
three concludes with a description of the effectiveness and ineffectiveness of the 
traditional informed consent practices for genetic testing; the examples of effective and 
ineffective informed consent practices for genetic testing are drawn from journal articles, 
textbooks and clinical experiences working as a genetic counselor. I provide my own 
analysis of informed consent practices for genetic testing by comparing these current 
informed consent protocols to the original intent and ethical motivations for creating 
informed consent protocols described in chapter two; and explore the reasons current 
informed consent protocols for genetic testing are not effective at fulfilling the ethical 
obligations of informed consent.  
 Building upon the fundamentals of the rationale and effectiveness or 
ineffectiveness, of current informed consent practices for genetic testing, I introduce the 
technology of genome sequencing in chapter four and describe the ways in which 
WGS/WES produce a more complex set of consequences to the individual undergoing 
sequencing, and new challenges to the traditional informed consent process. After 
reviewing the complexities of the technology, I describe current proposals identified in 
the literature and obtained from clinical practices, for how to tackle the informed consent 
challenges of WGS/WES. I conclude this chapter with a discussion about why existing 
informed consent protocols for genetic testing and the new proposals for how to obtain 
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informed consent for WGS/WES are not effective at fulfilling the goals of informed 
consent or addressing the challenges of this technology.  
 The second half of this dissertation describes novel solutions for how to respond 
to the complexities of WGS/WES and improve upon existing informed consent protocols. 
The solutions presented in chapters five and six are drawn from the historical summary of 
the original ethical obligation of informed consent practices in medical care (described in 
chapter two) and the analysis in chapter three on which components of traditional 
informed consent protocols are effective at achieving the ethical goals of informed 
consent. In chapter five, I outline the solutions for how to more effectively fulfill the 
ethical and legal obligations of informed consent. These solutions are describe in four 
principles drawn from the original intent of informed consent (both from a legal and 
ethical perspective), and based on my own clinical experiences for what constitutes an 
effective consenting experience for individuals undergoing WGS/WES. The ways in 
which these four principles have the potential to create an informed consent process that 
is more effective than current informed consent protocols are explored at the conclusion 
of chapters five and seven.  
 Chapter six describes each step of a novel informed consent process for 
WGS/WES, which is shaped by the four principles discussed in chapter five. The first 
objective of chapter six is to demonstrate the process of a novel informed consent 
protocol for WGS/WES by providing examples of how an individual would be 
consented, including explicit descriptions of each step of the informed consent process. 
The second objective is to explain how this novel informed consent process is more 
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effective at fulfilling the ethical and practical obligations of informed consent while also 
capable of addressing the complexities of WGS/WES.  
 Chapter seven presents a model for how to incorporate informed consent into the 
multiple systems of WGS/WES. The systems of WGS/WES include, the individual 
undergoing sequencing, physician(s), the sequencing laboratory, the ancillary medical 
services within the health system (health insurance companies, electronic medical record 
systems, and pharmacies), the individuals’ family and other support networks (friends 
and online support groups) and medical research studies. In chapter seven, I describe how 
the consent process discussed in chapter six can be integrated into the systems of 
WGS/WES; and I review how the consenting process provides a framework for how to 
integrate genomic data reported from WGS/WES, into the larger medical model. 
 This dissertation concludes in chapter eight with a summary of the evolution of 
informed consent protocols, from the original implementation of informed consent into 
medical care, to the incorporation of genetic testing informed consent protocols, and new 
ways in which WGS/WES is challenging us to find a better approach for fulfilling the 
ethical obligation required from the consenting process. I review how the challenges of 
WGS/WES provide opportunities for researchers and medical practitioners to better 
understand why we have been consenting the way we have and whether this is the best 
way possible, or whether there might be alternative, more fulfilling ways in which to 
achieve an even better outcome from the informed consent process. 
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CHAPTER 2 
CLINICAL AND RESEARCH MEDICAL INFORMED CONSENT 
Informed consent was implemented into clinical medicine to protect patient rights and 
promote patient autonomy. In the clinical setting, informed consent is designed to move 
decisions regarding medical procedures and tests away from a paternalistic approach of 
medical decision making into a shared decision making model between the patient and 
their physician. The content of an informed consent conversation is based on legal 
requirements and is standardized to include a discussion of: the risks, benefits and 
limitations of a recommended treatment as well as alternative options and consequences 
of not pursuing a recommended treatment (Plaut, 1989).  
 The rationale for incorporating informed consent practices into the medical model 
is grounded in the philosophical argument of what “must” be done. The legal 
interpretation of informed consent is characterized by a “rule-based method” of providing 
information without undue coercion or influence (Goldstein, 2010). In this sense, 
informed consent is achieved by following rules and requirements that satisfy a specific 
institution’s practice of health care (Behrman & Fowler, 2007). The combined rulings 
from two pivotal legal cases from the early and mid 1900s shaped the five principles that 
embody the current doctrine of informed consent in medical care; disclosure of: 1. the 
diagnosis and the nature of the patient’s condition; 2. the nature and objectives of a 
recommended medical course of action; 3. the expected outcome and probability of 
success; 4. the attendant risks and benefits; and 5. all alternative procedures, and their 
respective risks and benefits, including the risks of not consenting to the recommended 
medical course of action (Sharpe, 1994). The four exceptions to standard informed 
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consent are: 1. emergency; 2. waiver, 3. incompetence and, 4. therapeutic privilege 
(Plaut, 1989).  
 Unlike the rule-based, legal interpretation of informed consent stating what 
“must” be done, the ethical grounding of informed consent is based on what “ought” to 
be done (Goldstein, 2010). The core ethical principle of autonomy embodies the principle 
of voluntary consent. Individual autonomy is defined by two core conditions: 1. freedom 
from controlling influences and 2. the capacity to make intentional choices (Hamilton & 
Bowers, 2003). The ethical applications of informed consent have primarily been linked 
to medical research. In medical research, informed consent evolved from an ethical 
concern over the abuse of human subjects enrolled in medical trials. The ethical 
principles justifying the rationale for proper utilization of informed consent in a research 
study evolved in parallel to the legal ruling resulting in the implementation of informed 
consent into clinical medicine. While there are similarities in the rationale and 
justification for legal and ethical interpretations of informed consent, the embodiment of 
the two approaches for informed consent have been accurately characterized by 
bioethicists Ruth Faden and Tom Beauchamp as two “common, entrenched, and starkly 
different meanings of ‘informed consent’” (Faden & Beauchamp, 1986). These two 
interpretations of informed consent will be explored fully in this chapter and serve to set 
the backdrop for understanding the rational and ongoing motivations for sustaining 
traditional models of informed consent for genetic and genomic testing. 
 The first reported legal case, which predicated the eventual inception of informed 
consent as a legal requirement in medical care, was Scloendorff v Society of New York in 
1914 (Schloendorff v. Society of New York Hospital, 1914). The ruling in this case was in 
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favor of a patient who sued her surgeon for removing a tumor despite her wish not to 
have the surgery performed (Hamilton & Bowers, 2003). The judge for this case provided 
this argument for his decision: “Every human being of adult years and sound mind has a 
right to determine what shall be done with his own body; and a surgeon who performs an 
operation without his patient’s consent commits an assault, for which he is liable in 
damages” (Schloendorff v. Society of New York Hospital, 1914).This case provides the 
first example of considering patient rights in health care decisions and thereby introduces 
concepts of self-determination and rationale decision-making into medical care 
(Hamilton & Bowers, 2003).  
 Informed consent became a requirement in medical research studies before the 
legal incorporation of informed consent into clinical care. Informed consent in medical 
research occurred in response to the atrocities revealed from the Nazi experiments during 
World War II and was supported by the rise of the human rights movement. The 
Nuremberg Trials in 1946 signify the first discussion about ethical treatment of research 
subjects in medical trials (Rothman, 2003). The Nuremberg Trials were the legal 
proceedings brought against the medical professionals and scientists conducting unethical 
medical experiments on prisoners in the concentration camps in World War II. The direct 
outcome of these trials was the creation of the Nuremberg Code in 1947. The Nuremberg 
Code is known as the first accepted code of ethics in medical research (Mascalzoni, 
Hicks, Pramstaller, & Wjst, 2008). The Nuremberg Code lists ten moral imperatives for 
conducting research studies; the first principle states, “The voluntary consent of the 
human subject is absolutely essential” (Rothman, 2003). On the heels of the publication 
of the Nuremberg Code, the National Institutes of Health (NIH) created a human subjects 
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review board known as Clinical Research Committees (CRC) in 1953. CRCs represent 
the first formal committee review process for evaluating the ethical components of 
medical studies. The format and role of CRCs became the model for today’s Institutional 
Review Boards (IRB) (Stark, 2012).  
  Before the legal mandate of informed consent was implemented in clinical care, 
patients were expected to follow their physicians’ advice without questioning. This was 
known as a paternalistic model of medical care. An example of the paternalistic model of 
medical care was the common practice for a physician to keep the knowledge that his 
patient had cancer from the patient, to protect the patient from psychological distress 
associated with the knowledge of their condition (Gefenas, Cekanauskaite, Tuzaite, 
Dranseika, & Characiejus, 2011). Physicians practicing medicine in the early 1900s were 
revered as the “medical expert” capable of unilaterally recommending a treatment plan to 
save or prolong the life of the patient; a paternalistic model of patient care was accepted 
in part because patients in the early 1900s respected physicians’ expertise. Physicians 
practicing medicine in this era of medicine also believed patients were unable to reason 
when it came to medical matters (Stark, 2012). Edward Shorter wrote about the 
relationships between patients and physicians in his book, Bedside Manners, and 
describes physicians who practiced medicine between 1880 and the late 1940s as healers, 
who possessed inspirational qualities, capable of healing patients by offering 
explanations for why a patient was ill. According to Shorter, doctors in this era were 
friendly, attentive, humane and treated their patients respectfully (Shorter, 1985). 
 The landmark case resulting in the actual incorporation of the doctrine of 
informed consent as a legal requirement in medical care is (Salgo v. Leland Stanford etc. 
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Board of Trustees, 1957). In this case, the plaintiff, Mr. Salgo testified that his physician 
did not properly inform him about the potential risks from a surgery, which ultimately 
left him paralyzed. The court ruled that the surgeon was negligent as he had a duty to 
disclose all facts and possible risks resulting from the surgery. Only when the patient has 
all the facts can he make a fully informed decision (Hamilton & Bowers, 2003). The 
Salgo case resulted in the first legal requirement of informed consent into the medical 
care model in 1957. Since the California court introduced informed consent as a legal 
requirement, at least twenty-three states have adopted similar informed consent statutes 
(Andrews, 2001).  
 Around the same time the Salgo case ruled in favor of patient rights in medical 
decision-making and informed consent practices become mandated into clinical practice, 
patients in this country were beginning to lose confidence in their doctors as healers. 
Shorter explains that with the development of the first sulfa drug, sulfanilamide, in the 
1930s, doctors began to practice medicine based on the medications that were available to 
treat ailments. The availability of novel, miraculous in some cases, new medications gave 
physicians a new sense of empowerment. Enamored with their ability to cure some 
diseases, physicians no longer practiced medicine the same way and the focus shifted 
from talking to patients about their illnesses, to prescribing medications (Shorter, 1985).  
 As patients and doctors grew apart from lack of communication, patients lost trust 
in their physician’s ability to heal. “By the end of the 1960s, doctors noticed they were 
dealing with a new kind of patient, one unwilling to accept doctor as priest, or medicine 
as series of holy rites” (Shorter, 1985). Shorter’s account of the changing dynamic 
between doctor as healer and patient as skeptic, coincides with the initial legal 
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proceedings brought against physicians in 1957, resulting in our current informed consent 
mandates. Informed consent practices implemented into medical care reflect patients’ 
dissatisfaction with the lack of communication between doctors and patient about 
medical treatment plans and options for treatment. Echoing the same theme as Edward 
Shorter, physician and law professor Jay Katz wrote about the lack of conversations 
between physicians and their patients; Dr. Katz is well known for his quote; ‘hospital 
rooms before the 1970s have been portrayed as silent worlds’ (Stark, 2012). 
 The lack of communication between physician scientists and research subjects 
was demonstrated in medical research studies throughout the 1960s and 1970s. In 1964, 
an article was published in the journal Science, describing the research violations of a 
study conducted at New York’s Jewish Chronic Disease Hospital. This widely cited study 
describes lack of informed consent practices when two physicians admitted that they 
injected 22 patients (some who were diagnosed with cancer and some who did not have 
cancer) with cancer cells, without obtaining consent from the patients (Langer, 1964). 
The same year this research trial was exposed for its ethical violations, the World 
Medical Association updated the Nuremberg Code with a set of recommendations for 
medical research practices that was less restrictive for the contemporary medical 
researcher who knew “right from wrong” (Mascalzoni et al., 2008). 
 The 1960s proved to be a disappointing time in medical research, as Dr. Henry 
Beecher revealed abuses within the medial profession in 1966. Dr. Beecher is known as 
the physician who bravely published an essay in The New England Journal of Medicine, 
describing 22 examples of “unethical research” carried out by his colleagues at renowned 
universities (Beecher, 1966). Feeling the pressures from these abuses, the government 
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acted again; in 1966, Surgeon General Stewart, announced to the research community, 
that hospitals, universities and other research institutions needed to establish human 
subjects review boards if they wanted to receive federal funding (Stark, 2012).  
 Also in 1966, the premiere research institute in the United States, the National 
Institutes of Health, began to encourage researchers to obtain a signed form from research 
participants as evidence of consent (Stark, 2012). Researchers however, were very 
resistant to follow this mandate arguing that they had other ways to document consent, 
such as making notes in the medical charts. They fought to employ their professional 
discretion for determining what constitutes evidence that study participants knew they 
were participating in a research study. Despite the fact researchers claimed to know what 
was best practice for informed consent, it was well known that conversations between 
researchers and research subject were ephemeral during the 1950s and 1960s (Stark, 
2012). 
 A second horrific example of the failure of informed consent in medical research 
occurred in 1972 when researchers failed to protect the autonomy of research participants 
in the infamous Tuskegee Syphilis Study. In this study, researchers were observing 
African-American men diagnosed with syphilis without offering or even discussing the 
availability of a treatment for syphilis once it became available. The purpose of the study 
was to document the “natural course of the disease,” but the men were never made aware 
of the fact they were participating in a study and further, they were never told that 
treatment for their condition was available at the time they were being observed (Faden & 
Beauchamp, 1986). The study aim was prioritized over the rights of the study 
participants. This case illustrates additional failure of the moral imperatives from the 
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Nuremberg Code and the role of the Clinical Research Committees charged with 
overseeing the ethical components of research studies.  
 As the medical research community was struggling to uphold the moral principles 
they were required to embody, the informed consent mandate in clinical care was 
undergoing its own challenges. The initial mandate requiring informed consent from the 
Salgo case created the legal principle of informed consent, but left room for physicians to 
use their own “discretion” for how much information about risk from a procedure, is 
necessary to disclose to their patients (Hamilton & Bowers, 2003). Therefore, further 
legal cases resulted in additional requirements for informed consent protocols. The case 
that settled the issue for how much information regarding risks related to medical 
procedures is necessary to reveal in the consent process was Canterbury v. Spence, 1972 
(Canterbury v. Spence, 1972). The court again ruled in favor of a patient who became 
paralyzed after a laminectomy because the physician was negligent for failing to properly 
inform the patient on all possible risks which could result from his surgery. The outcome 
of this case signified a shift from an emphasis on the physician’s professional judgment 
about the extent of risk information necessary to discuss surrounding a medical procedure 
to a legal requirement where it became necessary to disclose enough information about 
risk to enable a “reasonable person” to make an informed choice (Hamilton & Bowers, 
2003).  
 The informed consent dialogue expanded after the Canterbury v. Spence case with 
additional requirements that information provided to patients by a physician should not 
only be comprehensive enough to allow for a patient to withhold consent, but also stated 
in language the patient can understand (Ormond, Banuvar, Minogue, Annas, & Elias, 
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2007). Additional medical legal cases throughout the 1970s and early 80s continued to 
increase patient rights and involvement in their own medical decision- making. Further 
requirements of the informed consent process include the expectation that physicians 
assess how well the patient understands the information he is hearing throughout the 
consenting process, to ensure the patient is making a fully informed decision. 
Additionally, physicians need to establish that their patients are not under duress at the 
time of consenting and that in their role as a medical expert, they do not influence or 
pressure their patient into making decisions they might feel are the best for the patient. In 
other words, the physician presents the discussion about a recommended course of 
treatment and all possible risks, in an unbiased manner, such that the ultimate decision for 
a recommended course of action is a voluntary act (Lidz, 1983). 
 Discussion about patients’ rights and the protection of subjects in medical 
research was reenergized in the United States again in the 1970s, following the previous 
decade of disappointing ethical failures in medical research trials. An extension of the 
Surgeon General’s suggestion that a human subjects review committee should be 
established for proposed research trials in the U.S. in 1966, became a requirement by the 
government with the National Research Act in 1974 (Stark, 2012). Several noteworthy 
outcomes from this legislation included; empowerment for the federal government to 
regulate research studies conducted on people, and the creation of the National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research. In 1979, the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research published a statement of principles on research 
ethics known as the Belmont Report (“The Belmont Report,” 1979). As with the 
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Nuremberg Code, the first ethical principle of the Belmont Report is respect for persons. 
The Belmont Report states that respect for persons incorporates two ethical convictions: 
first that; ‘individuals should be treated as autonomous agents’ and second, that; 
‘protection should be provided for persons with diminished autonomy’ (“The Belmont 
Report,” 1979). Bioethicists have touted the legal mandate embodied within the National 
Research Act, as a triumph for the protection of research subjects (Stark, 2012).  
 The current ethical criteria all informed consent protocols must fulfill are based 
on the international guidelines from the Nuremburg trials and the American Belmont 
report. These guidelines are well described and delineated in research literature and 
required as part of federal guidelines and state laws for both clinical care and as a 
component of medical research studies. The core principles of informed consent are the 
same for clinical medicine as well as for medical research studies. The legal mandate of 
informed consent protocols in clinical care resulted in the creation of a checklist of 
required information to be disclosed with the patient by the physician recommending the 
procedure, test, or treatment. Ethical obligations for informed consent in clinical care are 
based on the principles of promoting patients’ self-determination and rational decision-
making about their medical care (President’s Commission for the Study of Ethical 
Problems in Medicine and Biomedical and Behavioral Research: Making Health Care 
Decisions, 1982). The core ethical principle of autonomy is at the heart of the idea of 
self-determination (Goldstein, 2010).  
The ethical rational for informed consent in medical research protocols is the 
same as informed consent obligations in clinical care, although the focus in medical 
research is towards ensuring that study participants are fully aware of any possible risks 
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from participating in a study. The voluntary nature of participation in a medical research 
study is emphasized more strongly in the research informed consent process compared to 
clinical informed consent protocols. Laura Stark describes the aims of informed consent, 
as portrayed by medical researchers, to get potential research participants to recognize 
themselves as “human subjects” (Stark, 2012). The ethical requirement of a conversation 
between study participant and researcher, might never occur because this requirement is 
instead met by the ‘network of declarative bodies’ (IRBs), which serve to evaluate the 
ethics of medical research studies on behalf of the patient (Stark, 2012). The failure of 
medical research studies at fulfilling the ethical obligations will not be explored in this 
dissertation since the focus of this dissertation is on the effectiveness of informed consent 
protocols in clinical medicine, in particular for genetic/genomic testing. I felt it was 
important to mention the struggle of medical research studies at fulfilling the ethical 
obligations of the informed consent process since, throughout the remainder of this 
dissertation, I discuss how and why informed consent protocols in clinical medicine, fail 
to fulfill the ethical obligations of the consent process. After exploring the reasons 
informed consent practices in clinical medicine have failed to fulfill the ethical 
obligations in chapter three, I come back to this rationale for why informed consent 
practices in clinical research have failed to illustrate how the failures between clinical and 
research consent are similar.  
 The fact that informed consent practices in clinical care struggle to fulfill the 
ethical obligations of the consent process was highlighted in the 1980s when a second 
federal commission was created in response to the perceived failure of the informed 
consent process, as well as the lack of regard for the informed consent mandate. In 
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response to criticism by physicians that the informed consent process is burdensome to 
medical practice as well as ineffective for medical decision-making, the President’s 
Commission for the Study of Ethical Problems in Medicine and Biomedical and 
Behavioral Research issued a report in 1982. In the summary of this report, the 
Commission wrote that informed consent is not just a legal imperative, but an ethical 
imperative as well. The Commission reminded physicians that an “ethically valid” 
consent process includes a conversation in which physicians treat the patient with respect 
and reach a mutual decision regarding health care decisions (President’s Commission for 
the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research: 
Making Health Care Decisions, 1982). 
 Throughout this dissertation, I explore why our current informed consent 
protocols fail to fulfill the ethical obligations summarized in the 1983 President’s 
Commission for the Study of Ethical Problems in Medicine and Biomedical and 
Behavioral Research. This historical background describing the legal and ethical 
obligations of informed consent practices provides the necessary foundation for building 
a discussion in the next two chapters for how genetic and genomic testing introduce new 
complexities for informed consent practices in clinical care. These informed consent 
practices were struggling to fulfill the underlying ethical obligations they were meant to 
protect before more complex testing became available. I reference Bill and Melinda’s 
genome sequencing experience to answer the question of whether our current informed 
consent practices succeed in providing adequate information to individuals about genetic 
and genomic tests. I also discuss whether current informed consent practices provide an 
opportunity for individuals to fully explore their understanding of genomic testing and 
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time to discuss individual goals for undergoing genomic testing. Finally, I explain why 
all of these components are necessary to fulfill both the legal and the ethical obligations 
of informed consent mandates. 
 To illustrate how informed consent is achieved in clinical practices today and to 
delineate the complexities of informed consent practices in genomic medicine, the next 
chapter introduces the field of genetics into clinical care and describes how informed 
consent protocols from the 1950s were rewritten to address the challenges of genetic 
testing. The last section of chapter three provides an analysis of the perceived 
effectiveness and ineffectiveness of current informed consent practices in medical 
genetics. 
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CHAPTER 3 
EVOLUTION AND EFFECTIVENESS OF INFORMED CONSENT PRACTICES FOR 
GENETIC TESTING                    
The field of genetics was first described in 1905 by an English biologist, William 
Bateson. In a letter to a colleague, Bateson used the word genetics as a noun to define a 
new field of science with a focus on the medical and biological study of heredity and 
variation (Bateson, 2002). The creation of the field of genetics occurred on the heels of 
the suggestion in the late 1800s by Francis Galton: “eugenics” is the study of “agencies 
under social control that may improve or impair racial qualities of future generations, 
either physically or mentally” (Baker, Schuette, & Uhlmann, 1998). William Bateson’s 
definition of a new field in genetics provided a scientific method to fulfill the ideals of 
eugenics; improving the human condition through the identification of hereditary factors 
that contribute to social and behavioral conditions such as poverty, crime and mental 
illness (Baker et al., 1998).  
 The eugenics movement gained notoriety in this country with the creation of the 
Eugenics Records Office in 1910 at Cold Springs Harbor, Long Island (Baker et al., 
1998). The Eugenics Records Office was partially funded by the Carnegie Institute of 
Washington’s Department of Genetics and was the country’s central training facility for 
eugenics. Eugenic field workers gathered data about human traits by drawing family 
pedigrees. This data was used by the Eugenics Records Office to influence families’ 
reproductive decisions after they had a child affected with a birth defect or abnormality 
(Stern, 2012).  The Eugenics Records Office disbanded in 1939, primarily from criticism 
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over their methods of data collection, which was reported to be scientifically unsound 
because the studies were influenced more by political and social agendas than science 
(Baker et al., 1998). This criticism was less about the eugenics movement and more about 
the politics behind the studies conducted at the Eugenics Records Office. Despite the 
closing of the Eugenics Records Office, the eugenics movement continued to gain 
momentum in the U.S. and across Europe and Scandinavia in the early 1900s. By the late 
1920s, 23 of the 48 states in the U.S. passed laws mandating sterilization of the “mentally 
defective.” In 1939 it was legal to euthanize the “genetically defective” resulting in the 
death of over 70,000 individuals with a hereditary disorder (Baker et al., 1998).  
 Shortly before the Nuremberg Trials began, three heredity clinics were founded in 
the United States in 1941; the three clinics were instituted at the University of Minnesota 
Dight Institute, the University of Michigan Heredity Clinic and Wake Forest University 
(Stern, 2012). These clinics were all founded on eugenics principles and supported the 
sterilization laws from the 1920s and 1930s. Throughout the 1940s, 1950s and 1960s 
many geneticists did not object to the characterization of applied medical genetics as the 
practice of eugenics (Stern, 2012). 
 During the mid-1940s however, diagnostic testing to confirm a suspected 
hereditary disorder was not yet available and therefore conversations about genetic risk 
factors were based on empirical observations. Human geneticists worked to assess the 
relationship between actual or potential medical conditions and genetic inheritance based 
on family pedigree analysis (Stern, 2012). This practice constitutes the emergence of 
genetic counseling. In 1947, Sheldon Reed, a geneticist and director of the Dight Institute 
at the University of Minnesota, was credited for coining the term “genetic counseling” 
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(Kessler, 1979). Reed however, began to distance himself from eugenics ideas by 
counseling families on genetic disorders and providing risk information in a non-directive 
manner to empower individuals to make decisions most consistent with their cultural, 
religious and personal values (Stern, 2012). 
 The next decade began with a pivotal scientific breakthrough by James Watson 
and Francis Crick who published their understanding of the physical structure of the 
DNA molecule in 1953 (Watson & Crick, 1953). A second pivotal breakthrough for 
genetics was the identification of the correct number of chromosomes reported in 1958 
by Tijo and Levan (Dave & Sanger, 2007). The discovery of the DNA molecule and the 
corresponding relationship to human chromosomes, signify the beginning of the modern 
era of genomic medicine in which genetic testing was used as a tool for establishing or 
confirming a suspected genetic diagnosis. By the late 1950s it was possible to 
characterize and diagnose common chromosomal alterations such as Trisomy 21 (Down 
Syndrome), Klinefelter’s Syndrome (47, XXY) and Turner Syndrome (45,X) (Baker et 
al., 1998).  
 The ability to diagnose chromosomal alterations and some biochemical genetic 
disorders made it possible to diagnose a fetus in utero (through an amniocentesis 
procedure) with a possible genetic condition or chromosomal alteration, by the late 1960s 
(The NICHD National Registry for Amniocentesis Study Group, 1976). An 
amniocentesis procedure is performed by inserting a long thin needle into the amniotic 
sac to withdrawal amniotic fluid containing fetal cells (Mueller & Young, 2001). The 
cells are then cultured in a laboratory and examined for a particular condition. While the 
first amniocentesis procedure was performed in the 1800s to remove excess fluid from 
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the amniotic sac (Genetic Counseling Faculty, 1993), it wasn’t until 1967 and 1968 that 
amniocentesis was performed during the mid-trimester of a pregnancy (15-17 weeks 
gestation) to diagnose a fetus with a metabolic disease or chromosomal alteration (The 
NICHD National Registry for Amniocentesis Study Group, 1976).  
 With the availability of prenatal testing, couples were faced with options 
surrounding what to do with the genetic information they learned about their unborn 
baby. These options were often not straightforward and further, the amniocentesis 
procedure itself has the potential to result in serious complications to the pregnancy, such 
as a miscarriage (The NICHD National Registry for Amniocentesis Study Group, 1976). 
A medical specialist trained in the area of genetics and counseling was needed to discuss: 
risks from the amniocentesis procedure, risks for having a child affected with a genetic 
disorder, and to provide information about a hereditary condition and help couples handle 
the difficult information they are learning, to facilitate the process of making decisions 
about the pregnancy or help them adjust to the new diagnosis.   
 The fact is genetic testing provides information with a more complicated set of 
medical consequences than most other medical tests. The diagnosis of a genetic disorder 
is problematic for most individuals because a genetic disease is a permanent condition. 
Many genetic conditions are untreatable and, most significantly, a hereditary condition is 
transmittable to future offspring and has possible implications for other blood relatives. 
Lori Andrews, a prominent lawyer specializing in policy issues surrounding genetic 
testing, has published extensively about implications of genetics diseases on individuals 
and on society. In the 2001 Washington University Law Quarterly she summarizes the 
social and psychological implications of genetic testing: “Genetic testing generates 
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information unparalleled in scope compared to other areas of medicine. People can learn 
that, decades later, they will suffer from an untreatable disorder, that they have an 
increased risk of cancer, or that their children have a one-in-four chance of dying of a 
serious disorder in childhood. The impact of this knowledge can affect people’s lives by 
challenging their self-image, by altering their cultural and social identity, by changing 
their relationships with family and friends, and by causing them to think about their life, 
health, and responsibilities in new ways” (Andrews, 2001). Researchers estimate that 
approximately 30% of patients with a genetic condition will adjust in maladaptive ways 
after learning about the possible risk of being diagnosed with a hereditary disorder or the 
knowledge they have a genetic disease (B. Biesecker & Erby, 2008). In response to the 
need for this type of medical provider, along with the anticipation that additional types of 
genetic testing would be available in the future, the field of genetic counseling was 
created (Stern, 2012). 
 The first graduate program in genetic counseling was established in 1969 at Sarah 
Lawrence College in Bronxille, New York (Marks & Richter, 1976). The training in this 
profession was designed as a terminal master’s degree with two years of graduate training 
focusing on the medical, psychological and social aspects of a genetic disease (Baker et 
al., 1998). Genetic counselors today are trained to present complex technical and 
scientific information in understandable language and assist individuals in the process of 
determining the most appropriate next steps (Stern, 2012). Genetic counseling is 
essentially a comprehensive in-person method for obtaining informed consent before 
undergoing genetic testing. The original definition of genetic counseling proposed by the 
American Society of Human Genetics (ASHG) in 1975 is cited in many publications:  
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“Genetic counseling is a communication process, which deals with the human problems 
associated with the occurrence or risk of occurrence of a genetic disorder in a family. 
This process involved an attempt by one or more appropriately trained persons to help the 
individual or family to: (1) comprehend the medical facts including the diagnosis, 
probable course of the disorder, and the available management, (2) appreciate the way 
heredity contributes to the disorder and the risk of recurrence in specified relatives, (3) 
understand the alternatives for dealing with the risk of recurrence, (4) choose a course of 
action which seems to them appropriate in view of their risk, their family goals, and their 
ethical and religious standards and act in accordance with that decision, and (5) to make 
the best possible adjustment to the disorder in an affected family member and/or to the 
risk of recurrence of that disorder” (American Society of Human Genetics Ad Hoc 
Committee on Genetic Counseling, 1975).  
 The core tenet of the genetic counseling process is to promote autonomy and 
place a priority on the need(s) of an individual and/or their family, over society’s 
concerns (Kessler, 1979). The practice of genetic counseling was purposefully designed 
to reject the traditional paternalistic model where the physician advises a patient on a 
particular course of care without incorporating the values of the patient. This goal is 
fundamentally in line with the legal obligations and the ethical underpinnings of informed 
consent.   
 For approximately twenty years after Watson and Crick published their 
description of the double helical structure of the DNA molecule, genetic testing was used 
infrequently and primarily to diagnose a chromosomal alteration or some biochemical 
  39 
diseases. Hereditary traits however, had already been classified over a hundred years 
before Watson and Crick’s publication in 1953. In 1865 Gregor Mendel presented the 
findings of his breeding experiments on garden peas (Mueller & Young, 2001). While 
Mendel’s work did not receive much attention in his time, genetic diseases were initially 
defined as Mendelian because they occur statistically, in fixed proportions among 
offspring of the same parents. Initial descriptions of Mendelian inheritance patterns for 
genetic diseases were simplistic by modern comparisons, because most disease were 
thought to be caused by a single genetic mutation, otherwise referred to single-gene or 
monogenic disorders. These inheritance patterns were known as: autosomal dominant, 
autosomal recessive and X-linked (Nussbaum et al., 2001). In clinical medicine, before 
the availability of molecular genetic testing (the ability to identify genetic mutations in 
the laboratory by analyzing a gene with a known association to a hereditary disease), a 
pattern of inheritance was based on observation of the clinical expression of a particular 
phenotype in family history (Stern, 2012). Initially Mendelian disorders were catalogued 
in several large volumes of a textbook known as Mendelian Inheritance in Man (MIM). 
The first print edition of MIM was published in 1966 and featured 1,486 entries; most 
were clinical descriptions of suspected hereditary conditions (Yakutchik, 2010). 
 The field of genetics evolved very rapidly after the development of recombinant 
DNA technology in 1972 (Nussbaum et al., 2001). Recombinant DNA technology made 
it possible for scientists to isolate fragments of DNA and analyze these fragments for 
possible variants, or mutations. The isolation of these fragments allowed for an efficient 
method of replicating DNA to search for genetic mutations (Nussbaum et al., 2001). With 
improved technologies, scientists became better equipped to appreciate more 
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sophisticated molecular causes of genetic disorders. This resulted in the description of 
more complex types of monogenic inheritance; mitochondrial inheritance, imprinting and 
expanding triplet repeat disorders (Nussbaum et al., 2001). The number of Mendelian 
disorders grew so rapidly that the written volumes of Mendelian Inheritance in Man was 
replaced with an online version in 1985, now known as Online Mendelian Inheritance in 
Man (OMIM) (McKusick, 2013). 
 Due to the rapid increase in the number of genetic tests available by the early 
2000s, as well as the variety of adult onset or predisposition genetic tests available, the 
National Society of Genetic Counselors revised the original definition of the purpose of 
genetic counseling in 2005, to reflect a broader scope of practice for genetic counselors.   
“Genetic counseling is the process of helping people understand and adapt to the medical, 
psychological and familial implications of genetic contributions to disease. This process 
integrates; interpretation of family and medical histories to assess the chance of disease 
or occurrence or recurrence; education about inheritance, testing, management, 
prevention, resources and research; counseling to promote informed choices and 
adaptation to the risk or condition” (National Society of Genetic Counselors, 2013).  
Informed Consent Practice Guidelines for Three Types of Genetic Tests 
 
 The non-directive practices embraced by the genetic counseling profession are 
reflected in the informed consent protocols written for individuals considering genetic 
testing in the 1970s and 1980s. To maintain a safe ethical distance from the eugenics 
movement, professionals in medical genetics labored extensively over the informed 
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consent protocols to be followed before ordering any type of genetic test, to ensure both 
the legal and ethical obligations of informed consent were achieved.   
 These practice guidelines serve as a mechanism for genetic counselors to fulfill 
their professional obligations to promote autonomy while educating individuals about the 
issues associated with genetic testing and have been widely published in the literature. 
The reasons the informed consent protocols for genetic testing have been more widely 
published than any other type of informed consent protocols in medicine is because 
decisions made about undergoing a genetic test are multiple and sequential; decisions are 
based on probabilities and uncertainties; genetic testing has broader implications for 
family; genetic testing can disrupt an individual’s sense of themselves and their place in 
the world; and genetic testing can lead to worries over insurability, job stability and 
relationships. Medical geneticists define an ideal type of informed consent process for 
genetic testing as a non-directive genetic counseling session that includes pre and post-
test counseling (Burgess, 2001). The genetic counseling process is truly an oral dialogue 
and many in the field of genetics will criticize a written document as the only required 
method of informed consent.  
 This section will summarize the practice guidelines for three types of informed 
consent protocols in genetics to provide a thorough background of current genetic 
counseling practices before exploring the effectiveness of these practices. The application 
of these practices for WGS/WES will be explored in the next chapter. The three types of 
consent protocols I will review are pre-disposition genetic testing, carrier screening in the 
prenatal setting, and genetic testing for hereditary cancer syndromes. Throughout the 
discussion of these three informed consent protocols, I will explore the rationales offered 
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for why informed consent protocols for genetic testing have been so widely studied and 
scrutinized in the literature, compared to other standard medical consent protocols.  
 The first type of genetic test most relevant to the consenting issues also pertinent 
to WGS/WES is pre-disposition genetic testing or genetic testing for adult onset 
disorders. Pre-disposition testing is controversial within and outside the field of medical 
genetics. Many argue that it is futile to test for any condition that may or may not affect 
someone in the future and for which no treatment is readily available. Huntington’s 
disease has been the most widely cited disorder for which pre-disposition testing remains 
problematic and controversial (Sharpe, 1994). Huntington’s disease is an adult onset 
neurodegenerative disorder that affects individuals at the prime of their lives, between 35 
and 44 years old (Warby et al., 2010). The symptoms of Huntington’s disease are so 
significant that an affected individual can expect to have to quit their job, change how 
they communicate and interact with family and friends and require assistance eating, and 
taking care of themselves at the end of life.  Most tragically, until treatment options 
become available, an affected individual has to prepare for an eventual demise within 
fifteen to eighteen years of diagnosis. The suicide rate for individuals with Huntington’s 
disease is four times higher than what is reported in the Caucasian population in the 
United States (Andrews, 2001).  
 Even when individuals who are at risk for Huntington’s disease learn they do not 
carry the mutation, they often suffer from “survivor’s guilt,” and a loss of who they are. 
Many report only thinking of themselves as being at-risk for this devastating disease. 
After learning she tested negative for the HD mutation, one at-risk woman stated; ‘If I’m 
not at risk-who am I? (Andrews, 2001).’ Others assume they have the genetic mutation 
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and live as though they are positive (even before undergoing genetic testing). One 
gentleman, believed he was destined to have this disorder, and made decisions not to 
commit to a long-term relationship, get married or have children, to ensure he would not 
pass the genetic disorder to subsequent offspring. He spent frivolously, and ran up credit 
card debts. Later in life he elected to undergo testing only to learn that he did not have the 
genetic mutation associated with Huntington’s disease (Andrews, 2001). 
 The reason Huntington’s disease became one of the first adult onset genetic tests 
available was because the testing was highly specific, and because the relatives of an 
affected individual often had very strong feelings about whether they wanted to know if 
they would be affected with the condition in the future. To prepare individuals to learn 
whether they inherited the genetic mutation associated with Huntington’s disease, 
detailed guidelines for obtaining informed consent were published in the American 
Journal of Medical Genetics (AJMG) in 1994.  The requirements for informed consent 
for Huntington’s disease are summarized in the AJMG article written by Neil Sharpe who 
wrote that informed consent should include a discussion of: 1. “Potential limitations in 
securing test results, 2. Explanation “that linkage or mutation analysis is not synonymous 
with a diagnosis of HD”, 3. “That at this time, neither linkage nor mutation analysis 
provides an ability to predict the phenotype”, 4. “Of the potential psychological responses 
that may occur both before, during, and after, testing”, 5. “Of the potential effects of a 
positive or negative result on the patient’s family, including emotional and psychological 
effects of a positive or negative result on the patient’s family, including emotional and 
psychological distress that may be experienced by relatives, 6. “of the potential hazards, 
including stigmatization, insurance and employment discrimination”, 7. “of the patient’s 
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attitude toward sharing the diagnostic results”.  Sharpe’s article also emphasizes the 
importance of allowing enough time before scheduling the genetic test so the patient may 
consider the information and make a thoughtful and certain decision (Sharpe, 1994). The 
process of undergoing genetic testing for Huntington’s disease is so controversial, that 
many clinicians and researchers who work with individuals at risk for Huntington’s 
disease recommend that everyone who elects to undergo genetic testing must follow a 
specific protocol including a neurological evaluation, a psychiatric evaluation and genetic 
counseling (Wexler, 1990) (Quaid, 1992). This recommendation is a means to ensure the 
informed consent process has been fulfilled due to the perceived high stakes of learning 
about such a devastating genetic disorder.  
 Returning again to our couple, after receiving the reports from their whole 
genome sequencing studies, Bill and Melinda spend the next six months scheduling 
appointments and meeting with various medical professionals. Melinda was informed she 
carries an adult onset disease, familial amyloidosis, which is similar to Huntington’s 
disease in that her symptoms would not begin until she was in her 40s, or 50s or older. 
Melinda and Bill met with specialists in cardiology, hematology and neurology. She 
underwent numerous blood and imaging tests to determine whether she was beginning to 
exhibit symptoms of this condition. This couple spent thousands of dollars on the medical 
expenses incurred from her multiple physician visits. From a psychological standpoint 
Melinda could not stop worrying about whether she would suffer the same early demise 
as her father. She starts to wish she was not pregnant and became convinced she had 
already passed both of her genetic mutations to her baby.  
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 If Melinda had undergone a more comprehensive informed consent process, she 
would have understood before she underwent genomic sequencing the fact that she might 
test positive for an adult onset disorder, with many implications for her health. She would 
have understood that obtaining health insurance would have been a good idea in the event 
she did test positive for a medical condition requiring many diagnostic tests and 
physician appointments. In addition, she also might have been better prepared 
psychologically for learning about a disorder that would have a significant impact not 
only on her life, but for her future children as well.  
 An individual who tests positive for a deleterious gene mutation, whether the 
mutation increases the probability to have an affected child with a hereditary condition, 
or whether the mutation causes symptoms in the individual himself, will often struggle 
with self-esteem and experience a loss of sense of who they are. Psychologist Seymour 
Kessler spent his career researching the psychological ramifications of being diagnosed 
with a genetic disorder. He writes that the process of undergoing the diagnosis of a 
hereditary disorder is; “ego-threatening in that the counselees must expose themselves to 
the risk of being shown to be flawed, imperfect, defective or abnormal” (Kessler, 1979). 
 The possible emotional reactions after learning about a hereditary condition can 
also have implications on intimate relationships between spouses or with a significant 
other. Because a genetic diagnosis often infers risks for future offspring to also be 
affected, couples considering having children are forced to reconcile their desire to have a 
child with the potential risks to pass a hereditary condition to their child. The ability to 
reproduce and give birth to a healthy child has long been an acknowledged and expected 
rite of passage into adulthood. Some couples elect to end a relationship after undergoing 
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genetic screening and discovering both partners are carriers for the same autosomal 
recessive disorder. A research group in Greece conducted a study in which they surveyed 
couples’ decisions regarding marriage after learning information about their carrier status 
for sickle cell anemia. This study reported that 20% of sickle cell carriers broke off their 
engagement after learning their partner also carried the same sickle cell mutation 
(Andrews, 2001).  
 Cystic fibrosis is the most common autosomal recessive disorder in the United 
States and United Kingdom (Nussbaum et al., 2001). Carrier screening for this condition 
was initially controversial for two reasons; the first is because the disease does not result 
in developmental or intellectual delays, parents who had a child affected with CF 
advocated against carrier screening during pregnancy because of their fear many couples 
would terminate an affected pregnancy; and second because the detection of mutations in 
the CF gene was initially quite challenging due to the sheer number of mutations present 
in the gene. Nevertheless, a multidisciplinary group of scientists, medical professionals, 
and parents of children with CF, convened in 1998 to explore the process for 
implementing carrier screening into clinical practice. This group addressed such issues as 
patient and provider education, and laboratory requirements and protocols for follow-up 
after a positive screening result (Haddow, Bradley, Palomaki, & Doherty, 1999). The 
recommendations for how to implement carrier screening into prenatal practice were 
published in the Journal of Medical Screening in 1996 and provide justification for why 
and how to implement genetic screening into prenatal care clinics (Haddow et al., 1999).  
 One interesting aspect of this publication is that informed consent is only briefly 
mentioned in the article. There is one small paragraph devoted to this topic entitled, ‘How 
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will consent be obtained?” The authors agreed that while carrier screening for cystic 
fibrosis is performed under research protocols, then “written informed consent” is, as a 
rule, required. They went on to write that when carrier screening for cystic fibrosis 
transitions from the “research stage” into “clinical practice,” then informed consent 
should be performed by a health care provider and involve an oral consent process 
(Haddow et al., 1999). The authors did not offer the details of what should be discussed 
during this oral consent process, but one could assume the protocol would follow the 
recommendations for informed consent for other hereditary disorders. 
One rationale I suggest for why the details of the oral consent process was not 
discussed in this article is because the researchers who were interested in implementing 
cystic fibrosis carrier screening into clinical practice were biased by their own 
motivations of promoting carrier screening for this common disease. The inherent bias of 
this group of experts slanted the recommendations towards the implementation of the 
process, without considering or more fairly remembering, that individuals have a choice 
of whether they want to undergo screening, and this choice should always be emphasized 
or at least available to parents throughout the screening process.  
 The third type of informed consent protocol most commonly cited in the literature 
is a protocol for genetic testing for hereditary cancer syndromes. A hereditary cancer 
syndrome is another type of adult-onset disorder, which significantly increases an 
individual’s risk for cancer above the general population risk. Hereditary breast and 
ovarian cancer syndrome (HBOC) is the model disorder for this type of informed consent 
protocol. HBOC syndrome is caused by a mutation in one of two tumor suppressor genes, 
BRCA 1 and BRCA 2, known collectively as BRCA. These genes were isolated in 1994 
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(Miki et al., 1994) and 1995 (Wooster et al., 1995) respectively. A mutation in either 
gene is associated with an increased risk for breast, ovarian and other cancers (Barnes-
Kedar & Plon, 2002). 
 To reduce increased risks for breast and ovarian cancer, many women choose to 
undergo genetic testing before a diagnosis of either breast or ovarian cancer. When a 
woman tests positive for a BRCA mutation, she is faced with complex decisions 
regarding follow-up screening and surveillance or prophylactic surgical options. After 
learning about her positive BRCA result, one woman was quoted to say; “It felt as if 
there was a time bomb ticking away inside of me” (Andrews, 2001). Many other women 
who tested positive for BRCA 1 mutation reported experiencing psychological distress 
(Andrews, 2001). The diagnosis of HBOC creates a heavy emotional burden for women 
who are in their 20s and 30s, given the decisions young women are forced to deal with, 
such as whether to undergo risk-reduction surgery, or more frequent screening. Both 
options are likely to result in more stress and worry. Many women in their 20s or 30s 
have not yet married, and a positive BRCA result can cause additional complications with 
dating and finding a partner who will accept them despite their “genetic imperfections.” 
Additionally, women who carry a BRCA mutation are recommended to undergo a 
preventative oophorectomy in their 40s (Barnes-Kedar & Plon, 2002) which further 
complicates decisions about whether to have children.   
 Shortly after the BRCA 1 gene was cloned, the NIH recommended genetic testing 
for HBOC is offered only under strict research protocols before allowing the test to 
become available in the clinical setting. It should be noted that this reaction to requiring 
that informed consent protocols be developed in the research setting before offering 
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genetic testing in clinical care, occurred in response to the development of most new 
types of genetic tests, such as Huntington’s Disease, cystic fibrosis and now whole 
genome/exome sequencing. The NIH funded several studies in 1994 to investigate the 
ethical and psychological implications of cancer predisposition testing. A group of 
investigators established a task force to better understand the issues related to informed 
consent, both in the research and clinical arena for HBOC (Geller, Botkin, et al., 1997). 
The publications summarizing the findings from these research studies recommended the 
informed consent process include a discussion about women’s personal beliefs and 
understanding of cancer. 
A truly informed patient, according to a summary of several focus groups whose 
purpose was to assess women’s attitudes towards informed consent protocols for BRCA 1 
testing, should incorporate an assessment of women’s perceptions about breast cancer 
risks, causes and treatment for cancer, into the pretest education part of the consent 
process. The individual obtaining consent should clarify any misconceptions women had 
about any issues related to breast cancer as well as incorporate women’s values and 
experiences into the consenting dialogue. In other words, the consenter should ask the 
woman undergoing genetic testing what her understanding is of her risk for being 
diagnosed with breast cancer based on a positive genetic test result and clarify any 
inaccuracies or misconceptions about the accuracy of the test. In addition, a consenter 
should ask the woman undergoing genetic testing how she is feeling about undergoing 
genetic testing and ask the woman to share her experiences with a family member who 
might have been diagnosed with breast cancer and acknowledge her feelings throughout 
the consenting process (Geller, Strauss, & Bernhardt, 1997).   
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 In anticipation of future genetic tests for other hereditary cancer syndromes and 
other adult onset genetic disorders, the informed consent protocols for HBOC were 
written as a model for informed consent protocols for other types of hereditary cancer 
syndromes. The central components of informed consent for hereditary cancer syndromes 
were published in the Journal of the American Medical Association in 1997 and include a 
discussion about; “the purpose of the test (including testing which is part of a research 
protocol), costs, turnaround time, and documentation of results, the predictive value of a 
positive, negative or indeterminate result, and corresponding cancer risk information 
(Geller, Botkin, et al., 1997).” Implications for possible cancer treatment and protocols 
for cancer screening and management if the test were positive, negative or indeterminate 
need to also be reviewed. Possible psychological reactions to the test results and 
implications to family members as well as a discussion about insurance and job 
discrimination concerns and protective legislation for those concerns are components to 
be addressed as well. As is true for all types of medical consent protocols, patients should 
have time to consider their options and be informed of their right to choose not to 
undergo testing as well as to delay testing until a future time (Ensenauer, Michels, & 
Reinke, 2005).  
 The American Society of Clinical Oncology (ASCO) published their 
recommendations for informed consent before ordering genetic testing for HBOC in 1996 
and updated their recommendation in 2003. Both versions are greatly watered down 
when compared to the checklist published in the JAMA article in 1997 as they were 
written to address only the backbone of the informed consent process recommended by 
genetic specialists. ASCO recommends pre- and post-test counseling and suggests the 
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content of these session include a review of the medical options and consequence of test 
results on family members in the pre-test session; and a discussion about recommended 
follow-up and test interpretation in the post-test session (American Society of Clinical 
Oncology, 2003). The ASCO recommendations lack the requirement for detailed 
discussions about the psychosocial and psychological components associated with 
undergoing genetic testing stated in the genetic counseling protocols. This notable void 
creates a tension in the informed consent process for genetic testing between what is 
“minimally required” and what “should” be addressed. Ultimately, the justification for 
what to include while consenting a patient is based on the bias of the professional society 
or organization writing the consenting guidelines.  
 A review of the literature focusing on the rationale for informed consent in 
genetic testing as well as the practice guidelines for how to obtain consent, suggest that 
the methods for obtaining consent vary greatly based on who is performing consent, the 
expertise, experience, and communication style of individuals obtaining consent. Also 
time spent consenting the patient is variable. The reason for this variability is because, 
while multiple published guidelines for what should be discussed during an informed 
consent protocol are available, there is no standardized requirement for how to obtain 
informed consent before genetic or genomic testing. As a result, informed consent can be 
achieved in a conversation between the consenter and the patient in a shared decision-
making format where patients and the consenter engage in a dialogue regarding options 
for testing, implications of testing and a discussion of how the results will affect medical 
care and what psychosocial and psychological consequences the results will have on the 
patient and their relatives. The length of the conversation and extent to which questions 
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are solicited by the consenter varies according to the amount of time allowed for the 
consent process and is largely determined by the consenter. 
 Another method for obtaining informed consent would be to ask a patient to read 
and sign an informed consent form, without engaging the patient in a dialogue and 
allowing time for the patient to ask questions and consider options. The published 
practice guidelines from professional genetics organizations state that written consent is 
not truly informed consent because individuals are not given the opportunity to ask 
questions, and engage in a dialogue about anticipated reaction to a positive or negative 
test result. What confounds the discussion at this point is that, by signing an informed 
consent paper, most institutions have fulfilled their legal obligation to promote patient 
autonomy because these informed consent documents are written to state that the inherent 
risks, benefits and limitations of the recommended test have been reviewed by a 
physician and that the patient has been given a chance to ask questions. Whether or not 
these issues were reviewed by the physician, evidence that informed consent was 
attempted and achieved is illustrated by the signed informed consent form. While a 
signed informed consent form provides a legal documentation that consent was achieved, 
there is no method for determining the degree to which the information was understood 
by the patient. Many laboratories require a signed document when a specimen is 
received, but according to most genetics professionals, this document does not guarantee 
informed consent was successfully obtained (Miesfeldt, Jones, & Cohn, 2000). Neil 
Sharpe is an outspoken critic of written consent. He believes the act of signing a paper 
provides no evidence that the patient has an understanding of the information they 
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received or were given time to ask questions and consider the potential risks and 
consequences of genetic testing (Sharpe, 1994).  
 Despite the criticism from genetic professionals over written consent, medical 
institutions and laboratories require only a signed informed consent form as evidence that 
consent was obtained. A written consent form often serves as documentation that the 
consent process took place and provides the patient with written information about the 
information discussed during the consent process. The tension between fulfilling the 
minimal legal obligations and fulfilling the ethical obligations for informed consent is a 
problem that has existed since the inception of informed consent practices for genetic 
testing in the 1960s.  
 Despite this tension, institutions continue to perpetuate the practice of informed 
consent for genetic testing by using the written consent form to satisfy the legal 
requirements for informing patients. The laboratory that performs genetic testing for 
hereditary breast and ovarian cancer syndrome requires all Medicare patients sign a 
consent form before undergoing genetic testing for BRCA 1 and BRCA 2 mutation 
analysis, but, if the patient is not a Medicare patient, then the informed consent signature 
is optional. The point is, Medicare patients may or may not have undergone genetic 
counseling, or engaged in an in-depth conversation with their physician, but as long as 
they sign the paperwork, their test is processed and paid for by Medicare. The same 
policy is in place for the commercial labs offering genetic testing for Huntington’s 
disease. As long as the laboratory receives a signed informed consent document which 
states that the patient was offered genetic counseling and had an opportunity to have their 
questions answered before undergoing testing and acknowledge that the test is optional, 
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the test will be completed and results will be reported back to the ordering physician. 
Therefore, institutions offering genetic testing through a clinical practice defer to the 
laboratory conducting genetic testing to fulfill the legal obligation that consent was 
obtained.  
 The laboratories, in turn, trust that physicians have fulfilled their obligations for 
consenting a patient and can be entrusted to provide the appropriate follow-up counseling 
and recommendations once the results are returned from the lab. Medical institutions 
assume their physicians are competent and adequately trained in the area of genetics to 
provide consent. While informed consent documents must be scanned and recorded into 
the medical records before a surgery or minor medical procedure, there are no legal 
requirements for such documentation for the medical institutions that offer genetic 
testing. This legal requirement is mitigated by the fact that the laboratories where their 
patient samples are sent are obligated to fulfill the legal obligation of ensuring patients 
fully understand the ramifications of undergoing genetic testing vis-a-vis the signed 
informed consent document that accompanies the patient’s sample.   
 Returning again to the case of our couple, Bill and Melinda, for whether legally 
informed consent was obtained. The laboratory met their legal obligations by providing a 
written consent document. The form states that WGS results might benefit healthcare 
decisions and that it might not benefit health care decisions, but no specific examples 
relevant to this couple are provided. The consent form also states results from WGS are 
similar to all other types of genetic tests, in that genomic results might have 
consequences to family members. Again, no global, hypothetical examples are provided 
on the form, or examples relevant to Bill and Melinda specifically. The possibility that 
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genomic information could lead to insurance, job or other types of discrimination is 
mentioned on the form, but, for details, the form states individuals should contact their 
physician or a genetic counselor. 
 Ethically, can it be argued that informed consent was obtained? The answer to this 
question ultimately depends on how medical professionals define their ethical obligations 
for obtaining informed consent. Some would argue that the ethical requirements of 
informed consent were appropriately met assuming the written consent explicitly 
reviewed the options for learning results and by stating that this type of testing is 
voluntary. Others would argue that to fulfill the ethical obligations of informed consent, 
the consenting process should be completed within a conversation between the consenter 
and the individual. A major component of the genetic counseling practice is an informed 
consent dialogue. If individuals are not referred for genetic counseling before undergoing 
genetic testing, it does not represent a violation of the legal requirement for informed 
consent.  
 The ethical obligation for a medical institution or laboratory to ensure that 
informed consent is obtained is, in reality, a conceptual ideal. The ideal consenting 
process is what is described in the literature through practice guidelines and professional 
recommendations. The oral consent process for genetic counseling is both well described 
and delineated in the literature. Professional training in the practice of genetic counseling 
is available as well as board certification requirements. There are however, no legal or 
ethical obligations for institutions to employee genetic counselors as the designated 
medical professional capable of performing informed consent and no legal obligation to 
guarantee those providing consent are competent. Despite published findings that the 
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most effective form of informed consent for genetic testing is that of an oral consent 
process (Burgess, 2001), there are no legal implications if genetic counseling is not made 
available to individuals undergoing genetic testing. As a result, the informed consent 
process prior to undergoing genetic testing including the extent of a consent conversation 
before undergoing genetic testing is highly variable between institutions and between 
laboratories. 
Analysis of Informed Consent Practices in Medical Genetics  
 
 Since the inception of the legal requirement for informed consent in medical care, 
the informed consent process has been criticized as largely ineffective and more of 
burden to patient care than a benefit. Empirical research and clinical observations have 
reported that the informed consent process is an empty ritual where patients are given 
complex information they cannot understand and which ultimately does not impact their 
decision making process (Lidz, Applebaum, & Meisel, 1998). Physicians have expressed 
their frustration over the informed consent model and report that it is a waste of their 
valuable time. Further, many physicians believe that the consenting process produces the 
opposite outcome it is intended to in that patients ultimately make the wrong decisions 
surrounding their medical care (Lidz et al., 1998). 
 As Laura Stark points out, the Salgo case had only a symbolic effect on doctors’ 
practices. She also alludes to the fact that in medical research, the institutionalization of 
the IRB process has perpetuated practices that change little over time because these 
practices came to be intuitive to their participants and required less justification and 
explanation over time (Stark, 2012). As I describe in the next several pages, this 
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explanation is similar to the explanation for why informed consent practices fail in 
clinical care as well, linking the two practices of informed consent together.  
 Informed consent practices for genetic testing have also been criticized for a 
variety of reasons. The ineffectiveness of an informed consent process for genetic testing 
has been blamed on the following issues: physician lack of knowledge and understanding 
about genetic diseases and risk probability, and likewise, inability for many patients to be 
able to understand risk information and apply statistical data to their own situation, 
especially while experiencing emotions associated with learning about the possibility of 
being diagnosed with a hereditary condition. Melinda’s emotional reaction to her 
genomic test results is a good example. She was so overwhelmed with the fear that she 
might die from the same disease as her father, and with feelings of guilt over possibly 
passing on her mutations to her baby, that she had a difficult time coping and 
understanding the data presented in her genomic sequencing report. Melinda would have 
benefited from the opportunity to talk with someone during the informed consent session 
before deciding to undergo genome sequencing, about her fears that she might someday 
be affected with the same illness as her father, or pass along this genetic condition to her 
own children. The idea is that if she had an opportunity to express her concerns and fears 
before she learned her test results, she would have either been more prepared to hear the 
information, or she might have elected not to undergo genome sequencing at all. Finally, 
individuals vary in the ways in which they learn and communicate.  
 The reason that physicians and medical providers are blamed for the failure of the 
informed consent process for genetic testing is because several studies published on 
providers’ knowledge about genetic disease, report that many physicians struggle with 
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understanding risk assessment and probability (Kegley, 2003)(Miesfeldt et al., 2000). The 
uncertainty in understanding and interpreting genetic test data often results in clinicians 
purposefully avoiding the discussion about important probabilities on the accuracy of the 
test or risk for a genetic disease (Metcalfe, Hurworth, Newstead, & Robins, 2002). In 
addition, incorrect information may be communicated to their patients about the genetic 
test results. One study reporting on the use and interpretation of genetic testing for 
familial adenomatous polyposis (FAP), an autosomal dominant hereditary colon cancer 
syndrome, concluded that 20% of physicians erroneously ordered genetic testing for this 
condition. Their findings also indicated that physicians misinterpreted the results in 
31.6% of the cases (Giardiello, Brensinger, Peterson, Luce, & Hylind, 1997). In addition, 
physicians are criticized for not recognizing the standards of communication and 
counseling that are components of the informed consent process for genetic testing 
(Sharpe, 1997).  
 The National Coalition for Health Professional Education in Genetics developed a 
document on Core Competencies in Genetics for Health Professionals in 2007 (National 
Coalition for Health Professionals Education in Genetics, 2007). This document provides 
a comprehensive coverage of the necessary knowledge base a medical professional 
should have in genetics, however no mechanism is in place in our health care system to 
evaluate clinicians on their understanding and use of such competencies in everyday 
practice. As with published informed consent models, the written requirements for 
establishing competency do nothing for determining the level of competency of a 
provider consenting patient. There are also competencies written for medical geneticists 
and genetic counselors. The American Board of Medical Genetics (ABMG) requires that 
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physicians, PhD geneticists, as well as genetic counselors, master the communication 
skills necessary to; “elicit necessary information from the patient or family to reach an 
appropriate conclusion; “and “transmit pertinent information effectively, i.e., in a way 
that is meaningful to the individual or family (American Board of Medical Genetics, Inc, 
1992). In addition, the ABMG, the Royal College of Physicians and Surgeons of Canada 
issue similar standards of care in medical genetics (Royal College of Physicians and 
Surgeons of Canada, 1992). These competencies and certification requirements do not 
guarantee the medical provider is capable of fulfilling these obligations, or even more 
concerning, that a medical provider is willing to fulfill his professional obligation to 
provide informed consent.  
 A consequence of the fact that physicians are critical of the informed consent 
process is that they do not respect the very process they are obligated to perform. This 
results in a consenting process that is often overlooked, abbreviated or performed 
incorrectly. In most cases, the act of consenting a patient occurs just before a blood or 
tissue or saliva sample from the patient is collected (Lidz, 1983). At this point, the 
decision to undergo genetic testing has already been made and the consenting process 
becomes just a formality. The responsibility for who should be consenting a patient is 
often not even considered since the signed consent form is all that is required to meet the 
legal and ethical obligations to verify consent was obtained. The exception to this 
situation is when a patient undergoes genetic counseling during which a formal informed 
consent process occurs. Outside of a designated genetic counseling consult, there is no 
consistently established time or “space” for consenting to occur before most patients 
undergo genetic testing. 
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 A similar concern surrounding the effectiveness of the informed consent process 
for genetic testing is whether the patient understands the information provided to them. 
Research studies have reported that patients struggle with understanding genetic terms 
and risk information (Robert Klitzman, 2010). This fact places additional requirements 
on the consenters, who need to have the necessary expertise in genetics and an 
understanding themselves of the medical and psychological implications of a genetic 
condition, to be capable of explaining the information in a meaningful way to the patient. 
Variability of patient comprehension of science and mathematical probabilities requires a 
stratification of the scientific and mathematical information presented during informed 
consent sessions.  
 Another significant challenge to the informed consent process from the patient 
perspective is the fact that individuals vary considerably regarding their interest in 
learning about their own genetic makeup, along with how they respond to a positive or 
negative test result. Patients also differ widely for learning preferences and likewise, how 
they incorporate complex information into their lives and derive meaning from such 
information. Some researchers therefore advocate for the inclusion of individual 
decision-making styles into the design of informed consent protocols (Ormond et al., 
2007).  
 The criticism of the informed consent process in medical care and genetic testing, 
stems from the inability to apply a legal doctrine onto a constantly evolving, interactive 
and complex medical decision making process that occurs when deciding whether or not 
to undergo genetic testing. Our current informed consent protocols provide no ability to 
factor in the inherent trait of uncertainty present in daily medical care into the model. 
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Katz has written, “The prevailing climate of professional conduct is first to pay lip 
service to uncertainty and then to proceed, while interacting with self and patients, as if 
uncertainty did not exist “ (Plaut, 1989). Genetic testing and the subsequent test results 
have an inherent component of uncertainty and whole genome sequencing is sure to offer 
more uncertainty than actionable and interpretable knowledge.  
 Other reasons the informed consent process for genetic testing has been found to 
be ineffective is the overwhelming burden for some when learning new statistical risks, 
while experiencing a range of emotions in response to the scientific information. Multiple 
studies report how patients are unable to correctly interpret and apply risk information to 
their own situation (Miesfeldt et al., 2000). The psychological implications of learning 
about a genetic diagnosis, confounds the ability to correctly understand and act upon risk 
information provided during pre-test genetic counseling. 21% to 75% of individuals do 
not remember or understand the information they received following a content-only 
orientated counseling session (Kessler, 1979). Therefore, for informed consent to be 
successful, many argue that medical providers or those providing the consent need to 
address the emotional issues when providing statistics and information about genetic 
conditions (Robert Klitzman, 2010).  
 I, along with others, blame the ineffectiveness of the informed consent process in 
both medical decision making and informed consent practices for genetic testing, on the 
fact that the informed consent mandate is being perpetuated as a legal doctrine based on 
underlying legal requirements, with no relevance to the realities of medical decision 
making (Lidz, 1983). The medical care of a patient, especially when considering a 
complex test such as whole genome sequencing is constantly changing and evolving. 
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Multiple decisions are required over time in patient care, but the process of informed 
consent was established as an event that occurs in one visit. Even some lawyers have 
agreed with this criticism arguing that despite the fact promoting patient autonomy was 
the driver for writing informed consent, the legal framework of the protocols fails to 
encourage individual values of patients (Goldstein, 2010). A member of Duke 
University’s institutional review board summarized the current status of the informed 
consent in medical research in a recent Nature article; “Institutions use informed consent 
to mitigate their own liability and to tell research participants about all the things they 
cannot have, and all the ways they can’t be involved (Hayden, 2012b).”  
 Is there really any way to measure the effectiveness of informed consent? What 
would be the outcome that would signify a successful consent process? Consider the fact 
that one woman who tested positive for a BRCA 1 mutation elected to undergo bilateral 
mastectomies to reduce her risk for developing breast cancer. Following her surgery she 
said, “I had wonderful counseling beforehand but nothing prepared me for the feeling of 
loss [and] of mutilation. A woman’s breasts are very much tied up with the image she has 
of herself and however perfect the reconstruction you are aware they are not your own. It 
was far more emotionally traumatic than I had expected” (Andrews, 2001). This scenario 
really begs the question, is any form of consenting really capable of fully preparing 
patients for possible emotional responses to a positive genetic test result and the 
consequences on their lives?  
 Many believe there is no real medical benefit that can be measured from the 
informed consent process of genetic testing given the very fact that the testing is designed 
to determine whether someone will be affected with a hereditary disorder that cannot be 
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cured. Therefore, the effectiveness of the informed consent process in research studies 
has focused more on the psychological outcomes following genetic testing. A Canadian 
study on the effectiveness of the pre- and post-test genetic counseling sessions before 
Huntington’s disease genetic testing, reported positive outcomes from the patients who 
underwent testing through this protocol. The positive findings included increased patient 
autonomy and improved emotional welfare (Burgess, 2001). Overall benefit reported 
from a thorough informed consent process for genetic testing are: increased sense of 
empowerment, improved understanding of a medical condition, and a sense of having 
more choices (Burgess, 2001).  
 Genetics professionals advocate for informed consent protocols that focus on the 
psychological consequences of a genetic diagnosis. They believe that if these issues are 
addressed appropriately, the medical provider has the possibility to intervene if necessary 
when someone is not adjusting appropriately to the information, and in turn positively 
encourage the individual as they adjust to the risk for or diagnosis of a genetic condition 
(B. Biesecker & Erby, 2008) (Robert Klitzman, 2010). 
 The precise nature of an effective informed consent process is difficult to define, 
as the goals of consenting are really determined by the individual who is undergoing 
consent. In other words, the consent process was designed on the principle of autonomy; 
every person has his own personal manner of dealing with a medical diagnosis and 
recommended treatment, etc. While a particular treatment plan might be based on 
standardized protocols, the reaction to the treatment plan will vary from patient to patient, 
thus the rationale for why informed consent was implemented into medical care. In 
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chapter five, I describe an informed consent process that is capable of responding to an 
individual’s goals for undergoing WGS/WES.  
 In the meantime, the effectiveness of informed consent practices in medical 
genetics, as with other medical specialties, is legally achieved by a signed informed 
consent document. This signed form represents the minimal requirement of informed 
consent practices in clinical care and neither guarantees that consent was adequately 
obtained, nor that a conversation occurred between the consenter and the individual 
undergoing testing. The institutional requirement that a signed informed consent 
document is all that is necessary to demonstrate consent is achieved, when in fact a large 
part of the consent process is neglected, follows the pattern established with the creation 
of informed consent practices in medical care and medical research just reviewed in 
chapter two. This is the reason the practice continues to perpetuate without consideration 
of whether the practice of informed consent meets the ethical obligations it was written 
for.   
 As illustrated throughout this chapter, a signed informed consent form is not 
evidence the ethical obligations of promoting patient autonomy and informed decision 
making are accomplished. The next chapter describes how a more complex type of 
genetic test (WGS/WES) further challenges the already ineffective practice of informed 
consent. After reviewing the complexities of WGS/WES, I describe the proposed and 
current informed consent practices for WGS/WES and assess whether they achieve the 
ethical obligations of informed consent.  
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CHAPTER 4 
HOW WGS/WES TECHNOLOGIES CHALLENGE EXISTING INFORMED 
CONSENT PROTOCOLS FOR GENETIC TESTING 
As a more sophisticated understanding of single gene disorders was elucidated, scientists 
began to suspect complex genetic contributions to common diseases, such as 
cardiovascular disease, diabetes and cancer (Mueller & Young, 2001). The traditional 
assumption that genetics was a rare specialty in medicine began to fade as researchers 
started to identify underlying genetic etiologies for most common diseases. In 1987, the 
term “genomics” was coined and defined as: “the study of the functions and interactions 
of all the genes in the genome (Guttmacher & Collins, 2002)”. The new appreciation of a 
genomic contribution to disease became the driver and rational for mapping a human 
genome. In 1988 the U.S. National Research Council of the U.S. National Academy of 
Sciences announced their support of a 15-year project to map the human genome to better 
understand and treat all diseases. The official funding for the Human Genome Project 
began in 1990 with an astounding budget of $200 million a year (Collins, Morgan, & 
Patrinos, 2003).  
 The Human Genome Project was completed ahead of schedule, and under budget 
with a total cost of three billion dollars (Collins et al., 2003). The reason for a more 
timely completion of the project was because of advances made in DNA sequencing 
techniques. DNA sequencing is the name of the technology used to sequence a DNA 
molecule and can be described in three simple steps: 1. Sample preparation: 2. Physical 
sequencing: and 3. Re-assembly of the sequenced DNA (Schadt, Turner, & Kassarskis, 
2010). To better manage the 3.2 billion base pairs found on a single strand of DNA, the 
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first step in the sequencing process is to break up sections of the genome into multiple 
fragments that are more manageable for the process of sequencing. In many cases, these 
fragments are copied multiple times to have enough DNA sample to complete the 
sequencing steps. During the second step of the process, physical sequencing, each base 
pair of the fragment is read, one at a time. A read length is defined as the number of bases 
in a specific fragment. The third step in the process of sequencing is reassembly of the 
fragments creating a contiguous sequence of base pairs representing an individual 
genome. Bioinformatics software is a critical component of the reassembly process 
because it helps identify where to align overlapping reads.  
 The first generation of sequencing technology was developed by Frederick Sanger 
in 1975 and is known as the Sanger method or the chain-termination method (Schadt et 
al., 2010). The Sanger method was performed manually when the Human Genome 
Project began, but became automated during the project, which allowed for a more 
efficient and less expensive endeavor. Despite these advances, first generation 
sequencing is still more costly than current technology and is only able to produce read 
lengths between 800 and 1,000 bases (Meyerson, Gabriel, & Getz, 2010). In 2003, 
marking the fiftieth anniversary of Watson and Crick’s publication on the structure of the 
DNA helix, Francis Collins and Craig Venter announced the completion of the first draft 
of a complete human genome (E. Green & Guyer, 2011). Seven years after the 
completion of the human genome project, the online version of Mendelian Inheritance of 
Man (OMIM), reported over 20,000 entries of genetic conditions (McKusick, 2013).  
The ultimate benefit to humankind from mapping the human genome through the 
Human Genome Project was to fulfill the promise of individualized medicine. 
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Individualized medicine is defined as the ability to; tailor treatments for individual 
patients based on their own genomic profile; more accurately predict genetic risk factors 
for common diseases such as heart disease, cancer, diabetes and others; better understand 
individual susceptibility or response to infectious diseases and; determine the etiology for 
hereditary disorders with a known mendelian inheritance pattern, but a yet elusive genetic 
cause (Drmanac, 2011).  
 Once a complete human genome was mapped, these initial promises (many of 
which were published before the completion of the Human Genome Project) were still 
only promises. In reality, the hard work had just begun. That is, understanding the 
meaning of the sequence of our 3.2 billion base pairs and the function of the approximate 
50,000 genes (now believed to be roughly 22,000 genes) and the biologic pathways of 
gene-gene and gene-environment interactions (Collins et al., 2003).   
 After sequencing a genome, the 3.2 billion base pairs need to be read, aligned and 
interpreted. The sequencing platforms produce a series of bases (A, T, C and G), also 
described as nucleotide reads which are reported, but just reporting a large number of 
base pairs is not informative. The data needs to be interpreted. The first step of data 
interpretation incorporates computational software programs which both instructs the 
laboratory where and how to string together the nucleotide bases. A gene is a series of 
bases strung together. Mutations are identified when the software detects a nucleotide 
that is out of order from what is expected, based on the template produced from the 
Human Genome Project.  
 Once the template is constructed, laboratories apply various types of 
bioinformatics software programs to each genome to identify variants or mutations. The 
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type of variant identified is based on the choice of the software analysis program and 
what kinds of variants the software is programed to identify. For example, if an 
individual was aware of a strong family history of colon cancer, the lab could then sort 
that person’s genome data for the known variants associated with a hereditary colon 
cancer syndrome. Identifying the variants that cause a more common disease, such as 
heart disease or diabetes is a much more complicated process, because many of these 
variants have not been identified yet, and those that have been identified, may not confer 
a very strong association to a disease. In addition, variants suspected of being associated 
with a common disease have to be validated through numerous studies to convince 
scientists of its association. Whenever a suspected variant within a gene is identified, 
validation studies are performed to essentially prove that the variant is disease causing, 
versus a normal alteration, known as a polymorphism. From a biological standpoint, the 
progression of common disease is complicated by the fact that there are environmental 
factors and gene-gene interactions that work together to cause a disease (Cirulli & 
Goldstein, 2010). This type of data interpretation and the identification of rare variants 
that are less well defined complicate the process of reporting these findings. 
 Francis Collins and two other leaders of the Human Genome Project published an 
article in Science just after the announcement of the completion of the human genome 
mapping. This article urged biologists, leaders in science and academia, leaders in 
societies all over the worlds, as well as industry representatives, to collaborate in efforts 
to understand the data produced from the Human Genome Project and translate this 
information in a clinically applicable and useful manner (Collins et al., 2003). 
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 In the year 2013, just ten years after the completion of the Human Genome 
Project, the medical community is introducing genome sequencing into patient care with 
great vigor. Despite this enthusiasm, many still argue that the promises widely published 
on the benefits of mapping our individual genomes are still just promises, with little 
practical implications at this time (Offit, 2008). Ignoring the naysayers, with the hope that 
whole genome sequencing will improve patient care, institutions around the world are 
becoming entranced with the possibilities of this sexy new sequencing. Whole genome 
sequencing and whole exome sequencing are currently offered in clinical settings at 
institutions across the world and incorporated into many research protocols. While the 
complete map of a human genome opened a window for the future utilization of WGS, 
second-generation sequencing, also referred to as next-generation sequencing, has 
essentially opened the door for wide access to WGS and WES.  
 Second-generation sequencing technologies apply the same steps in the DNA 
sequencing process as first-generation sequencing technology. The major differences 
between the two generations of sequencing technologies are accuracy, efficiency and cost 
(Meyerson et al., 2010). Second-generation sequencing became available in 2005 and 
consists of several different platforms (or methods), offered by various commercial 
laboratories. There are minor differences between each platform concerning the 
technology, but fundamentally, the outcomes are similar. Second-generation sequencing 
is more accurate than first generation sequencing because the process is digital, compared 
to the analogue approach of first-generation sequencing (Meyerson et al., 2010). This 
digital component of the sequencing technology allows for the ability to over-sample the 
genome, also known as coverage depth. The more times the sequencer reads a particular 
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section of the genome, the more accurate the results because experimental noise can be 
eliminated, resulting in easier detection of genetic mutations (Meyerson et al., 2010).  
 Second-generation sequencing platforms provide a higher throughput than first-
generation technology as larger numbers of DNA strands are sequenced in parallel. Some 
sequencing machines are reported to generate more than 300 gigabases of DNA in a 
single run (Schadt et al., 2010). This greater efficiency drives down the cost of 
sequencing as well. With first-generation sequencing used to map the human genome, it 
cost $100,000 to sequence 1 million bases. Comparatively, it costs less than $1 to 
sequence 1 million bases using second-generation sequencing (Lifton, 2010). Many 
journal articles as well as articles in the lay press, have predicted the $1,000 and $100 
genomes in the not too-distant future (Robertson, 2003) (Zimmerman, 2013). Today, it is 
estimated to cost between $24,000-$9,500 to sequence an entire genome in a clinical 
laboratory (Bick et al., 2013). This amount includes the cost required to run the 
sequencers as well as the cost for data interpretation. It should be noted that because 
WES is a more targeted approach sequencing only the protein-encoding exons of 
approximately 22,000 genes, as compared to sequencing the majority of the 3.2 billion 
base pairs in a genome, WES is less labor-intensive, and correspondingly less expensive 
than WGS, with the estimated cost of $4,000 (Lifton, 2010). In addition, there are 
predictions of third-generation sequencing, which will improve both accuracy and 
efficiency of sequencing as well as make the process even cheaper than second-
generation platforms (Schadt et al., 2010).   
 Whole genome and whole exome sequencing are used in clinical care today in 
medical oncology, pediatric and adult genetics clinics and in select internal medicine 
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clinics, for healthy patients who are interested in learning about future disease risks. The 
medical benefits from undergoing WGS/WES, is in a large part, determined by the 
indication for why an individual is undergoing the sequencing. In the case of medical 
oncology, the benefits for a patient with advanced cancer is to learn about a possible 
chemotherapy regimen that would target cancer cells and hopefully result in remission of 
their disease. For the child or adult with an unknown genetic condition, WGS/WES might 
identify the underlying genetic mutation responsible for a disease, but finding the genetic 
mutation responsible for the condition, often does not lead to a treatment option. Finally, 
for the healthy patient, the results from genome sequencing might provide information 
about possible risk factors for a hereditary or common disease. The hope is that this 
genomic information might be actionable, that is, lead to a possible preventive treatment, 
and avoid being affected with the disease.  
 As was initially predicted, the first area in medicine where WGS/WES is 
clinically applied to patient care is in the field of oncology (Pasche & Absher, 2011). 
Even before WGS/WES was available for oncology care, using single gene testing, 
researchers had identified mutations occurring in common cancers which can then be 
targeted with specific chemotherapy agents designed to destroy specific types of cancer 
cells based on the genetic profile of cancer cells. Several treatment regiments in clinical 
oncology practice are available now which are targeted to a specific genetic mutation 
expressed in the tumor tissue. One example is the use of trastuzumab to treat women with 
breast cancers that over-express a protein from the proto-oncogene HER-2/new (Hudson, 
2011). Trastuzumab works as an anti-HER-2 antibody, blocking the expression of the 
HER-2/neu protein, resulting in decreasing the risk of recurrence of breast cancer (Ross 
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& Fletcher, 1998). While this is a good illustration of personalized medicine, I want to 
note that this and other examples of targeted therapies for specific forms of cancer are 
based on a single gene mutation identified in a tumor genome. The differences between 
the application of this type of treatment and whole genome sequencing is that there is 
much more data generated on the tumor genome with WGS/WES and the fact that 
patients germline genome is also sequenced which is considered by most to be 
“incidental” data.  
 Since 2010, many large academic cancer centers all over the world have been 
offering whole genome tumor sequencing for individuals with metastatic cancer (Hudson, 
2011). The knowledge that cancer is caused by a series of mutations that diverge from a 
normal germline cell, establishes cancer as an ideal disease model to determine how 
useful whole genome sequencing will be for treating a disease for which a cure has long 
eluded scientists. The side-by side comparison of the cancer genome to the germline 
genome allows researchers the ability to detect multiple types of genomic alterations: 
single nucleotide substitutions, chromosomal rearrangements, and copy number repeats, 
all of which have a role in cancer initiation and progression (Meyerson et al., 2010). 
Expanding our understanding of additional molecular processes of cancer development 
and metastasis will enable researchers to improve tumor diagnosis and classification 
techniques and subsequent treatment protocols (Drmanac, 2011).  
 There are some successes reported in the literature demonstrating how sequencing 
patient’s tumor and germline informed the treating oncologists of a more effective and 
novel treatment option. The number of patients however who are benefiting from this 
sequencing technology, is still fewer than a hundred reported in the literature (Welch & 
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Link, 2011). Understandably this number is small in large part because the technology 
has only been available for several years, so with time, it is expected that more success 
stories will be published. In the meantime, most patients, after learning about the great 
promise of WGS/WES, are willing to make the emotional and financial investment and 
face the uncertainty of whether there will be any clinical benefits from undergoing 
sequencing, for the chance to extend their life, if even by only several years. Many cancer 
patients who undergo WGS/WES even state that, if they cannot benefit from the test, they 
are willing to pay the expense and risk the disappointment of a uninformative result, if 
the data produced on their own tumor genome sequencing might help researchers better 
understand their particular type of cancer and how to more effectively combat their 
disease for the benefit of other patients who have their same type of cancer.  
 Along with important information about the tumor genome, cancer patients who 
undergo WES/WGS may learn they carry a variant of mutation for a hereditary disease. 
Because the germline genome is sequenced alongside the cancer genome, laboratories are 
able to analyze the patient’s inherited information to determine if the patient may be 
carrying a mutation that could predispose them for other diseases. WGS/WES will also 
identify many variants of uncertain clinical significance. These variants may or may not 
have any proven disease association and others may have some potential associations to 
common diseases. It can be argued that cancer patients, while not seeking WGS/WES to 
learn about hereditary disease, may benefit from this information because these 
conditions also have implications for their relatives. Most patients, when learning this 
possibility, are excited about the possibility to benefit their relatives and want to be 
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informed of possibly hereditary risk factors identified from sequencing their germline 
data. 
 Demand for WGS/WES is going to increase. The reason many physicians will be 
pursuing WGS/WES for their patients is not just because the cost of performing the 
sequencing is decreasing. The demand will be driven by the possibility that WGS/WES 
might provide missing data about a patient that will dramatically improve their patient’s 
health condition, either with a more effective treatment or even an allusive cure for a rare 
disease. In other cases, the possibilities of WGS/WES are not as ambitious as improved 
treatments, but simple. Some families who have a child affected with a rare genetic 
disorder want to understand the cause of the disease; they need an explanation. As 
WGS/WES becomes mainstreamed into medicine, I anticipate this technology will also 
be very popular amongst a subset of the healthy population who will be keen on learning 
about possible risk factors facing them in the future, and even risk factors for their unborn 
children.  
 Many of these scenarios have yet to be fully realized, so instead I want to focus 
on the practical benefits of WGS/WES that can be appreciated today. Bill and Melinda’s 
case nicely illustrates some of the benefits from WGS/WES. Both Bill and Melinda might 
benefit from knowing about several genetic risk factors all at once and furthermore, be 
able to act on any of those risk factors promptly. For example, when Melinda received 
her results, she immediately sought out more information about familial amyloidosis, and 
since she was already early in her pregnancy when she received her results, she was 
aware of the risk to pass this condition to her future offspring. Also, since both Bill and 
Melinda were carriers for cystic fibrosis, immediately they knew there would be a 25% 
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chance to have a child affected with cystic fibrosis. Knowing these risk factors early in 
the pregnancy give Bill and Melinda options to pursue prenatal diagnosis during the 
pregnancy if they were interested. Even if they were not interested in pursuing prenatal 
testing, the knowledge that their child may be born with cystic fibrosis might help them 
feel more empowered and help them prepare for caring for a child affected with a 
hereditary condition.  
 Another immediate benefit garnered from Bill’s WGS experiment with his wife, 
was an ability to improve their current health status. Melinda shared her drug metabolism 
profile with her psychiatrist who was able to alter her antidepressant dose, which resulted 
in a more effective response to the medication and improvement to her overall quality of 
life. Pharmacogenomics profiles obtained with WGS/WES is one of the most concrete 
examples of personalized medicine. Physicians can tailor the class of medication and the 
amount to prescribe, based on the patient’s ability to metabolize the medication, 
identified by mapping the various genetic variants we carry in genes that metabolize 
common medications. 
 Bill’s WGS results indicate that he is at an increased risk for prostate cancer. 
While he was found to carry a gene alteration with only a modest risk for prostate cancer, 
Bill could seek out early prostate cancer screening and at least discuss his screening 
options further with his physician. Bill might have felt more empowered with this 
information since he had already suspected he was at a higher risk, and this test just 
verified what he had suspected. In the case of our couple, WGS fulfilled some of the 
promises the technology offers; personalized medicine, disease prevention and improved 
overall health status. This scenario of course, represents the most optimal utilization of 
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WGS for a healthy couple, but most certainly, there are many unknown variables arising 
from the complexities of WGS/WES.  
 The complexities of WGS/WES resulting in several unknown variables include; 
how to analyze, report on, and store the large volume of data produced from sequencing a 
genome; the unknown analytic validity of the data analysis component of WGS/WES; the 
uncertainty of how to adequately interpret genomic data (for example, variants of 
uncertain clinical significance); how to apply genomic results to patients existing medical 
care; and; how to contact patients with updated genomic information? 
 The enormity of genomic data produced from WES/WGS is at the heart of the 
dichotomy of this technology. The ability to produce large volumes of data predicting 
individuals’ potential disease risk factors is what associates WGS/WES to its promises. 
Yet, the overwhelming volume of data is also what defines the current limitations and 
complexities of how to use the data in a clinically relevant manner. Determining a 
context for undergoing WGS/WES, based on the clinical situation of an individual, is one 
approach to managing the data and has even been proposed as a solution for how to 
manage the complexities of WGS/WES (Berg, Khoury, & Evans, 2011). This approach 
will be discussed in the second half of this chapter when I review proposed informed 
consent protocols for WGS/WES.  
 The sheer volume of data produced from WGS/WES leads to several inter-related 
complexities described in the following five paragraphs. The volume of data produced 
from WGS/WES is perhaps the most complicating factor inherent to the sequencing 
process. One dilemma from producing large amounts of data, is how or whether to report 
on the numerous variants that are detected when sequencing a genome? Approximately 
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20,000-100,000 variants could be reported with every genome sequenced (E. Green, 
2013). Thousands of variants will be reported which have clinical validity but limited 
actionability and only approximately ten to hundreds of variants with clinical 
actionability are expected to be reported (Berg et al., 2011). Further complicating the 
situation is there is no consensus for how laboratories will report these variants, or 
agreement on how to report them and whether some variants should be reported if they 
are not related to the clinical indication for testing or have unknown clinical utility. 
 The next issue related to variants is the controversy surrounding how laboratories 
report novel variants and variants suspected of being related to a common disorder such 
as cancer. Many rare variants are now believed to be related to some common diseases 
and based on preliminary sequencing data, researchers expect to identify between 
hundreds and thousands of novel variants in every person sequenced (Nelson et al., 
2012). Traditionally, more common variants believed to be associated to common 
diseases were based on the data reported from genome wide association studies (GWAS) 
(Drmanac, 2011) (Cirulli & Goldstein, 2010). While, several direct-to-consumer labs 
were quick to begin reporting disease associations as part of their genomic sequencing 
profiles, academic institutions have been critical of the labs for publishing on a disease 
association prematurely without the necessary science to validate the disease link. There 
is a consensus at this time that to fully appreciate the clinical implications of many of 
these variants, more studies (upwards to sequencing 20,000-100,000 people) needs to be 
completed before being able to fully comprehend the health implications of these rare 
variants, and more common variants, both believed to have a role in common diseases 
(Hayden, 2012a).  
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 With respect to the uncertainty of the analytic validity of WGS/WES, the fact is 
that even though WGS/WES can sequence all 3.2 billion base pairs in the body, it is not 
capable of reporting all types of genetic mutations for all genetic disease described. For 
example, because the sequencers read a genome one base pair at a time, there are entire 
sections of an individual genome that could be deleted or even duplicated, but because 
the end-to-end matching of bases during the process of realigning base reads finds the 
same base pairs around the deletion or duplication that are normally aligned, the 
particular deletion or duplication will not be detected.  
 An example of how WGS/WES cannot detection a genetic disorder is in the case 
of triplet repeat conditions. Huntington’s Disease is a triplet repeat disorder. A triplet 
repeat condition is a genetic disease caused by a sequence of three bases which are 
normally strung together in a series and repeat multiple times, for example, CAG, CAG, 
CAG, etc. Within a normal gene, the three bases are repeated between 10 and 26 times. 
When a mutation occurs, the triplet repeat is expanded beyond 36 repeats (Warby et al., 
2010). WGS/WES is designed to sequence the triple repeats but cannot accurately 
determine how many times these bases are repeated. In order for a patient to learn if they 
carry such a disorder, they will have to undergo more traditional Sanger sequencing (Bick 
et al., 2013). 
 A final example of the unknown accuracy of WGS/WES results is because 
WGS/WES is performed on several different types of sequencing platforms at different 
companies, there is varying depth of read coverage for each genome sequenced. These 
variations will lead to some labs under reporting variants with potential clinical 
implications and other labs over reporting variants with unknown clinical significance. 
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Therefore, the type of sequencing technology chosen adds another layer of uncertainty on 
the accuracy of the reported results (Bick et al., 2013). 
 Moving beyond the uncertainty about the accuracy of the data reported from 
WGS/WES is the issue of the clinical utility of the data. How will genomic results be 
applied to patients’ existing medical care so that the data can be used in a clinically 
meaningful way? There are practical considerations of how to integrate this technology 
into patient care, our current medical model and even into society. All three of these 
issues are still being sorted, as WGS/WES is already available in clinical care today. The 
resolution of some of these practical concerns is important to watch and learn from for 
application to future technologies that will also be producing large volumes of data. Other 
examples of biomedical tests that will produce large amounts of data include proteomics 
(understanding the role of proteins expressed by genes) and applying the science of 
understanding the genomes of our microbiomes, to clinical care.  
 Concerns over data volume and data management resurface when considering 
how the data generated from WGS/WES will be stored. To sequence, analyze and store a 
genome it costs approximately $50,000 a year (Brown, 2011). It is estimated to take 
about 10GB of disc space costing $5,000 a year; sequencing, analyzing and storing a 
genome requires eight medium computers costing $40,000 a year; and 512 GB of 
memory costing about $50,000 a year (Brown, 2011). Technology is moving fast and 
soon chips will be developed to store large volumes of data. Until this occurs however, 
practical limitations are such that if an individual requests his or her raw data, they would 
need to be equipped with enough computers, memory and hard disc space to handle the 
demands of data generated from WGS/WES.  
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  A logical next step when considering how to manage the volume of data 
produced from WGS/WES is how and what type of data should be included in a patient’s 
medical record? Most medical records will be electronic by the year 2015 
(MedicalRecords.com, 2013), so obviously an electronic transfer of genome sequencing 
data would be ideal. The question that needs to be sorted through is what type of genome 
data should be included in a medical record? Should the raw data be available in the 
medical records to facilitate future analysis of the patient’s genome? Due to the 
overwhelming volume of data generated, would this place too much of a burden on the 
health record storage systems? Even more relevant however, is what would a physician 
do with genomic information? Will physicians know or understand how to integrate 
WGS/WES into the patient’s medical care?  
 When planning WGS/WES data storage, data transfer and data management, it is 
important to attend to the privacy and confidentiality concerns of protecting genomic 
information. Downloading a genome sequence into medical records at a hospital or 
physician’s office, cause many to worry about creating opportunities for misuse of the 
information resulting in harm to the patient in some way. The reality is that there have 
been only a handful of cases reported in the literature on a patient who was discriminated 
through loss of health insurance or loss of employment because of a positive genetic test 
result or a genetic diagnosis. The Genetic Information Nondiscrimination Act (GINA) 
was signed into law in 2008 and enacted in 2009 (U.S. Equal Employment Opportunity 
Commission, 2008). This law offers federal protection from discrimination by health 
insurance companies as well as protection from employers who are not permitted to use 
genetic information in the hiring process, or in firing and promotion decisions. While this 
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law alleviates some concerns about discrimination based on genetic test results, many 
physicians still warn their patients before undergoing genetic testing that they might 
experience some type of insurance discrimination after undergoing genetic testing. The 
law does not provide protection from life insurance discrimination, or disability and long 
term care insurance (U.S. Equal Employment Opportunity Commission, 2008). 
 The incorporation of genomic information into patients’ medical records will 
eventually extend beyond a physician’s office. As more facilities standardize medical 
records, patient’s medical information will be transferred electronically across facilities. 
Eventually software will be written which enables WGS/WES data to become imbedded 
into the patient’s medical record so it can be interpreted over a period of several years 
and be incorporated into the patient’s ongoing plan of care. Pharmacogenomics is an area 
in patient care where genomic information is automatically applied to patient’s ongoing 
care. For example, before pharmacies will fill a prescription for a commonly used blood 
thinner, Warfarin, a physician is encouraged to order the CYP2C9 and VKORC1 gene 
analysis to determine how effectively or ineffectively as the case may be, their patient 
will metabolize this medication. This information has proven to be lifesaving in enough 
cases that has become a recommendation by the Food and Drug Administration (FDA 
Center for Drug Evaluation and Research, 2010). I anticipate that this type of information 
about patient responses to treatments will become more widely applied to medical care 
very rapidly. Therefore, in the not too distant future, the data produced from WGS/WES 
will need to be applicable to real time patient care. 
 As data management issues are being sorted, working towards a better 
understanding of the clinical significance of the novel variants now being identified is 
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ongoing. This process is not simple and will not be completed in the next several years. 
To understand the clinical implications of the variants identified, the data analysis of 
variants sequenced from thousands of different individual will need to be reported and 
then compared to one another, to determine the clinical and biological outcomes of the 
variants on individuals in our population. The more individuals who undergo genome 
sequencing, the more data can be collected about the biological and clinical implications 
of the variant (Hayden, 2012a).  
 Collaboration among laboratories, researchers and physicians all over the world is 
necessary to better characterize and classify variants. After all the data has been sorted 
and analyzed, it will hopefully be applied in the manner that it is intended: to predict 
common diseases, to confirm suspected genetic diagnoses in already symptomatic 
patients, to identify novel genetic conditions, and to inform clinicians on more effective 
treatment regimens for patients. Until the time in which the evidence for disease 
association of these variants is confirmed, (and arguably even when this information is 
better characterized) individuals who are considering WGS/WES need to be able to 
understand the information being reported to them. Chapters five and six of this 
dissertation address how I propose to help individuals better understand the current 
limitations of the technology and the current and future implications of the information 
available from the technology. Chapter seven provides a solution for how to incorporate 
WGS/WES into our current medical model.   
 As variants are becoming classified over time, older results generated from 
WGS/WES will soon be outdated. This leads into the complexity of how to contact 
patients with updated genomic information. Some individuals may carry a variant, which 
  83 
will eventually be identified as a disease causing mutation. How will an individual 
undergoing sequencing in 2013 learn about any possible updates to their genomic data in 
a year or two years? Who should be responsible for notifying a patient when a new 
finding with clinical implications is available? Will laboratories require another blood 
sample from the patient or charge the patient for an additional analysis? Currently many 
laboratories are electing not to re-contact the patient with any new information that 
becomes available after the initial results were reported back. Medical geneticists were 
surveyed in 2001 on their opinion of whether it was their responsibility to re-contact a 
patient when new findings were available about a patient’s genetic test result, and they 
ultimately were divided about their duty to re-contact patients. It was concluded that 
while the recommendation to re-contact patients with new findings was ethically 
desirable, it was not a realistic expectation (Pyeritz, 2011). In fact, most laboratories are 
stating this fact in their consent forms so that patients will be informed before initiating 
the test that they will have to request additional sequencing if new information becomes 
available in the future (Ambry Genetics, 2013). This is also the current policy in place for 
all single gene testing performed in a clinical lab. Because of the enormity of genomic 
information analyzed through WGS/WES, I am not convinced the current guidelines and 
policies will be adequate for a test like WGS/WES and will propose an alternative 
solution in chapters six and seven. 
 A related issue, which arises from identifying variants of uncertain significance, is 
the fact that most variants, not already known to be associated with a Mendelian disorder, 
are not enough in of themselves to cause a particular disease. There have already been 
many publications supporting the hypothesis that variants for common disease are 
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influenced by environmental factors and even other genetic variants (gene-gene 
interactions). This type of disease process has long been defined as multifactorial, in 
which there are multiple genetic and environmental components working together to 
cause a disease (Nussbaum et al., 2001). Therefore, researchers working to understand 
the variants will be reporting on the additive effects of multiple causation of a disorder 
over time, as the data generated from sequencing many genomes accumulates. 
Individuals undergoing WGS/WES need to be able to appreciate these complexities when 
receiving their results. In my opinion, a person’s ability to understand of all of these 
complexities regarding the use and interpretation of their own genome data will 
ultimately determine the clinical usefulness of whole genome and exome sequencing.  
 After undergoing WGS Bill and Melinda might be more informed of risk factors 
for future diseases, and the next step would be for both of them to individually 
communicate this information to their physicians. The responsibility for reporting results 
to medical providers may be placed with the individual patient. The medical providers, in 
turn, are responsible for correctly interpreting the results and ordering the necessary 
medical tests and screening procedures. Finally, the individual undergoing WGS/WES 
will need to be diligent in following their physician’s recommendations. These three 
steps encompass the actionability component of WGS/WES. The medical actions 
resulting from WGS/WES results, is what ultimately will translate this sequencing 
technology into successful health outcomes. Data needs to be interpreted and once it is 
interpreted and assuming it was interpreted correctly, the real health outcomes will be 
determined by the combined effort between patients and their physicians. 
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 Bill was reported to have a particular variant in a gene that has been found to be 
associated with an increased risk for prostate cancer. Because he has a family history of 
prostate cancer, Bill, as would most individuals in his situation, associate this result as 
confirmation of what he was already suspecting, and that is he is at an increased risk for 
prostate cancer. The fact that his genome result indicates a possible risk, is not a 
guarantee that Bill will be able to convince his physician that he needs to have more 
frequent prostate cancer screening and needs to start screening at a younger age than his 
counterparts.  
   Assuming Bill could convince his physician that he should undergo prostate 
cancer screening beginning at a younger age and more frequently, previous studies 
assessing behavioral health modification after learning about disease risks, have not 
proved to be optimistic. Most patients were reported to have difficulty implementing the 
necessary lifestyle changes after being counseled about the need to do so to decrease a 
risk for a particular disease. This fact has been one which many critics of WGS/WES 
used to discourage incorporation of personal genome information into patient care. Many 
criticized WGS/WES for not having any clinical relevance to patient care because even 
when aware of disease risk factors, patients have not demonstrated the ability to make 
effective lifestyle changes to modify their disease propensities (Scheuner, Sieverding, & 
Shekelle, 2008). On the other side of the argument are those that criticize WGS/WES 
because this type of information may not be applicable to much of the population, thus 
resulting in minimal impact on improving health outcomes for our health care system 
(Schultz, Caldwell, & Foster, 2003). There has been reported concern about those who 
choose not change a potentially harmful health related lifestyle if their genomic markers 
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suggest no increased genetic risk factors (Sanderson, O’Neill, White, Bepler, & Bastian, 
2009). 
 The layered complexities generated by WGS/WES sum up to a real dilemma for 
how to adequately inform individuals before undergoing WGS/WES. Whole genome 
sequencing produces a significant amount of genetic data and subsequent disease risk 
factors at one time, when compared to traditional genetic testing. Before the availability 
of WGS/WES, healthy individuals curious about their risk factors for a hereditary 
condition had the option to learn about only one hereditary condition at a time (single-
gene testing). Our current informed consent protocols for genetic testing are designed to 
inform patients about implications of learning one disease at a time. WGS/WES moves 
the traditional model of genetic testing from a stepwise approach to the opposite extreme, 
which is to learn about everything possible at one time. There are efficiencies to this 
approach and in the cases where time is of upmost importance, such as a patient with a 
metastatic cancer and no additional treatment options, the advantages of WGS/WES most 
certainly outweigh any potential disadvantages.  
 However, there are additional burdens to the healthcare system expected with the 
implementation of WGS/WES into clinical care. It has been estimated the informed 
consent process for WGS/WES will require 6 hours of face-to-face counseling (Mayer, 
Dimmonck, & Area, 2011). The results disclosure discussion sessions are estimated to 
last 5 hours (Ormond et al., 2010). There are multiple models already proposed for how 
to tackle the multiple complex and heterogenous issues of WGS/WES. Many institutions 
and researchers are investigating the effectiveness of various protocols. Other institutions 
offering WGS/WES on a clinical basis are implementing existing informed consent 
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protocols into the informed consent sessions and prospectively evaluating the outcomes 
and effectiveness of these traditional models. In the next section of this chapter, I will 
outline research and clinical informed consent proposals being proposed for WGS/WES 
and evaluate the potential effectiveness of these protocols at fulfilling the ethical 
obligation of informed consent while also addressing the complexities of WGS/WES. 
 
Informed Consent Proposals for WGS/WES 
 
 Practice guidelines for how to provide informed consent for WGS/WES have not 
been formally published, however there are numerous published recommendations for 
how to approach the complexity of consenting individuals interested in undergoing 
WGS/WES. Following the pattern from all other new genetic tests that become available 
for use in clinical care, for example, Huntington’s disease and cystic fibrosis genetic 
testing discussed in chapter three, clinicians are looking to the research community for 
guidance on how to proceed with creating informed consent protocols for WGS/WES. 
The hesitancy towards implementing a particular set of recommendations too quickly 
stems from clinicians’ angst and concern about the implications of undergoing 
WGS/WES on patient wellbeing, longstanding historical concerns over confidentiality 
and privacy of patient genetic test results, and the potential consequences, both good and 
bad, on patient care. Therefore, as with all other forms of genetic testing, it is expected 
that these complex issues will be sorted out through research studies aimed at better 
understanding the effectiveness of various consent approaches. In this section of chapter 
four, I identify the major themes emerging in the ongoing debate about how to conduct 
informed consent before undergoing WGS/WES. I first review recommendations from 
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the literature discussing both how to design a research study which involves WGS/WES 
and second, will summarize the conclusions from research studies for how to address the 
complexities of WGS/WES in clinical care. The last section of this chapter reviews the 
types of informed consent protocols currently used in clinics offering WGS/WES.  
 Before I review the research recommendations, I want to point out a distinction 
worth acknowledging between a research approach to understanding the informed 
consent process for WGS/WES and the clinical approach for understanding the informed 
consent process. Most obvious, the research approach is designed to understand the issues 
surrounding informed consent, possibly studying the effectiveness of various approaches 
and ultimately proposing models of implementation into clinical care. The goal of a 
research approach to the informed consent process for WGS/WES is to inform the 
clinical models. Yet, at the same time, the recommendations for conducting research that 
utilizes WGS/WES technology, address issues more pertinent to designing a study in 
which patients consent to undergo WGS/WES. Despite these differences, there seems to 
be much overlap in the recommendations and strategies for addressing informed consent 
protocols in the research setting as well as the clinical setting. The research studies aimed 
at developing strategies for how to properly implement informed consent protocols used 
before undergoing WGS/WES have reported on the major complexities inherent to the 
technology but have offered limited novel solutions. The solutions offered from these 
studies are based on components of existing informed consent protocols. 
 One of the first attempts at defining an informed consent process for managing 
large amounts of genetic data can be found in a JAMA publication from 2001. This article 
was notably published before the completion of the Human Genome Project 
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foreshadowing the complexities of large volumes of genomic data. This article 
summarizes a suggested informed consent protocol for enrolling patients into population-
based research studies (Beskow et al., 2001). The significance of this document is that it 
represents an early proposal offering strategies for how to corral large amounts of genetic 
data, with a focus on lower penetrant genes available from population studies, while also 
addressing some of the problematic components of genetic studies. The problematic areas 
of genetic studies identified by the paper’s authors are; whether to disclose research 
results; whether and how to re-contact study participants; and how to maintain privacy of 
study participants. To maintain compliance with the legal and ethical obligations of the 
informed consent process, the suggested informed consent script proposed in this article 
is based on federal policy recommendations for the protection of human research 
participants and the authors met their ethical obligations by referencing the report from 
the National Bioethics Advisory Commission (NBAC) (Beskow et al., 2001). The twelve 
elements included in a written informed consent document for population-based genetic 
research studies are information about the; overview of the study; purpose of the study; 
nature of participant involvement; privacy of the data; risks; benefits; and costs of 
participation; disclosure of results; future use of participants sample; rights of 
participants; contact information; and consent and signature for whether the participants 
want to be re-contacted (Beskow et al., 2001). While these elements of informed consent 
can be uniformly applied to all types of genetic or genomic studies, a key conceptual 
component of this informed consent document and those proposed for WGS/WES studies 
is whether researchers intend to report results to study participants. 
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 The reasons the authors of this JAMA publication give for why they do not believe 
it is necessary to report results echo the same complexities of the informed consent 
process for WGS/WES. They advocate against informing participants their results 
because most population-based research projects involving genetics produce results that 
lack of clinical validity (association to a disease) of the genetic findings to a specific 
disease. The second reason not to report results is because in order for the results to be 
used in a clinical setting, results have to be independently confirmed in a CLIA approved 
laboratory and most research studies are not able to validate the results in their own 
laboratories. The third reason for not reporting results is a weaker rationale in my 
opinion, is because it represents a study design dilemma, not reflecting issues relevant to 
producing large amounts of genetic information. This last reason researchers stated for 
not reporting results is because they designed the study intentionally not to report results 
back to participants and by reporting data, the study would be violating its own consent 
promises. Finally, the authors write that researchers should not be reporting results, as 
this responsibility is one that falls outside their role as a researcher. They argue that 
physicians are trained to discussed the relevance of genetic data on current or future care 
of a patient, but a researcher is not qualified to act in this role and would be stepping 
outside their area of expertise if they acted as a physician (Beskow et al., 2001). 
 The first tension emerging from this early recommendation is whether to report 
results with unknown clinical utility and validity. This theme is central to all the current 
publications addressing research ethics of WGS/WES. In 2008, Nature Reviews 
published an article on the ethical concerns and challenges of whole-genome sequencing. 
The first major ethical consideration the authors addressed was circumstances where 
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research results are disclosed to the study participants (McGuire, Caulfield, & Cho, 
2008). Because multiple results are generated with this technology, the issue is not just 
whether to report results but if some results are reported, which ones and why? When not 
reporting results, what is the rational for these decisions? When results are reported, how 
will they be reported?  
 A qualitative thematic review of 30 written consent forms used in cancer genome 
sequencing research studies conducted across the world was published in 2011 in the 
BMC Medical Ethics. The authors conducting this review reported that 30% of the studies 
sampled stated general study results would be available to study participants. Of these ten 
studies, only one of the research groups provided participants a choice whether they 
wished to learn their individual results. One study stated individual results would be 
returned (with no choice given to participants), seven indicated no individual results 
would be made available to research participants and one study did not mention the return 
of individual results (Allen & Foulkes, 2011). The remaining twenty studies segregated 
similarly in that nine studies indicated individual results would not be available, three 
studies did not state whether individual results would be available and four stated 
individual results will be returned whether the participant wished to receive them or not. 
Four studies gave participants the option for whether they wanted to learn their individual 
result (Allen & Foulkes, 2011).  
 What is noteworthy about this particular publication is that the author identified 
seven themes in her qualitative review of the written informed consent documents for 
cancer genome sequencing studies, but return of results was not considered a separate 
theme. Instead it was incorporated into the category of re-contacting study participants. 
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The reason for not including return of results as a separate theme in my opinion is 
because the studies she reviewed were not emphasizing the return of results for the 
reasons already discussed. This review article demonstrated a lack of resolution in the 
research studies on whether it is necessary to report results. Because the issue has not yet 
been resolved, many have not started to formulate strategies for how to report results on 
incidental findings generated from WGS/WES research studies.  
 A commentary piece published in Genome Medicine in 2010 highlights ten core 
scientific, cultural and social components necessary to consider when writing informed 
consent protocols for genomic research. One of the ten components discussed is whether 
to report individual study results to participants. The authors do not advocate for or 
against reporting individual study results, but rather suggest that when study results are to 
be reported, researchers should effectively state the risks and benefits of learning 
genomic information in a manner which is consistent to the study participants’ cultural 
and socioeconomic environment (Rotimi & Marshall, 2010). Essentially, the authors 
advocate for incorporating a discussion of the social, psychological, family, financial and 
medical implications of learning genomic results from a research study and incorporating 
these possible implications into the informed consent documents (Rotimi & Marshall, 
2010). This article provides more guidance on what the authors consider to be key 
components of what should be included in a study design with the aim of reporting 
research results. Yet, these components do not differ from those already endorsed in our 
current informed consent protocols for single gene testing.  
 After determining whether to return research results, the next problem to solve is 
what type of result will be reported? This is the second theme I identified in a review of 
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informed consent proposals for genomic research studies. The long-standing ethical 
obligation from genetic research which resonates into WGS/WES studies, is that before 
reporting a research generated result to a study participant, the result must have 
demonstrated clinical utility to the study participant and be validated by an outside 
clinical laboratory. This guideline has proven to be problematic when it is applied to the 
large volume of variants identified through WGS/WES, many of which currently have 
uncertain clinical validity or utility, but have the potential to later be associated with a 
known disease and therefore become clinical useful.   
 Additional themes were noted in most of the publications I reviewed are whether 
researchers will re-contact study participants when more data becomes available and 
when the study is designed to re-contact participants, it becomes important to state how 
and when the investigators will fulfill this obligation. The importance of making data 
available to other research studies was a noted theme as was the emphasis on 
recommending study participants share any data revealed from the study with family 
members. All the publications I reviewed discussing WGS/WES studies agreed that when 
designing studies, researchers should take all of these issues into account. There was also 
consensus reached on the issue that informed consent protocols for WGS/WES should be 
first evaluated in a research setting, before implementing into clinical practice (Rotimi & 
Marshall, 2010).  
 In response to the many ethical dilemmas rising to the surface from the initiation 
of WGS/WES in the research and clinical arenas, the Presidential Commission for the 
Study of Bioethical Issues published their report on Privacy and Progress in Whole 
Genome Sequencing in October of 2012 (Presidential Commission for the Study of 
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Bioethical Issues, 2012). The focus of their document was on the privacy issues 
associated with WGS, however an important component of the privacy issues is informed 
consent, which was addressed in four recommendations. These four recommendations are 
based on the ethical principle of respect for person, as was initially described in the 
Belmont Report. The commission further described “privacy” in the context of WGS to 
be synonymous with autonomy when associated with self-regarding conduct. The 
commission intended to use the definition of privacy for the purpose of WGS/WES as the 
“absence of substantial government or other outside interference with individual’s 
decisions and choices.” With this background in mind, the commission recommended the 
consent process adequately inform research participants and patients who will have 
access to their data and how the data might be used in the future. The commission 
recommended that informed consent documents for WGS fulfill Common Rule 
obligations to: 1) describe whole genome sequencing and analysis; 2) state how the data 
will be used in the present study, and state, to the extent feasible, how the data might be 
used in the future; 3) explain the extent to which the individual will have control over 
future data use; 4) define benefits, potential risks, and state that there might be unknown 
future risks; and 5) state what data and information, if any, might be returned to the 
individual (Presidential Commission for the Study of Bioethical Issues, 2012).  
 Incidental findings are also to be discussed within the context of the consent 
process and, specifically, the commission recommends that individuals be made aware of 
the possibility of incidental findings and recommended studies inform participants how 
and which findings will be communicated, and to whom. Finally, the commission 
recommends that those who support WGS invest in studies to better understand methods 
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for reporting incidental findings, and individual preferences and expectations for learning 
about incidental findings (Presidential Commission for the Study of Bioethical Issues, 
2012).  
 These last few recommendations by the commission really emphasize the fact that 
incidental findings are the central, recurring theme for WGS/WES simply because, the 
number of variants that would be expected to be reported is so great. While many of the 
early genetic studies followed the underlying assumption that results will not be reported 
to the patient (Beskow et al., 2001), there is increasing pressure for researchers to report 
results back to study participants. The rationale now given for why it is important to 
report back results is because the generation of so much data makes it much more likely 
results with important clinical implications will be revealed making it imperative that 
researchers provide this information to patients (Rotimi & Marshall, 2010).  
 The reporting of incidental findings is not new to medical research studies. A 
brief review of how these issues have been addressed in the past might provide insights 
that can be applied to the informed consent process for WGS/WES. A research group 
from Stanford University, concerned over the ethical dilemma of re-contacting research 
participants if an incidental finding was clinically significant, specifically one related to a 
fatal disease responsive to therapy or that might alter a couple’s reproductive planning, 
recommend researchers use thoughtful consideration for this type of ethical situation 
when planning and designing a study. While this group did recommend incorporating 
research ethicists, clinical geneticists and genetic counselors into the discussions 
surrounding study design, they offer no specific strategies for tackling this issue (Tabor & 
Cho, 2007).  
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 The Institute of Human Genetics in Germany published their own response for 
managing incidental findings in the clinical findings in the Journal of Medical Genetics 
in 2009. This group revised their informed consent protocol to include three options for 
patients potentially faced with an incidental finding: learn about genetic findings that 
have implications for the patients’ health and possibly his/her family members; learn 
about these types of genetic findings only if effective treatment options or surveillance 
programs are available; and learn about carrier status for an autosomal recessive disorder 
(Netzer, Klein, Kohlhase, & Kubisch, 2009).  
 The data produced from studies conducted using individual samples stored in 
large bio-banks is another example of an area in research that recently began addressing 
how to manage incidental findings. In a collaborative effort, a large group of researchers 
from 19 major academic institutions across the US and Canada, published ten specific 
recommendations on the roles and responsibilities for the return of incidental findings 
and individual research results. The ten recommendations are quite detailed and do a 
thorough job of explicitly stating the roles and responsibilities of all the players involved 
in designing and managing bio-banks. These recommendations are certainly worthy of 
mentioning but do not offer specific guidelines for how to re-contact study participants or 
how to disclose those results. 
 Some bioethicists and others in the research and clinical communities even 
question whether there is an ethical duty to disclose research results. Miller, et al. argue 
against the ethical duty to disclose research results given a lack of agreement over what 
types of results should be disclosed and further, how to accomplish the disclosure in 
clinical practice (Miller, Christensen, Giacomini, & Robert, 2008). The summaries from 
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studies on incidental findings have made broad conclusions that provide no useful 
guidance for the WGS/WES process. The conclusions have essentially all been similar: 
researchers conducting genetic studies in which genetic test results might reveal 
information that has clinical relevance outside the intentions of the study being conducted 
should state this possibility in the consent forms (Cooper, Nelson, & Ross, 2006).  
 The experiences published to date for how to report unexpected genetic test 
results further informs the academic, scientific and medical communities on how to think 
about handling these issues, yet no specific resolution has been offered for managing the 
issue in real-time. In addition, these previous examples were not adequate for tackling the 
scope of the data produced from WGS/WES. Finally, while the above examples provide 
recommendations specific to addressing incidental findings, and most medical 
professionals involved in genetics today will agree that WGS/WES are fraught with the 
complexity of dealing with incidental findings, I demonstrate in chapter seven when 
considering the technology of genome sequencing, if individuals request to learn as much 
as they can about their genome, there are no “incidental” findings.   
 The two largest ongoing studies working to address the informed consent 
dilemmas created by WGS/WES are the Coriell Personalized Medicine Collaborative 
(CPMC study), and the ClinSeq project conducted at the NIH Clinical Research Center. 
The Coriell study is the first collaborative effort for exploring the implementation of 
genomic information into the clinical arena. The study has already enrolled 6,000 
individuals and provides personalized reports on genetic and non-genetic risks for 
multifactorial diseases, such as cardiovascular disease and diabetes (Keller, Gordon, & 
Stack, 2010).  
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 A secondary aim of the study is to learn how to better educate individuals 
interested in undergoing WGS/WES as well as medical providers and the public about 
the components of personalized medicine and facts about genomics. The evidence-based 
research conducted with this program is anticipated to help inform the discussion of best 
methods for informing patients on genomics and personalized medicine. In this study, 
participants are given the option of receiving their results as part of the study design. The 
initial outcomes from disclosing results for potentially actionable health conditions to 
study participants discuss the group’s development of a method for reporting results, 
which they argue is more effective than the methods used by DTC genetic testing 
companies. The Coriell group elected to present genomic risks for actionable diseases 
only. An independent advisory board known as the Informed Cohort Oversight Board 
(ICOB), reviews the variants identified during the sequencing to determine which 
variants associated with common diseases can potentially be prevented with specific 
actions (such as medical or lifestyle interventions) (Stack et al., 2011). These results are 
reported in relative risks to study participants and according to the Coriell investigators, 
this is a more understandable format for individuals to comprehend risk factors than 
methods used by direct-to-consumer testing laboratories (comparing genetic risk factors 
to non-genetic risk factors or general population risk factors) (Stack et al., 2011). Study 
participants in the Coriell project are offered in-person or telephone genetic counseling, 
but beyond this mention, little has been written about informed consent protocols for 
individuals enrolled in this study (Keller et al., 2010).  
 The second project is being conducted through the NIH Clinical Research Center 
and is known as the ClinSeq project. This is a pilot project designed to investigate 
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utilization of whole-genome sequencing in clinical research (L. Biesecker et al., 2009). 
The goal of the project is to learn how to apply large-scale medical sequencing (LSMS) 
into a clinical setting. In order to narrow the focus for the initial pilot study, the 
investigators choose atherosclerotic heart disease as a prototype for other phenotypes 
they expect to study in the future. Study participants were selected therefore to represent 
a spectrum of atherosclerotic heart disease based on the Framingham score (L. Biesecker 
et al., 2009). This pilot study was designed to use LSMS focusing on candidate genes for 
cardiovascular disease, but the expected 1,000 study participants will also be consented to 
undergo WGS for additional disorders in the future. The primary goal of the ClinSeq 
project is to create an infrastructure and protocols for conducting clinical research studies 
focusing on understanding the genetic basis of health, disease and drug response. A 
secondary aim of this study is to ultimately develop informed consent protocols for 
participants undergoing similar studies as well as protocols for how to return results and 
incorporate data into the clinical setting (L. Biesecker et al., 2009).  
 The ClinSeq project acknowledges the difficult consenting issues inherent to 
WGS and in response to these challenges in this project implemented a conceptual 
consent form and process for the participants to have control over the type of results they 
receive through an “opt-in, opt-out” model (L. Biesecker et al., 2009). The study 
investigator however, designed the consent form with the expectation that only results for 
disease-causing variants, and specifically high-penetrance, mendelian variants, would be 
reported to participants. Less-penetrant variants would not be reported for fear that 
participants would be overwhelmed with the amount of information presented to them 
and that the results themselves would not be clinically useful (L. Biesecker et al., 2009). 
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What is problematic about this study design choice is how would it be possible to 
determine a participant’s choice for what type of genomic information they desire, if not 
all the information is available for them to learn? As with all other genomic research 
studies, all results reported to participants in the ClinSeq project are validated in a CLIA 
approved laboratory before being reported back to the participant and only the CLIA 
approved results are entered into the medical record.  
 Participants in the ClinSeq pilot study were asked to complete a baseline survey 
designed to better understand participant intentions for learning their own results. This 
survey was completed in conjunction with an in-person informed consent interaction with 
a genetic counselor. The genetic counselor explained the type of results WGS/WES could 
produce along with benefits and limitations of the technology; un-interpretable results, 
limitations on understanding results in our current time, with the possibility this would 
change over time, etc. The participants then completed another survey asking again about 
intention to receive results and whether results might affect their health-related behavior. 
Participants were given four categories of possible results to consider: variants with a 
known association to a disease that is preventable or treatable, variants with a known 
association to a disease that is not preventable or treatable; variants that establish a carrier 
for a disease (such as an autosomal recessive condition); and variants of uncertain clinical 
significance (L. Biesecker et al., 2009).  
 Recently, the investigators of the ClinSeq pilot published their findings on the 
first 311 participants enrolled into their study and to the investigators’ surprise, all but 6 
of the participants indicated they wanted to learn their results. The other six did not state 
they did not want to learn their results. They were undecided meaning that none of the 
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participants declined the opportunity to learn results. Another surprising revelation 
reported by the investigators, was that study participants were more interested in learning 
about variants of uncertain significance than they had anticipated. The authors concluded 
that while the study participants clearly expressed confidence that the data generated 
from sequencing would have a positive impact on their overall health, this finding was 
concerning because the hopes perceived from the study participants are likely to 
overshadow the numerous limitations of WGS/WES. They even suggest that 
investigators might need to learn how to “temper” such expectations for future study 
participants (Facio et al., 2013).  
 Before discussing current informed consent protocols for WGS/WES in the 
clinical setting, I want to first review several literature reports for how to tackle these 
issues. I have selected two proposals that attempt to create more innovative approaches to 
the informed consent process. This review will be followed by a summary of current 
clinical practices of informed consent for WGS/WES. I will conclude with an analysis 
about whether the themes emerging in the literature and in current research studies and 
clinical practice, translate into recommendations that will effectively address the complex 
issues generated from WGS/WES.   
 Acknowledging the difficult data management issues head on, several geneticists 
published their suggestions for implementing WGS/WES into the clinical setting with a 
commentary piece published in Genetics in Medicine in 2011. The approach they 
recommend is essentially to downsize the data to manage it more effectively. The 
downsizing of data refers to a method of compartmentalizing the data into “bins” that are 
characterized based on results with clinical utility (bin 1), clinical validity (bin 2) and 
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unknown clinical implications (bin 3) (Berg et al., 2011). The clinical validity bin is 
further divided into three subsets, “low risk incidental information”, “medium risk 
incidental information” and “high risk incidental information.” The variants reported in 
each bin are further characterized according to whether it is an allele that is known 
deleterious, presumed deleterious, a variant of uncertain significance, presumed benign 
and known benign (Berg et al., 2011). The overall approach to data management is one in 
which decisions about what type of variants should be used in clinical practice is based 
on the clinical context of the reason for pursuing WGS/WES. The fundamental 
component of this model is different clinical contexts require distinct approaches and that 
the consent process, as well as data analysis, results disclosure and recommendations for 
how or whether to use incident findings in clinical care, should be based on the specific 
context in which WGS/WES is applied (Berg et al., 2011).  
 To manage the consent issues, the authors are recommending a traditional model 
of informed consent, but one, which focuses on the type of results expected from the 
sequencing, based on the clinical context of the situation (bin) chosen for the patients. 
This system, they argue, allows patients the opportunity to be informed about possible 
implications of learning the results to prevent any adverse and negative consequences on 
patient wellbeing. In addition, they argue genetic counseling hours can be scaled to a 
manageable time and the impractical discussion about possible variants can be avoided 
(Berg et al., 2011).  
 The problem inherent to this type of model is that many clinical contexts will not 
be known when WGS/WES is ordered. In addition, as was demonstrated in the ClinSeq 
pilot, patients are expressing a desire to learn as much information as they can about 
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possible health issues and may want to be informed about variants. As a result, it would 
seem to be a bit paternalistic for the clinician to determine what type of information the 
patient has access to, regardless of the clinical utility of the data. This proposal is not 
suggesting an innovative approach for informed consent, rather another approach for 
managing the volume of data by applying the traditional model of informed consent into 
several different contexts.  
 A geneticist in Canada proposed an interesting approach to the informed consent 
conundrum with his article describing a “data-first” model (Trakadis, 2012). The “data-
first” model is designed to approach WGS/WES in a simpler manner, and that is run a 
patient’s genome through a search engine known as Individualized Mutation-weighed 
Phenotype On-line Search Engine (I-MPOS). This search engine will filter all irrelevant 
variants and match the patients’ variants that known a known pathogenic association to a 
disease that has been described. All other “incidental findings” will be ignored and not 
reported (Trakadis, 2012). This is an interesting approach and certainly offers a more 
novel way to look at the data, however the fundamental principles of the model are 
paternalistic in that a clinician controls how the data is analyzed based on phenotype 
information. Also, the model does not provide options for the patient to learn about other 
genomic risk factors, not related to their clinical presentation. 
 WGS/WES is currently offered in various clinical settings across the country. 
Recall, there are two primary reasons for pursuing WGS/WES in clinical care at this 
time; to assist with determining the cause of a genetic condition with a suspected, but yet 
unidentifiable genetic etiology; and in the area of oncology, to assist with identifying a 
treatment regimen for a patient with metastatic refractory cancer. The third indication for 
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pursuing WGS/WES is predisposition testing, similar to the sequencing experience of 
Bill and Melinda. Many healthy individuals interested in undergoing WGS/WES are able 
to undergo sequencing through a direct-to-consumer genomics company. I describe the 
manner in which informed consent is provided in this setting after reviewing informed 
consent protocols in the medical oncology and pediatric and adult genetics clinics.   
 The process of undergoing WGS/WES typically begins when a physician 
identifies a patient who is believed to be a good candidate based on the two indications 
mentioned above. The ultimate decision of whether a patient is a good candidate or 
eligible to undergo WGS/WES is often determined by a physician and in some cases, a 
committee of individuals with an expertise in genetics who discuss individual cases and 
reach a consensus for which patients might benefit the most from such sequencing. While 
clinicians want their patients to benefit from the possible findings revealed from 
WGS/WES, they are also quite cautious when pursuing the testing because of the 
uncertainty inherent in the process. In the history of medical tests employed in clinical 
practice, WGS/WES produces more uncertainty than clinicians are comfortable 
managing. Individuals also learn about WGS/WES through their own research or after 
reading articles in a publication or newspaper and seek out the sequencing on their own. 
 The overall integration of WGS/WES into the clinical model has been essentially 
parallel to the existing medical genetics informed consent construct. The type of 
consenting which occurs before WGS/WES in the clinical setting follows our current 
health care structure where the individual undergoing sequencing will meet with a genetic 
counselor or other health care provider trained in genetics and review together the 
implications, both good and bad, of learning about genomic information and uncertainties 
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expected from the sequencing results. This is an expanded version of the traditional 
model of informed consent, and is the template for what all clinics are following at this 
time. The content and details of information discussed in a consent session is likely to be 
inconsistent between institutions.  
 After informed consent is achieved, the clinician sends the appropriate patient 
sample to a CLIA based laboratory for analysis. The laboratories performing WGS/WES 
all require patients sign an informed consent document which state the type of results a 
patient can expect and the limitations of the laboratories’ interpretation of the results. The 
written informed consent document is intended as supplemental material to the more in 
depth informed consent process conducted by the clinician ordering the test. Families 
who elect to undergo WGS/WES to determine the genomic cause of a particular disease 
for their child, are required to submit a sample for the affected child, or children when 
more than one child is affected with the condition, as well as both parents.  
 Results from sequencing are interpreted by the laboratories and sent back to the 
referring physician, who will report them to the patients. The laboratories conducting 
WGS/WES publish their data on the success rates of sequencing that is how many 
patients received results, which provided either clinical resolution for a diagnosis or 
effective treatment in the case of cancer patients. The laboratories performing WGS/WES 
also decide which types of variants to report and how to report them.  
 Since WGS/WES has become available in the clinical setting one leading 
professional organization in medical genetics felt it was important that clinicians ordering 
genomic sequencing had some guidance for how to deal with incidental findings. 
Incidental findings are defined as any genomic result that does not directly relate to the 
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specific indication for why the individual is pursuing WGS/WES. After convening a 
working group to explore the issue in great deal, the American College of Medical 
Genetics recently published their recommendations for how the clinical community 
should respond to the ongoing controversy surrounding the management of incidental 
findings reported from WGS/WES. In their position statement released in March of 2013, 
the American College of Medical Genetics (ACMG) recommends that regardless of the 
clinical indication for WGS/WES, laboratories should report out mutations found in 57 
genes encompassing 24 Mendelian conditions (R. Green et al., 2013). The 
recommendation further states that this list is only the first attempt for addressing 
incidental findings, and clinicians should expect ongoing changes and additions. The 
Working Group from the ACMG also specified that mutations identified in the 57 
identified genes should be reported back to the clinician regardless of the age of the 
individual undergoing testing. A final key component of their recommendations I would 
like to comment on is the fact that the Working Group places the clinician who orders the 
initial WGS/WES test as the individual responsible for providing pre- and post-testing 
counseling to the patient regarding the implications of receiving possible incidental 
findings (R. Green et al., 2013).  
 This recommendation represents a significant departure from the traditional 
philosophical approach in medical genetics to honor autonomy. As a result these 
recommendations have generated tremendous amount of negative responses from 
individuals in the medical genetics community who provide clinical genetic testing. Most 
do not agree with these recommendations because by providing incidental findings to a 
patient in the manner suggested, patient autonomy is violated as the patient right to 
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choose what he wants to learn is taken away. Neil Holtzman wrote a letter to the editor in 
response to the ACMG recommendation and stated that the ACMG recommendations 
“are flawed scientifically as well as ethically (Holtzman, 2013)”. He goes on to make the 
argument that such recommendations are premature because no one has adequately 
established what the benefits, limitations or costs are from disclosing incidental findings 
(Holtzman, 2013).  
Another letter to the editor written by a group from the University of British 
Columbia wrote that these recommendations have not considered the voice of the patient 
and families who are considering genome sequencing. Similar to my own argument for a 
patient centered informed consent practice (discussed in chapters five, six and seven), this 
group argues that to produce a more ethical and effective outcome, recommendations for 
disclosing incidental findings must include patients’ perspectives (Townsend, Adam, 
Birch, & Friedman, 2013).  
 Healthy individuals interested in undergoing WGS/WES often seek out genome 
sequencing on their own and can accomplish sequencing through a direct-to-consumer 
laboratory. Direct-to consumer genomic testing provides direct access to genome 
information without the involvement of a physician or other medical provider. The debate 
over how to inform a patient on the implications of learning about multiple genetic risks 
factors identified through genome sequencing was initially addressed in 2007 with the 
introduction of personal genome testing marketed directly to consumers by commercial 
laboratories. These types of tests are marketed as a personalized risk assessment designed 
to provide individual information about genetic risk factors for a variety of common 
diseases, such as cardiovascular risk factors, cancer and other common illnesses. 
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Information about carrier status for more traditional Mendelian disorders such as cystic 
fibrosis or hemochromatosis as well as autosomal dominant conditions, are also available 
with personal genome testing. 
 Reaction to direct-to-consumer genetic testing from the academic medical and 
research communities was swift and sharp. Bioethicists, medical geneticists and academic 
researchers bemoaned the companies who offered genetic testing for not including a 
medical practitioner into the personal genome testing protocols. Most criticized these 
direct-to-consumer laboratories for offering genomic testing prematurely without the 
appropriate scientific validation for many of the common disease variants being reported 
or the required laboratory regulations in place (McGuire, Diaz, Wang, & Hilsenbeck, 
2009). Medical professionals and researchers feared DTC personal genome testing would 
harm individuals who underwent such testing. The chief medical director of the Cancer 
Genetics Clinic at Baylor College of Medicine expressed her concerns about direct-to-
consumer marketing of genetic testing in a New England Journal of Medicine article; 
“...members of the public are getting tests that they don’t understand, and their physicians 
may not understand, and they may be making big decisions that are ill-informed” 
(Wolfberg, 2006).   
 Individuals who participated in personal genome testing also expressed caution to 
others who are considering ordering a genetic test online. A survey conducted on social 
networkers attitudes about direct-to-consumer genetic testing felt it was important a 
medical professional who is an expert in the field of genetics, remain involved in the 
process of personal genome testing and be available to help individuals understand their 
results. This cohort of individuals also reported that they planned to consult with their 
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own primary care physician about their personal genome results which implies, that 
although the personal genome test was not designed to be used in medical decision 
making (as stated by the companies themselves), individuals undergoing personal 
genome testing consider the information reported to them to be medically actionable 
(McGuire et al., 2009).  
 The initial outcry after the debut of direct-to-consumer genetic testing has all but 
disappeared. WGS/WES sequencing has taken center stage. What solutions for how to 
better inform patients before undergoing personal genome testing were offered from the 
initial spark of interest generated from personal genome testing offered directly 
consumers? In my estimation, no solutions were proposed. The companies offering the 
testing claimed the type of information reported from their service is not intended to be 
used in standard medical care and therefore, they largely ignored the issue of informed 
consent. They fully informed individuals undergoing testing that the data should be 
considered research and not incorporated into clinical medicine. In addition, because this 
is a commercial product, as with any other product on the market, it is a buyer beware 
world. Direct-to-consumer marketing of personal genetic tests can be considered a 
superficial dry run of the issues now facing WGS/WES.   
  
Effectiveness of Informed Consent Proposals for WGS/WES 
 
 The problematic areas of the consenting process which have risen to the surface 
throughout this discussion are; (1) how to manage and report on a large number of 
variants, including mutations and variants of unknown clinical significance; (2) whether 
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and how to report variants of unknown clinical significance; (3) whether and how to re-
contact individuals when new information is made available about their genome; and (4) 
how to incorporate results into patient care and our current health care system. The 
solutions offered from a review of recommendations published in the literature for both 
research and clinical WGS/WES consent protocols offer no innovative approaches for 
addressing these consenting complexities. Instead, these solutions represent inconsistent 
solutions on how to report genomic data, due in large part to the lack of agreement on 
what type of data to report and how to interpret variants identified. Further, there is no 
standard method for incorporating data into a patient’s medical record. There is no 
solution proposed for how to follow-up with patients when new data is available about 
their WSG/WES results, and many times, much of the genomic data produced from 
sequencing is not made available to patients. Finally, there is no standard policy for how 
to report variants with unknown significance. 
 While there has been no consensus reached throughout the community of genetic 
stakeholders: research, medical, private sectors or patient groups, for how to obtain 
informed consent for WGS/WES, there is a unified appreciation of the complexity 
involved in obtaining informed consent for WGS/WES. All stakeholders agree that we 
are grossly unprepared for what is already upon us, and that is the desire to try and 
incorporate data generated from WGS/WES into a patient’s clinical care. Acknowledging 
the enormity of the situation and spotlighting some of the major departures from the 
traditional genetic testing model WGS/WES takes us, is where the common ground stops. 
At the point of considering a solution tailored towards solving informed consent issues of 
WGS/WES, clinicians and researchers alike are adhering to the traditional approach of 
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the existing model of informed consent. As has already been discussed, the nature of 
WGS/WES does not lend itself to providing an opportunity for patients, or their 
clinicians, to know exactly what will or will not be identified at the completion of a 
patient’s sequencing. Nevertheless, traditionalists adhere to their principles; reveal only 
genomic information that the patient consents to receive; incorporate genomic data with 
clinical implications only into the medical care of the patient; and develop practice 
guidelines for how to best present genomic information (McGuire et al., 2008).  
 There are some who I will refer to as innovators, who have started to discuss ways 
in which to consider new consent models. In response to the criticism of direct-to-
consumer marketing of genomic tests, an editorial written in Nature Biotechnology 
challenged the policy makers and members of the medical community to reevaluate their 
roles as gatekeepers for access to genomic testing (“In need of counseling?,” 2008). The 
author expressed concerns over the possibility that by promoting old models of informed 
consent in which the physician would determine who is best suited for undergoing 
genomic testing, the process of undergoing genomic testing and realizing the benefits 
from the testing will be stalled before the potential of this testing is even realized. A 
solution offered in this editorial would be to develop a system of stratification for the 
various tests based on which ones required medical oversight and which required no 
oversight (“In need of counseling?,” 2008). While the innovators are beginning to offer 
solutions that help researchers design informed consent models that push us to think 
outside the box, the suggestions offered are inadequate for addressing all the issues 
relevant to WGS/WES and further do not push the current standard of informed consent 
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models far enough to be considered novel and capable of managing the complexity of 
WGS/WES. 
 The status of the informed consent process for WGS/WES today is essentially at 
the point where most agree the current protocols are not going to be effective and many 
agree that pretest counseling for genomic testing is going to require significant changes to 
the existing models (Sharp, 2011). Yet, at this time, most proposals for informed consent 
are enhanced versions of the existing model, modified enough to incorporate discussions 
surrounding the different type of data produced from WGS/WES, but not enough to fully 
reflect on the dynamic nature of the technology. While many of the articles I reviewed 
focusing on informed consent challenges for WGS/WES, acknowledge the types of 
complexities inherent to genome sequencing, none of the articles or clinical protocols for 
WGS/WES consider the issue of whether the informed consent protocols used in clinical 
practice since 1957, are even effective at fulfilling the ethical requirements of the 
informed consent experience. In my opinion, the most concerning issue with the proposed 
informed consent protocols just reviewed is that while there is unequivocal 
acknowledgement that WGS/WES is a game-changer for the informed consent process, I 
did not review any articles or identify any studies that acknowledge the limitations and 
ineffectiveness of existing informed consent processes and the subsequent relevance of 
this fact to the discussion on how to write informed consent protocols for WGS/WES. 
This is problematic when considering how complex whole genome sequencing is as a 
technology, but what is more important, is that individuals who are seeking important and 
critical information for their health care, may not benefit from WGS/WES if the informed 
consent process is ineffective.  
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 As I discussed throughout my analysis of the existing informed consent process 
by physicians and health care providers in chapter three, most agree that the informed 
consent process is not focused on the goal of the informed consent process, but on 
whether consent is achieved and how institutions document the fact that the consent 
process occurred. The primary driver of the traditional informed consent process is to 
fulfill the legal obligation of informed consent as a requirement in medical care. While 
there are ethical underpinnings identified in the legal components of informed consent 
protocols, the consenting process is largely written as a check list of what information 
should be covered to ensure a patient is fully informed of the risks, benefits and 
limitations of a recommended test. The protocols are not written to allow flexibility for 
physicians to tailor the consent process towards the patient’s values, beliefs or goals. As a 
result, the consenting process never adequately addresses the purpose of informed 
consent, which is to ensure individuals fully understand the implications on their lives 
and their families for undergoing WGS/WES. Herein exists the most fundamental 
criticism of current informed consent protocols; the process was developed in response to 
the legal requirement to fully inform a patient of possible risks, benefits and limitations 
of a recommended procedure or treatment option, and continues to perpetuate in 
medicine, as a legal requirement, while largely ignoring or avoiding the question of 
whether the process itself is truly effective in achieving the goals of the informed consent 
process to promote autonomy, encourage rational decision making and self-determination 
in making medical decisions.  
 The fact that our current informed consent protocols for genetic testing are not 
effectively addressing the ethical obligations they are required to embody, but are 
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becoming implemented into the creation of informed consent protocols for WGS/WES, 
should be a real concern to everyone engaged in the conversations about how to design 
informed consent protocols for WGS/WES. My review of the literature and my 
experiences with the implementation of the informed consent process for WGS/WES in 
clinical care, and even within research protocols, identified no groups who are asking 
whether our existing informed consent protocols are adequately obtaining consent. 
Instead all the groups who are focusing on this issue at this point are struggling with the 
issue of reformatting traditional informed consent practices to fit around the complexities 
of WGS/WES. Much of the discussions surrounding informed consent are also focused 
on how to appropriately manage the information obtained from genomic sequencing. Yet, 
in the context of informed consent discussions, the term “manage” does not refer to how 
to analyze or interpret that data, but rather, how to control what type of genomic 
information an individual receives from their own genome sequencing and how to 
explain a large amount of information during a single informed consent session. While 
establishing what type of genomic information is relevant to the clinical care of 
individuals is no doubt a critical component of genome sequencing, this issue might be 
irresolvable because that data is continuously changing, and further, this issue in of itself 
does not deal with the underlying problem of how to properly consent individuals before 
WGS/WES. Most researchers and clinicians therefore, are not solving the right problem, 
which is; regardless of the complexities inherent to WGS/WES, how can medical 
providers effectively obtain informed consent in the manner that fulfills the underlying 
ethical obligations of the consenting process.  
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The remainder of this dissertation is going to focus on solutions for the two major 
issues discussed throughout this document; how to effectively consent individuals 
undergoing WGS/WES in a manner that upholds the underlying ethical obligations of the 
consenting process? And, how to perform informed consent for a complex technology 
such as WGS/WES? 
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CHAPTER 5 
SOLUTIONS FOR IMPROVING INFORMED CONSENT PROTOCOLS FOR 
WGS/WES  
The fact that we are considering alternative consenting protocols for WGS/WES provides 
an important opportunity to evaluate our current methods for obtaining informed consent. 
These alternative protocols should draw on the components of current protocols that are 
effective and work well. Yet, there is also a unique opportunity to evaluate the 
components of informed consent, which have not worked effectively in the past, and to 
modify these components when designing informed consent protocols for WGS/WES. 
Incorporating components of current informed consent protocols that are effective and 
modifying those that are not effective will ultimately result in the creation of a novel and 
more meaningful informed consent process for WGS/WES. As I demonstrated in 
chapters three and four, current informed consent protocols are largely ineffective at 
promoting patient autonomy or rational decision making because the process itself is 
more about an obligatory recitation of possible legal issues arising from undergoing a 
specific procedure or following a recommended therapy. The content of the consenting 
process is mostly designed to protect medical providers and medical institutions from 
litigation following an adverse outcome. In this chapter, I will offer a solution to this 
problem that will enhance the informed consent process for both patients and medical 
professionals. 
 The solution I offer to enhance the informed consent process for both patients and 
medical professionals is to restructure the informed consent process according to the 
original intent and goal of the process. The original ethical purpose of informed consent, 
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stripped of its legal underpinnings, is to tailor a consent discussion around the goals, 
values and belief system of an individual patient (President’s Commission for the Study 
of Ethical Problems in Medicine and Biomedical and Behavioral Research: Making 
Health Care Decisions, 1982). Much like an individual genome is unique to the person 
who is sequenced, so too should the informed consent process be unique to the person 
considering sequencing. The idea that a patient’s goal for undergoing WGS/WES should 
remain at the center of the informed consent protocol sounds intuitive, yet my analysis of 
the informed consent protocols for genetic testing and other medical procedures revealed 
that current protocols have not honored this objective. This chapter describes a consent 
protocol for WGS/WES that is structured around the patient’s goal(s) and/or intent for 
undergoing WGS/WES. I propose a design of an informed consent process for 
WGS/WES that is guided by four key principles that serve to preserve and enhance the 
existing informed consent process: 1. Identify patient goals for undergoing WGS/WES at 
the beginning of the informed consent process, 2. Structure the informed consent session 
around stated goals for undergoing WGS/WES and patient’s understanding of why they 
are pursuing WGS/WES, 3. Incorporate a psychological/psychosocial assessment into the 
informed consent process, 4. Offer online and in-person methods for obtaining informed 
consent.  
 These four principles are drawn from: original ideas grounded in the ethical 
principles of what informed consent was written to achieve, new ideas developed in 
response to the complexities of WGS/WES and, existing genetic counseling informed 
consent protocols. In this chapter I discuss how these four principles result in an informed 
consent process that empowers patients to make an informed decision about undergoing 
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WGS/WES. In the next chapter (chapter six), I describe each step of the informed consent 
process for WGS/WES and illustrate how the four principles outlined in this chapter 
guide the informed consent process to accomplish a more effective consenting interaction 
capable of responding to the complexities of WGS/WES. The subsequent chapter 
(chapter seven) demonstrates how the informed consent process described in chapter six 
occurs within the larger context of whole genome sequencing and how WGS/WES can 
operate within our existing medical model. Chapter seven concludes with a description of 
how the informed consent process and model described in chapters six and seven, 
enhance existing informed consent protocols, fulfilling the ethical obligations of 
informed consent and effectively addresses the complexities of WGS/WES. 
Principles of a Patient Centered Informed Consent Protocol for WGS/WES 
 
1. Identify patient goals for undergoing WGS/WES at the beginning of the informed 
consent process  
 
 Shaping the informed consent protocol for WGS/WES around the stated 
purpose(s) and goal(s) of individuals undergoing WGS/WES is accomplished by 
initiating the informed consent procedure with a discussion about the intention and/or 
understanding of WGS/WES from the patient undergoing the sequencing. The initial 
response from the patient will guide the consenter on what information is necessary to 
discuss with the patient to help the patient further understand and define their goals as 
well as manage expectations for what they hope to achieve by undergoing WGS/WES. 
Throughout the remainder of this document, I will use the term consenter to describe the 
role of the individual responsible for consenting patients. This individual could be a 
genetic counselor, a physician, a physician’s assistant, a nurse or even a psychologist or 
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psychiatrist. Consenters would undergo advanced training in genomics with an emphasis 
on many of the same counseling techniques taught to genetic counselors due to the 
similarities between the consenting process I propose for WGS/WES and components of 
a genetic counseling session.  
 If an individual states their goal for undergoing WGS/WES is to learn about their 
risk for developing any type of disease in the future, the first step in the consent process 
would be to further delineate which diseases they might be most concerned with and 
why? After establishing a more focused list of conditions (or even if the list remains 
broad), the consenter would inquire why the individual wishes to learn about possible 
disease risk factors? Perhaps there is a family history of a particular disease and this is 
why the patient is motivated to learn about their genomic risk factors. 
 Remembering our couple, Bill and Melinda, Bill is worried about his risk for 
prostate cancer because of his family history of prostate cancer. Melinda is concerned 
about possible diseases she and Bill might pass down to their future children. In this 
situation, one of Bill’s goals for undergoing WGS/WES would be to learn about his risk 
factors for prostate cancer. One of Melinda’s goals is to identify any genetic conditions 
they might pass to their children. The consenter at this point has a tangible goal to note 
and refer to throughout the remainder of the informed consent session. This goal may 
also be revised throughout the informed consent process as the patient learns more about 
the process of undergoing WGS/WES. This process will likely be repetitive as additional 
information is provided to the patient over the course of the consent discussion. The 
reiterative component of informed consent conversations, in the case of WGS/WES, is 
likely to result in a more comprehensive understanding of the type of information 
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individuals will garner from sequencing, in addition to a deeper understanding of the 
complexities of the sequencing process.  
 At the same time the patient is explaining their goals for what they hope to 
achieve after undergoing WGS/WES, the consenter can also ask the patient to tell them 
what they hope to learn, better understand or discuss during the informed consent 
process. If a patient had no expectations from the informed consent process, then the 
consenter could elaborate first on what types of information can and will likely be 
discussed during the consenting interaction. This review might prompt the patient to 
consider some component of the sequencing process they might want to know more 
about. Once the patient and consenter have agreed upon several outcomes that the patient 
would like to reach at the conclusion of the consent process, the consenter will document 
this information in the patient’s electronic record and ask the patient to complete a 
standardized form listing several common goals for informed consent, so that these goals 
can be scored at the completion of the process. Also, patients will have an opportunity to 
evaluate the process after they receive their first set of genomic results, if they choose to 
continue with genomic sequencing.   
 Individuals, whose physicians recommend they undergo WGS/WES, would 
likewise benefit from this type of informed consent protocol. When a physician 
recommends WGS/WES, a patient in this situation would begin their consent process by 
stating what they understand about the testing recommended to them and the possible 
results that would be available once testing was completed. The consenter is therefore 
going to help the patient define and understand the reasons WGS/WES was 
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recommended and how the sequencing might help them accomplish the goal of better 
defining, understanding and/or treating an ongoing disease.  
 Additional examples of how individual goals are obtained at the beginning of the 
informed consent process are provided in the next chapter as well. The goal of this 
chapter is to introduce the concept and principles of a patient centered informed consent 
protocol. 
 
2. Structure the informed consent session around stated goals for undergoing 
WGS/WES and patients’ understandings of why they are undergoing WGS/WES 
 
 Once a patient articulates the rationale and/or understanding of why they are 
requesting WGS/WES, or why their physician is recommending WGS/WES, the consent 
process should be shaped around this stated goal. In other words, all subsequent 
conversations surrounding scientific information about genomics, the limitations and 
benefits and unknowns of the technology, should always be discussed with the patient’s 
stated goals as a focal point. For example, Bill wanted to undergo WGS/WES to learn 
about his genetic risk factors for someday being diagnosed with prostate cancer. His 
session would therefore be focused around helping him understand how WGS/WES 
could better quantify, or subsequently not quantify, his risk for being diagnosed with 
prostate cancer in the future. To better understand his risk factors, the consenter would 
review his family history of prostate cancer and his personal history if relevant. The 
session would then move to a discussion about genomic concepts which would help Bill 
better understand types of results he can expect from his genome sequencing and how 
these results are used to predict disease risk.   
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 Already established informed consent protocols for genetic testing have identified 
the education component as a critical factor in fulfilling the obligations of informed 
consent. Most agree that the genomic education component of all informed consent 
protocols for WGS/WES needs to be enhanced from the traditional genetic testing 
protocols, to include additional genomic facts and definitions that are characteristics of 
the type of data produced by WGS/WES. In order for patients to make informed 
decisions, they must understand the information presented to them, and given the 
complexities of WGS/WES, education about genomic terms is absolutely necessary to 
enable patients’ ability to understand the results from WGS/WES. When patients 
understand the type of genomic information that WGS/WES can and cannot provide 
them, they will be better able to determine whether WGS/WES will accomplish their 
stated goals at the beginning of the informed consent session thereby feeling empowered 
to make a decision regarding what type of information available from WGS/WES about 
their genome they may wish to learn and why.  
  
3. Incorporate a psychological/psychosocial assessment into the informed consent 
process 
 
 Incorporating a psychological assessment into the informed consent process is not 
a requirement of the traditional informed consent requirements written in the 1950s, and 
was only added to the informed consent process once genetic testing became available in 
clinical care. A key tenet of genetic counseling theory is that complex genetic 
information provided without addressing underlying psychological concerns or responses 
to the information presented, will commonly result in the inability for a patient to 
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correctly understand the information provided to them. The ability to comprehend the 
inarguably complex medical information presented during an informed consent session is 
determined to some extent, by a patient’s overall psychological state. Studies I reviewed 
in chapter three suggest that patients are better able to incorporate the implications of 
being diagnosed with a genetic disorder or the implications of learning about carrying a 
risk for a genetic condition, and the subsequent implications for their own health and 
potential risks to relatives, if their psychological concerns are also being addressed (R 
Klitzman, 2009). Therefore, the psychological implications of undergoing genetic testing 
require an important space in the informed consent process. The studies which suggest 
that patients will understand statistical data better when their psychological issues have 
been addressed should guide us in providing more effective informed consent for whole 
exome and genome testing.  
 A recent commentary written by psychologist Steven Pinker, published in a 2009 
article in The New York Times, discussed the seemingly universal belief that individuals 
associate who they are as a person to be primarily determined by their genetic make-up 
(Pinker, 2009). Regardless of whether scientists support the genetic determinism 
argument, when a large majority of the population believes in it, then all discussions 
about individuals’ genetic makeups, and implications of such, should incorporate an 
individual’s belief system of how they think their genes define them as a person or the 
degree to which they believe their genetic make-up causes risk for specific medical 
outcomes. To adequately address an individual’s belief system surrounding their genomic 
make-up, a conversation needs to occur throughout the informed consent process to help 
individuals define, anticipate or even better understand, how they might be 
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psychologically affected when they learn information they might not be expecting and 
certainly information which predicts the possibility of having a disease they might have 
always been worried about.  
 While the incorporation of a psychological assessment of the patient into the 
informed consent process is new to most who have consented patients in the past, I argue 
that by addressing patients’ psychological status and important psychosocial issues, the 
informed consent process will become much more patient directed and focused on 
content that facilitates autonomous and rational decisions. For example, Bill is worried 
about his risk for being diagnosed with prostate cancer, therefore the consenter would 
spend time during the consent process providing anticipatory guidance for how he might 
respond to the information about prostate cancer risks derived from WGS/WES. The 
consenter would also incorporate a discussion about the type of screening for prostate 
cancer that would be available, if Bill’s WGS/WES results reported an increased risk for 
this cancer. Essentially, knowing what the patient wants to learn about from WGS/WES 
can guide the consent process to be as tailored as necessary to each individual case. 
 Melinda on the other hand is worried about passing on a hereditary disease to her 
future offspring, as well as possibly succumbing to the same illness as her father. The 
psychological issues to address with her would to help her anticipate any possible 
feelings of guilt she might feel if she were to test positive for any of the hereditary 
conditions she is worried about. She is more than likely also afraid of what she might 
learn from her sequencing and just asking her to acknowledge this fear, and reassuring 
her that this is a normal response to learning about her future medical risks, is a 
supportive strategy for her during her consent process.  
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4. Offer online and in-person methods for obtaining informed consent  
 Existing methods for obtaining informed consent before genetic testing vary 
widely, from structured in-person genetic counseling sessions to signing a form with no 
discussions about the implications for undergoing the testing performed, as summarized 
in chapter three. To clarify, I use the word method in this context to explain how the 
consent process is conducted, which is different from components of the process 
described in the next chapter. The informed consent process defines the steps of the 
consenting process and is consistent regardless of the method for obtaining consent.  
 A patient centered informed consent protocol requires evaluating new methods for 
obtaining consent. Also, a patient centered informed consent process designed around 
individual goals for undergoing WGS/WES needs to be accessible and understandable to 
individuals with varied backgrounds; including everything from gender and age, to a 
person’s cultural values, to education level and socioeconomic status. As I reviewed in 
chapter three, individuals have different learning styles, and preferences for how they 
best learn and communicate. This implies that some individuals will require in-person 
consenting procedures and others may prefer online methods for consenting. Therefore, 
several methods for obtaining informed consent should be made available to individuals 
undergoing WGS/WES.  
 To address the spectrum of differences between individuals who elect to undergo 
genomic testing, I propose an online version of informed consent, an in-person version of 
informed consent and a combination of both modalities. The online version of informed 
consent begins when the individual logs into an online patient portal. One online version 
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of informed consent could include a virtual face-to-face component over the internet, 
through a videoconference or Skype. The other type of online version is a self-guided 
process through the consent process. A self-guided consenting program would be 
designed to walk patients through the same steps they would take if they were meeting 
with a consenter in-person or if they were interacting through a videoconference or 
Skype. Patients who elect to undergo the online version without speaking to a person 
would be able to request an in-person conference at any point during the consenting 
process. Therefore, while the patient chooses the method they prefer when they enroll in 
the informed consent process, it would be possible to change methods at any point in the 
process. The in-person module begins the same manner, with the patient logging onto his 
or her own portal to begin the process. An appointment would then be established for the 
patient to continue with the consenting session in-person.  
 In my opinion, offering a variety of methods for obtaining consent will greatly 
improve existing consent procedures for several reasons. The first is that the structure of 
an online process will eliminate the vagueness of our current consenting process in which 
there are no specific protocols or methods for assigning responsibility for who obtains 
consent. Designing an informed consent model build for several types of consenting will 
result in the creation of set protocols for consenters to follow, which will serve to 
maintain consistency throughout all consent processes. In every informed consent 
process, an element necessary for the process to work effectively is to have a medical 
professional appropriately trained to perform the consent process. The on-line consent 
process will still include a consenter who interacts with the person undergoing 
WGS/WES, but it will be a virtual interaction rather than an in-person consult. Each 
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method however, will have a defined role for the consenter, which allows for not just an 
assignment of responsibilities, but also puts into place the accountability component of 
informed consent necessary to fulfill its legal obligations. 
 A second improvement to existing informed consent protocols achieved by 
offering several models to obtain consent is that by providing several methods for 
consenting, patients have specific options, based on their own preferences, for how to be 
consented. Offering options that fit patient preferences for learning and communication 
could enhance the practice of consenting by creating a positive, user-friendly experience 
for the patient. Because the younger generations are being raised with computers and 
grow up surrounded by technology, the online method for informed consent will most 
likely be their preferred method for managing health care issues, making this protocol 
ideal for future generations. I believe by taking ownership of the process, patients will be 
more invested in the outcome of undergoing WGS/WES and be attentive and interactive 
in the consenting process. The positive experience would likely result in increased 
understanding of the consequences from undergoing WGS/WES ultimately resulting in a 
more successful informed consent experience. 
 A third improvement is that the enthusiasm of the patient could also enhance the 
experience of the consenter. When a patient is participatory and interactive, the 
consenting process will be more effective and the individual providing consent will better 
appreciate their role in the process and feel that their interactions with the patient might 
make a difference with the patient, when results are disclosed after sequencing is 
completed. Another benefit for an online process of informed consent is how well it will 
work with electronic medical records as well as with the transfer of genomic data 
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between the laboratory and the patient as well as the physician’s office. This process will 
be further described in chapter seven. 
 These four principles, which shape a patient centered informed consent process, 
have the potential to be more effective at fulfilling the legal and ethical goals of informed 
consent as they were written in the 1950s. Constructing an informed consent process 
according to the patient’s goals allows the patient to guide the consent process thereby 
creating an environment where the patient is able to make an autonomous decision. In 
addition, patients will be active participants in their own health care decisions when 
informed by medical specialists on the meaning of possible genomic test results, 
implications of such results, and therefore, be empowered to make decisions that fit with 
their stated goals and understanding of the type of information available if they elect to 
undergo WGS/WES.  
 The education component of the informed consent protocol addresses the legal 
obligations for medical professionals and researchers to fully inform a patient regarding 
the possible limitations, benefits and consequences from undergoing WGS/WES. Also, 
the education component of the protocol provides the necessary information for a patient 
to feel empowered when making important decisions. The psychological component of 
the informed consent protocol allows space for the patient to consider some of the 
potential negative effects from WGS/WES and the consequences of knowing the results 
for themselves, and family members.  
 In addition, and perhaps most importantly, the informed consent process I am 
proposing is constructed around an ongoing conversation or dialogue with the patient. An 
ongoing conversation in this context refers to multiple consenting conversations, which 
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occur over several years in many cases. The example for how could be achieved is 
provided in chapter seven. A give and take exchange of information is more consistent 
with both the legal and ethical requirements of informed consent practices. Providing a 
“space” for this dialogue allows for patients to ask questions, and for the consenter to 
provide clarification to the patient. The goal would be for a patient to have enough time 
as well as opportunities to fully comprehend the implications of undergoing WGS/WES. 
I believe that this is the type exchange, which was initially intended by the authors of the 
initial informed consent protocols. 
In the next chapter, I apply these four principles for how to design and informed 
consent protocol for WGS/WES, to the actual consenting steps. Further elaboration for 
why and how this novel informed consent approach more adequately accomplishes both 
the ethical obligations of informed consent while addressing the complexities inherent to 
WGS/WES is reviewed at the end of chapter seven. 
  130 
CHAPTER 6 
PATIENT CENTERED INFORMED CONSENT FOR WHOLE GENOME AND 
EXOME SEQUENCING 
In this chapter, I outline the design of my proposal for a patient centered informed 
consent process for WGS/WES structured around the four principles reviewed in the 
previous chapter. To fully appreciate the components of my proposed informed consent 
process, I will describe the consent process for WGS/WES, from beginning to end, 
incorporating Bill and Melinda’s story to illustrate the real-time flow of the informed 
consent process.  
 A consenter guides the consent process. As described in the last chapter, a 
consenter is an individual trained in the area of genomics. The consenter in my model 
could also be an online module for patients who elect to undergo sequencing through a 
self-guided consenting process. The consenting steps I will outline in this chapter will be 
the same whether the consenting occurred through an online self-guided protocol, or 
online through a videoconference or Skype interview or with a traditional, in-person 
interview. The role of the consenter is to help the patient through the process of 
understanding the results and implications from undergoing WGS/WES, thus fulfilling 
the legal requirements of informed consent. The goal of a consenter is also to facilitate 
the patient’s process of undergoing WGS/WES by following the patient’s goals as 
discussed in the next nine steps, thereby fulfilling the ethical requirements of informed 
consent. 
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Informed Consent Process for WGS/WES 
 
1. Patient portal and data entry 
 In keeping with the theme that the patient, not the technology, the information, or 
the physician, should be the central focus of a more effective informed consent proposal 
for WGS/WES, I propose the informed consent process start when a patient initiates the 
process on their own. Initiation of informed consent specifically means that a patient will 
create their own portal by entering demographic information, family history, and medical 
history as well as stated goals and their understanding of why they are electing to pursue 
WGS/WES (or their physician is recommending the patient consider pursuing 
sequencing).  
 For example, if Bill were to log onto the patient portal, his goal for undergoing 
WGS might be to learn about his lifetime risk for prostate cancer and to learn whether he 
carries the genetic mutation for Huntington’s disease. Melinda’s stated goal might be to 
learn which genetic conditions her future children could be born with and to learn 
whether she has a genetic pre-disposition for heart disease. 
 Whether the patient or their physician is recommending WGS/WES, the patient 
will always initiate the process. Since the consenting methods include options for on-line 
consenting or in-person consultation, if the patient elects to meet with someone for in-
person consenting, the process will still be initiated with an online account created to 
maintain consistency of the basic demographic information, family and medical history 
as well as a summary of the stated goals for undergoing WGS/WES, from the patient. 
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The consenter will contact the patient to make an appointment to meet with the individual 
who will provide consent.  
 Upon completing the initial intake process, a software program designed 
specifically for the informed consent process for WGS/WES will format and analyze the 
patients’ demographic and medical information and the consenter, before the first 
interaction with the patient, will review the family history information. The individual 
who consents the patient will schedule either an interview with the patient through a 
videoconference, Skype, in-person or a final option for consenting, a self-guided online 
consent process. 
 
2. Stated goal(s)  
 The first interaction between a patient and consenter will include a discussion 
about the rationale for why the patient is interested in pursuing WGS/WES or the 
patient’s physician is recommending the patient consider WGS/WES. In the case where 
the physician is recommending the sequencing, the consenter will determine what the 
patient’s understanding is of the physician’s rational for recommending WGS/WES. 
Once the patient can articulate the rational for undergoing WGS/WES, the consenter will 
focus on defining the patient’s goals for pursuing WGS/WES. For example, a patient 
might tell the consenter; I am interested in having my genome sequenced to learn what 
my chances are for being affected with heart disease, colon cancer and multiple sclerosis 
in the future. When asked why they want to know about the risk to be affected with these 
diseases, the patient might respond: To inform my doctor of potential risks for heart 
disease for example, so that my doctor can ‘screen me more carefully.’ The consenter 
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would then pursue what ‘screening me more carefully’ means to the patient. At this point, 
the consenter would inquire why they are concerned about these diseases specifically. 
The patient’s family and medical history would be added to the discussion and reviewed 
with the patient at this point as well. Often patients have concerns because of a family 
history of a particular disease, and therefore, a review of the family history fits nicely 
while clarifying and understanding patients’ reasons for pursuing WGS/WES. In other 
cases, the patient may have symptoms that might suggest the patient has a possible 
disease so they elect to undergo WGS/WES for further clarification of a possible 
diagnosis or increased susceptibility for a disease.  
 If Bill were asked to state his goals for undergoing WGS/WES, he might 
prioritize the list of conditions he is concerned with: prostate cancer, Huntington’s 
disease, and possibly other conditions which he might pass along to his children. Bill 
would share his family history information and explain why he was interested in pursuing 
genetic testing for Huntington’s disease when he had no family history of this condition. 
The consenter would be able to explore Bill’s fears surrounding this condition, and 
provide the necessary education (next step) to help Bill understand why he is not at an 
increased risk for Huntington’s disease. 
 Melinda would state that she is primarily concerned with cardiac disease and any 
conditions that might affect her future children. The consenter would be able to spend 
time learning more about what types of conditions she was afraid to pass to her children 
and discuss why she was concerned about these particular diseases. Also, discussing the 
types of conditions, which she might pass to her future children at this point in the 
consent process, gives the consenter information for how to address Melinda’s education 
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section of the consent process. Specifically, that she needs to discuss autosomal recessive 
inheritance patterns and review prenatal testing and screening options with Melinda.  
 In many cases, a physician requests their patient undergo WGS/WES to provide 
additional support for a suspected diagnosis. When the physician is recommending 
WGS/WES, then the initial discussion regarding the goal for undergoing WGS/WES 
should be focused on what the patient understands about why their physician is 
recommending they pursue WGS/WES. If the patient does not fully understand the 
reasons, the consenter might inquire how much more the patient wants to learn about the 
reasoning for pursuing WGS/WES. I believe in many of these scenarios a patient will be 
appreciative of more discussion about the sequencing and what type of information is 
available and how the information learned from sequencing will help them from a 
medical standpoint.  
 Of course, there are other implications of undergoing WGS/WES, beyond just 
obtaining a better understanding of a specific diagnosis, and an ideal time to determine 
how much information beyond understanding the reason sequencing was recommended 
the patient would like to know is at the beginning of the consent process. The reason for 
this is so that the patient and consenter can decide together what type of information to 
focus on as they continue the consenting process. If the patient is unaware of what other 
diseases they might learn about through sequencing, the consenter might ask if they are 
worried about risks for other diseases or whether they might have concerns about 
diseases they could pass to their children?  
 As important as discussing what type of information patients want to learn from 
WGS/WES is, it is also important to review the type of genomic information regarding 
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possible risk for diseases the patient would not want to learn of. Focusing the first part of 
the consent process on what it is a patient may not want to learn is unique to WGS/WES 
due to the vast amount of information available at the conclusion of the sequencing. At 
this early stage of the consent process, it would be unrealistic to expect the patient to 
fully understand all the various types of results, which are possible from WGS/WES, and 
the purpose is not to insist that the patient fully understand the various results that might 
be available. The purpose of discussing what the patient would and would not want to 
know about the type of potential disease risks or carrier risk information obtained from 
WGS/WES is for the consenter to gain insight into what the patient understands about 
WGS/WES and what type of disease risk the patient does or does not want to learn before 
further information about WGS/WES is provided to them.  
 Bill might not have any concerns for learning about his genomic risk factors, 
whereas Melinda might not be interested in knowing about adult onset conditions for 
which there is no treatment due to her fear of passing this information to her children. On 
the flip side of course, she may want to know everything about all possible diseases. The 
consenting conversation is designed to elucidate what information matters to Bill and 
Melinda, and why, so the consenter can explain how well WGS/WES will accomplish 
their goals and what the limitations of the technology are for accomplishing their various 
goals. 
 The process described above can be compared to the first part of a genetic 
counseling session and is known as ‘contracting.’ Contracting is where genetic 
counselors learn what it is a patient understands about their genetic counseling 
appointment and why they were referred for genetic counseling. Contracting is a way in 
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which to establish ‘rapport’ with a patient, and build trust with the patient (Baker et al., 
1998) as well as establish agreed upon set of topics to review together during the genetic 
counseling appointment. After eliciting the patient’s understanding of the appointment, 
the genetic counselor will often clarify any misconceptions about the appointment if 
necessary, and then continue with a summary of what will be discussed with the patient 
during the genetic counseling session. The patient is also asked at this time whether they 
have additional questions or concerns they would like to discuss. Most genetic counselors 
have their own ‘checklist’ of issues they feel are relevant to helping the patient 
understand the type of genetic testing the patient was referred to discuss, as well as 
implications from the testing. Due to the often-large amount of information the genetic 
counselor feels is necessary to cover during the session, the priorities of the patient are 
often not readdressed because there is not enough time remaining in the session.  
 While my proposal for identifying a goal at the beginning of the informed consent 
process for WGS/WES is similar to the contracting component of genetic counseling, the 
major difference with my proposal is that after learning what the patient’s goals are for 
undergoing WGS/WES, the consenter remains focused on these goals. I am not proposing 
eliminating all the current informed consent components now recommended, but rather 
propose these comments be incorporated when possible, into the patient’s goal as 
discussed below. In my experience, the most effective informed consent sessions are 
those that remained focused on what the patients want to learn rather than on what the 
experts believe is most important to discuss. As I hope to illustrate as I continue to build 
my informed consent process, ultimately all the information about WGS/WES necessary 
for a patient to be able to fully understand the rationale and expectations and 
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consequences of undergoing WGS/WES can be addressed when the consent process 
remains focused on what matters to the patient.  
 
3. Education module 
 After the consenter and patient have agreed upon a preliminary list of the type of 
diseases the patient is interested in learning about through sequencing their genome, the 
education component of the consenting process begins. The education elements of the 
informed consent process consist of providing the necessary scientific background about 
genes, genomic testing, and methods of testing related to the various types of genomic 
information the patient is interested in learning. Critical to the education component of 
the informed consent process is a review of key definitions, such as understanding the 
differences between a mutation, a variant, a variant of unknown clinical significance and 
polymorphisms.  
 Other information reviewed with the patient at this point would be an overview of 
how risk for diseases is determined by the laboratories performing the sequencing, the 
accuracy of the information generated from WGS/WES and how and why the results 
might change over time. If the patient wants to learn about their risk for colon cancer, the 
education would build from basic genomic terms, to an overview of current 
understanding about the role of genetic mutation in causing colon cancer, to a discussion 
of inheritance patterns of known hereditary colon cancer syndromes, and concepts 
surrounding genome wide association studies. 
 Bill is interested in learning about risks for prostate cancer. Because most genetic 
risk factors for prostate cancer are based on genome wide association studies, the 
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education component for Bill would be shaped around the necessary genomic 
terminology relevant to GWAS, such as the definition of a polymorphism, a variant and 
mutation. Other necessary background information helpful for understanding GWAS is to 
provide an overview about the design of GWAS and how the data is analyzed and disease 
associations are identified.  
 Unlike all of our current, more traditional informed consent process, this consent 
process can occur online. Education material provided online provide a unique 
opportunity for the consenter to use visual aids to describe the genomic terms as well as 
to review concepts of risk. Even if a patient does not elect to be consented online, they 
would have access to online visual aids after their first in-person consenting session, 
which can be advantageous for many, since multiple exposures to this information will 
likely lead to better comprehension of the information. In addition, patients can review 
the education module after their results are available and share the visual aids with family 
interested in learning the information. 
 Melinda did not have the same background in science as Bill and therefore might 
have benefitted from spending more time understanding what type of information would 
be available from genome sequencing. It can be surmised that a better understanding of 
genomic information would assist her with understanding the implications of her results. 
Melinda’s schedule was sporadic because she did mostly freelance work. An online 
education module, that she could log onto at her convenience, would fit her lifestyle 
nicely and allowed her the freedom to go through the consenting steps at her own pace.  
 The purpose of incorporating an education module into the consent process at this 
point is to: 1. Prepare the patient for the risk assessment component of the informed 
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consent process where the consenter will explain how effectively WGS/WES might be 
able to meet the patient’s stated goals and 2. To assist the patient with understanding the 
consequences of learning information about their genome, for their own health, their 
future health (because results will be expected to updated over time) and for their family 
members. In addition, at this point in the consenting process, the consenter will be able to 
pause briefly to “check in” with the patient to inquire how they are handling the 
information. If the consent process occurs online, patients can stop the process at any 
point, or continue onwards depending on how well they understand the information and 
how they feel about continuing. Many may feel overwhelmed at this point or some need 
time to absorb the information and the online module provides an opportunity to pause 
the process and continue at another time.  
 
4. Risk assessment  
 The next component of the informed consent protocol would be consistent with 
existing informed consent protocols in genetic counseling practices (Baker et al., 1998) 
and that is to incorporate the patient’s medical history and family history into the 
discussion of the likelihood WGS/WES would be able to meet the patient’s expectations 
for WGS/WES. For example, an individual wants to learn about his risks for developing 
heart disease, colon cancer and multiple sclerosis. The consenter for this individual would 
take into account his family history, medical history, and integrate this into the discussion 
of what is known about cardiovascular disease genomic markers, colon cancer genomic 
markers, and multiple sclerosis genomic markers, to help the patient understand how 
effectively WGS/WES will better delineate their risk for developing these diseases. In 
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addition, the consenter would discuss whether other diseases the patient was interested in 
learning about could be identified during WGS/WES and how their baseline risk for the 
disease may or may not be changed at the completion of WGS/WES.  
 Also during this part of the consent session, the consenter would explain what 
other types of genomic data could potentially be revealed during WGS/WES, based on 
the individual’s family history or personal medical history or population statistics. For 
example, 1 in 40 individuals of Ashkenazi Jewish ancestry test positive for a BRCA 1 or 
BRCA 2 mutation (Struewing et al., 1997). The types of genetic conditions which might 
be revealed during genome sequencing are Mendelian disorders, rare hereditary 
conditions, common diseases caused by common disease causing variant and of course, 
while not definitively diagnosed with sequencing, individuals need to be informed about 
the possible of having a disease linked to a variant of unknown clinical significance, but 
until the variant is fully understood, the initial results will report an unknown significance 
to a possible hereditary disease.  
 Equally important to the discussion at this juncture is to review with the patient 
the type of information WGS/WES cannot provide. For example, at this time, there is 
limited data available to determine which variants are associated with common 
conditions, such as cardiovascular disease or multiple sclerosis and therefore the patient 
would be informed it is not as likely this information will be identified through 
WGS/WES.  
 Both Bill and Melinda would have benefited from a risk assessment discussion 
since they were both interested in diseases with complex genetic causes (prostate cancer 
and heart disease). Because Bill was interested in learning about his risk for Huntington’s 
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disease, which cannot be detected with WGS/WES, he would be informed at this point 
that this sequencing could not provide him with that information. Melinda would be able 
to inform the consenter about her family history of heart disease and the consenter would 
incorporate that information into her overall risk for developing heart disease based on 
her family history alone and based on the potential results from WGS/WES. 
 After reviewing the type of genomic information that could potentially be 
revealed at the completion of WGS/WES, the patient and consenter would reevaluate the 
patient’s initial goals for pursuing WGS/WES. The patient would be given an opportunity 
to articulate how well they believe WGS/WES will fulfill their goals based on their 
understanding of the technology. In addition, the patient could decide what other types of 
genomic information they may wish to receive regarding disease risk factors they might 
not have been aware they could learn about until this point in the conversation. 
Alternatively, they would be able to decide what type of information they do not want to 
know at this time.   
 
5. Psychological support 
 The psychological components of the consent sessions do not consist of a 
thorough psychological evaluation by a trained psychologist or psychiatrist, but are brief 
interludes conducted throughout the consent process to help a patient articulate how the 
information they are learning is affecting them. Most people are not aware that they 
might have an emotional reaction to the information they learn about their genome. 
Processing their emotions with another individual (consenter) provides an opportunity for 
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patients to be able to more effectively integrate the complex information they are learning 
about their genome into their psyche (sense of who they are) (Kessler, 1979). 
 The degree to which patients will require psychological support will of course 
vary with each individual, but, at a minimum, this part of the consent process might 
consist of a conversation with the patient about how they anticipate they will respond to 
the results, how they will communicate their results with family and friends and how this 
potential information will affect their medical care and lifestyle choices. Recall, 
addressing the psychological/psychosocial issues associated with a genetic diagnosis is 
already a standard part of the genetic counseling informed consent protocols discussed 
for Huntington’s disease and Hereditary Breast and Ovarian Cancer Syndrome in chapter 
three.  
 The psychological component of the informed consent process might be as 
straightforward and simple as acknowledging and validating the patients’ feelings at the 
time he is undergoing WGS/WES. For example, for a patient who learns through the 
consent process that their family history suggests a hereditary colon cancer syndrome and 
that WGS/WES would potentially be able to confirm this suspicion, the consenter might 
ask the patient if this new information was overwhelming to learn. The consenter would 
be validating the patient by stating that it is normal to feel overwhelmed with this 
possible threat of learning about a risk for colon cancer.  
 Providing normalization to feelings that arise during a discussion about genetic 
information is another genetic counseling strategy (Baker et al., 1998). Kessler has 
written that the knowledge one might be diagnosed with a genetic condition is all ego-
threatening (Kessler, 1979). Therefore, medical providers who are involved in presenting 
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genetic information, or making the diagnosis of a genetic disease, have an important 
opportunity to help their patients effectively incorporate the news of this diagnosis into 
their lives which can result in a positive psychological adjustment to this otherwise 
disappointing diagnosis (B. Biesecker & Erby, 2008) (Burgess, 2001). While not a 
guarantee, the more effectively a patient responds to the knowledge of a genetic disease 
or risk for a genetic disease, the greater the chance for the patient to be willing to follow a 
recommended treatments or lifestyle modifications.  
 Melinda potentially could have benefited a great deal from a consenting 
experience that allowed her time to realize emotions (guilt, fear, anxiety) she might 
experience about the possibility she could have a child born with a genetic disease. She 
would have also been given an opportunity to discuss how she planned to work through 
these emotions if the results indicated she might test positive for an adult-onset disorder. 
Alternatively, because of the strong emotional reaction she had when she did learn about 
the genomic risk factors, both for herself and future offspring, if she had the opportunity 
to think about this potential outcome before she underwent WGS, she might have elected 
not undergo WGS at this point in her life. 
 Melinda also did not have health insurance and Bill had not yet bought a life 
insurance policy. The best time for individuals to obtain life insurance is before they 
learn about future disease pre-dispositions and the consent process for WGS/WES would 
allow time for individuals to postpone the initiation of a genomic analysis until they felt 
they had the adequate insurance policies in place.  
 Ideally, the same person who starts the consenting process with the patient will 
continue to work with the patient throughout the consenting process allowing ample time 
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for the patient to establish a comfortable level of trust with the consenter. Since there will 
be multiple opportunities to assess the patient’s psychological status throughout the 
consenting process, there will be more opportunities for the consenter to intervene when 
necessary to assist the patient as they learn new, potentially threatening information. 
Psychological inventories, such as Beck’s Depression Inventory (Beck, Ward, 
Mendelson, & Mock, 1961), could be incorporated into the online only version of the 
consent process. When a patient’s survey noted a possible adverse psychological 
response, the on-line consent module would prompt an individual to reach out to the 
patient for an in-person discussion. 
  
6. Evaluation of goals 
 Following the education module, risk assessment component of the process and 
after several brief psychological assessments, the consenter and patient will review the 
patient’s initial goals for undergoing WGS/WES to determine whether these goals will 
remain the same or be altered because of new information learned through the consent 
process. For example, the patient who wanted to learn about his risk for heart disease, 
colon cancer and multiple sclerosis might learn that it will be unlikely WGS/WES will be 
able to delineate his risk for developing multiple sclerosis. The patient may choose not to 
learn about markers for this condition. Often times, patients may be informed that there 
are no identifiable genomic markers for a particular disease, but, in the future, this type of 
information might be available. Another possible scenario is that this patient may have 
learned that WGS/WES could inform him about whether he is at risk for carrying a 
mutation for a hereditary colon cancer syndrome. After learning of the possibility the 
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patient could review with the consenter the possible inheritance of the specific colon 
cancer syndrome he is at risk for and potential risks for developing colon cancer, the 
consent will check-in with the patient at this juncture to ask if this is information they 
may still wish to learn.  
 At this point in the consent process Melinda may decide not to learn about any 
possible adult-onset hereditary disorders because she knows she want to become pregnant 
soon. She might elect to only learn about any possible autosomal recessive hereditary 
conditions, which she might carry and potentially pass to her future children. The 
implications of knowing about these types of conditions might be all she could handle at 
one time.  
   
7. Identify preferences  
 At this point in the process, the consenter will also provide the patient a list of the 
types of diseases that were discussed during the consenting process. The limitations of 
what is known and not know about various potential results will also be reviewed with 
the patient at this time. In addition, the consenter will discuss the limitations of 
WGS/WES and the uncertainty inherent in the type of results which could possible be 
revealed upon the completion of WGS/WES. After all the patients’ questions have been 
satisfactorily answered, the patient will make their choices on what type of genomic 
information they wish to learn from their analysis.  
 The patient may select options based on their own goals for why they are pursuing 
WGS/WES or select options based on what their physician is recommending. The patient 
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may elect to learn no other information outside of their specific goals or they may elect to 
learn about as many diseases they can. 
  The patient will then be asked to select their preferences for how they want to be 
notified when their results are available. Because the process is online, patients may elect 
to receive an email message that their results are available. Patients can also elect to 
receive their results in person and request a phone call from the consenter to set up an 
appointment to discuss results together. A designated amount of time will be estimated 
for when results are available so that the follow-up can be scheduled at the appropriate 
time.  
 Due to the evolving nature of results generated from WGS/WES, patients will 
also be asked at this point in the process to select their preferences for receiving updated 
information. For example, when a variant of unknown significance is updated, patients 
select whether they want to be notified and if so, in what manner, either through email, 
letter, or a phone call, etc. For patients who are interested in having their genome 
reanalyzed over time, when the sequencing technology has been upgraded, there will be 
an option to select where they can be contacted when the technology has improved. In the 
next chapter, I discuss the manner in which a patient’s genome can be reanalyzed without 
requiring an additional blood sample be sent to the laboratory.  
 Patients can also select which medical providers they want their genomic analysis 
to be sent to by indicating preferences for data transfer. Patients may request that their 
genomic information also be de-identified and distributed to a research database. The 
research database would ‘store’ de-identified genomic data and share the patient’s data 
with the appropriate research studies. The communication of patient’s genomic 
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information between the sequencing laboratories, medical professionals working with the 
patient, research studies interested in obtaining genomic data and the patient’s family, 
will be further described in next chapter.  
 
8. Sample obtained  
 Once the patient has indicated their preferences for what type of genomic analysis 
they would like performed as well as how they want to be notified of their results and 
updated when new information is available, the patient will be scheduled to have their 
blood drawn and possibly also have a tissue sample obtained. In some cases, patients 
could collect their own saliva sample and send this directly to the sequencing laboratory. 
The decision for how the sample will be obtained and what type of sample is necessary 
will be dictated by the reason the patient is electing to undergo WGS/WES.  
 For example, if the patient wants to learn about genomic risks factors out of 
curiosity and personal interest, it would likely be most convenient for them to send a 
saliva sample to the laboratory themselves. On the other hand, if a patient does not feel 
confident in their ability to collect their own sample, they may want to schedule a blood 
draw with their physician’s office or go to a reference laboratory. Finally for some 
patients who are undergoing WGS/WES to study the genomic sequence of a cancer, a 
tissue sample must be obtained and processed through a pathology department in a 
hospital and sent along with their blood sample. This process will require coordination 
with the medical center treating the patient. 
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9. Results disclosure 
 As was described above, the patient will elect how they wish to receive their 
results before their sample is obtained and a genome is analyzed. When results are 
available, there will be several methods to select from for how they will receive their 
results. The first step after the patient has been notified their results are available is for 
the patient to log into their account to learn what type of result (such as a 
pharmacogenomics analysis) regarding a specific sequencing of their genome they 
consented to, is available. They will then be given an option to either review their results 
with a consenter in-person, or on-line through a Skype conversation with a consenter or 
by reading the report online. If a patient elects to review their results on their own, they 
have the option to schedule a time to discuss the result with the consenter in person or 
through a videoconference any time in the future.  
 If a patient selects an in-person or virtual conversation, there will be ample time 
available to discuss the results and implications of the results with the consenter. If the 
patient is informed of a result, which is uncertain (variant of uncertain clinical 
significance), they are given the option to be notified (or not) when additional 
information is available about this variant.  
 Also, if multiple results are available, the patient will be given the option to learn 
about as many or as few results at one time. A second result disclosure appointment 
would be scheduled at the completion of the first appointment. Regardless of the method 
of result disclosure chosen by a patient, each time a new result is available, the patient 
will be notified and re-consented to review the new result. Bill might be notified a year 
after his initial WGS results were available, that there are additional updates to the 
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GWAS determining his potential risk for prostate cancer. He would be notified of this 
availability and undergo a follow-up consent session to learn his options for receiving 
this updated genomic information. Before his results are disclosed, the consenter would 
review the same basic genomic terminology as occurred during his first consenting 
session.  
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Figure 1 Patient Centered Informed Consent Process for WGS/WES 
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CHAPTER 7 
CREATING SPACE FOR THE INFORMED CONSENT PROCESS WITHIN THE 
SYSTEMS OF WGS/WES 
A parallel concern associated with how to effectively consent individuals before 
undergoing WGS/WES is the seemingly insurmountable issue of how to adequately 
address the complexities of communicating patient preferences identified in the consent 
process, between the “systems” of WGS/WES. The complexities of the system were 
introduced in chapter four and include: the volume of genomic data produced by 
WGS/WES, the unknown analytic validity of data analysis, the uncertainty of how to 
adequately interpret genomic data (for example, variants of uncertain clinical 
significance), how to apply genomic results to patients’ existing medical care (clinical 
utility), and, how to contact patients with updated genomic information.  
 The multiple systems operating within the process of undergoing WGS/WES 
include: the patient, the patient’s physician(s), the laboratory where the patient’s sample 
is analyzed (including the sequencing, the bioinformatics analysis of the data, 
interpretation of the data generated from the bioinformatics laboratory and generation of 
a report), the medical environment surrounding the patient (including the electronic 
medical record, the health insurance company, the pharmacy), individuals the patient 
elects to share their data with (relatives, friends, and social networks), and, the research 
community where patients’ genomic information could be shared between multiple 
research protocols. To address the complexities between the systems inherent to 
WGS/WES, I propose the informed consent process become embedded with the systems.  
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 In this chapter I describe how to integrate informed consent throughout the 
sequencing process and explain why this is a more effective approach to the informed 
consent process than obtaining informed consent only at the beginning of the WGS/WES. 
Obtaining consent only once is what is being proposed at this time in research and 
clinical protocols reviewed in chapter four. Integrating the informed consent process 
around the systems of WGS/WES involves revisiting and re-discussing components of 
the informed consent process discussed in chapter six, multiple times during the 
WGS/WES experience. This chapter demonstrates how a reiterative informed consent 
process creates a fluid informed consent process shaped to respond to the data reported 
from WGS/WES and how a reiterative informed consent process is better suited to 
address the analysis and interpretation challenges characteristic of WGS/WES. The 
ultimate outcome from utilization of this type of consent process is to be able to more 
effectively prepare patients for the various types of results produced by the sequencing 
over a span of many years. Additionally, a reiterative informed consent process allows 
for a more practical integration of WGS/WES into our existing medical model. In this 
chapter I elaborate further on this point using diagrams to illustrate the implementation of 
WGS/WES into our current medical model.  
 The first step in the framing of an informed consent process around WGS/WES is 
to provide an environment where the six systems inherent to WGS/WES are capable of 
communicating with one another. The most effective method of communication between 
these systems could occur through the electronic transfer of patient’s interpreted genome 
data generated from WGS/WES. To allow for the electronic transfer of information, I 
propose patients who elect to undergo WGS/WES have their entire genome sequence 
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stored onto the patient’s portal, regardless of why they are undergoing sequencing. The 
data which has been interpreted will be formatted into a report and be available for 
transferring to other health care providers, etc., based on the preferences stated by the 
patient in step seven of the consenting process. A patient’s genomic information could be 
transferred between the laboratory, the patient’s home computer, and the physician’s 
office, as well as between the other systems encompassing WGS/WES.  
 To protect the privacy of the patient’s genomic data during the data transfer 
between the systems, informed consent is obtained before each point of data exchange. 
For example, once the patient’s results have been disclosed, the patient will be given the 
option to share their reports with their physicians, their pharmacist, family or friends, etc. 
The data will be sent electronically from the patient’s portal. The exchange of patient 
information will only occur when the patient has released their information, similar to 
current release of information policies, however in this instance, because the patient’s 
genomic results and data is stored electronically, the patient will provide an email address 
and point of contact to send their information from their own portal. During the informed 
consent process, patients will have already entered their preferences for who they would 
like to receive a copy of their results but, while being consented, they still might not 
know with whom they would like to share their information.  
 An advantage of the online system is that instead of sharing the entire genomic 
report, only portions of the data, such as a pharmacogenetics report, could be sent to the 
pharmacist. The patient could send a separate report to their relatives regarding possible 
hereditary conditions. Only the patient is able to select what type of results are sent out 
and to whom.  
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  Also, if the patient elects to have their genomic data updated over time, the 
patient will continue to be offered options to share results with individuals they specify to 
send the information to, when the updated version of the results are available. Another 
option would be for a patient to store his genomic report on his own computer and share 
this information themselves with their relatives, rather than having it sent from their 
portal.  
 The electronic format of data exchange would also make sharing data between 
multiple research studies more efficient. If, for example, a patient would like their 
genomic data to be shared with researchers who might have an interest in a specific type 
of variant they were found to carry, they could elect to have their genome stripped of 
demographic identifying information, and shared with a research portal. The purpose of 
the research portal is to store a patient’s genomic data and survey results for any findings 
that might be useful to various studies and then share the relevant genomes with the 
relevant studies.  
 An iterative informed consent process provides an opportunity for the technology 
to perform in the manner in which it was designed: interpret an individual genome in the 
most comprehensive manner possible and effectively apply this information to a patient’s 
medical care. At the same time, this iterative process may be a conduit for an effective 
informed consent process because the patient controls the type of genomic information 
they want to learn as well as how and when they receive and use the information. In other 
words, this model is built to prepare individuals for every type of genomic result now 
produced from WGS/WES, regardless of family history, medical history or clinical 
indication.  
  155 
 
Figure 2 Data Exchange Between the Systems of WGS/WES Process 
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In these next few paragraphs, I illustrate how this model is capable of 
systematically addressing the complexities of WGS/WES reviewed in chapter four and 
stated in the first paragraph of this chapter. First, the electronic storage of a genome onto 
a patient’s portal is a mechanism for the data to be transferred, updated and reanalyzed. 
Additionally, all the data can be maintained in one location for the lifetime of an 
individual. Current practices for reporting genomic results includes printing a paper 
report, with no electronic version available for the individual’s medical record. Rather 
than print a large amount of paper data, which is difficult to keep track of for the patient, 
and difficult to scan into an electronic medical record, the electronic information is easier 
to access for both the patient and physicians and other medical providers involved in a 
patient’s medical care. Also, the data is likely to be modified over time. An electronic 
update would be easier to link to an original report, versus generating a new report with 
every update or addition to the original genomic analysis.  
 A major limiting factor of WGSW/WES which results in lower utilization of the 
technology by medical providers is the inability to adequately understand the meaning of 
the thousands of variants identified through sequencing and apply the data in a clinically 
relevant manner. These limiting factors, however, are temporal and, while there is still 
much uncertainty on how much more understanding scientists will gain from studying 
our genomes over time, it is likely that much more information than we appreciate today 
will be clinically relevant in the next several to dozens of years from now. It would 
therefore seem to be shortsighted to design a temporary informed consent model that 
does not meet the demands of the technology from an ethical or practical perspective.  
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 Assuming all individuals undergoing WGS/WES can expect to be informed of 
new advances both to the technology and the implications of uncertain results, the 
electronic model I describe is prepared when the laboratory updates their sequencing 
technology or provides updates to variants of unknown significance. As variants change 
from unknown significance to deleterious, or become linked to a known disease, this 
information will updated electronically to the patient’s portal and a message would be 
sent to the patient informing them there is updated information available. By storing an 
entire genome on the patient’s portal, the data will be available when the patient wants to 
learn it. The patient can elect to learn about new disease risks factors several years after 
they started the process. Finally, the laboratory would be able to reanalyze genomic data 
without requiring the patient to submit another blood sample.  
 If an individual elects to learn the results, he will be re-consented at this time, as 
described in chapter six. The patient can elect to undergo a refresher consent process each 
time new genomic information is available. The consent session would review the type of 
genomic information that is now available, and most importantly, signify a point in the 
entire process where they patient can elect to decline learning new information.    
 From the clinical perspective, accurate and effective transfer of genomic 
information to all the individuals involved in a patient’s medical care is essential for 
proper utilization of the data. Clinical care of a patient has always been most effective 
when the communication of information about the patient is timely, accurate and reaches 
the necessary specialists involved in the patient’s care. The transfer of data therefore, will 
be much more efficient when the process of undergoing WGS/WES is structured in an 
electronic format. An online and interactive informed consent and data exchange process 
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will most likely be a necessity in the future, not only to meet the demands of the 
WGS/WES systems, but also to be able to address the face-to-face consenting burden of 
current informed consent practices.  
 Patients would manage their own data throughout the sequencing by selecting 
options for how to be re-contacted when new results are available and what type of 
information they wish to learn. Also, an electronic portal will allow patients to enter new 
medical information about their health over time and this could be considered when the 
genome data is reanalyzed. Another benefit of the electronic model for WGS/WES is 
when a patient moves and needs to establish care with a new physician, the electronic 
model provides an easy mechanism to transfer results without needing to request a large 
amount paper reports be sent from one physician’s office to another. 
Rationale for why a patient centered informed consent process for WGS/WES is 
better suited to fulfill the ethical obligations of informed consent than current and 
proposed informed consent protocols for WGS/WES 
 
 The institutional requirement that a signed informed consent document is all that 
is necessary to demonstrate consent was achieved has resulted in the current emphasis of 
informed consent to be about protecting institutions from litigation, and not about 
protecting individual rights. The resulting problems with addressing the consent process 
in this manner include: 1. Written consent forms scripted in a template format, 2. Consent 
processes and forms written by experts in the field of genetics, 3. A consent process that 
does not engage individuals in conversations about the issues inherent to WGS/WES, 
and, 4. A consent process that is incapable of responding to the complexities of 
WGS/WES. In the next few paragraphs, I discuss how these resulting problems prevent 
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the consent process from fulfilling the underlying ethical obligations of the informed 
consent process and describe how the informed consent process I outline in chapters five, 
six and seven is more capable of fulfilling the ethical obligations of the informed consent 
process for WGS/WES.  
 
1. Written consent forms scripted in a template format  
 The written informed consent forms for genetic testing and those used for 
WGS/WES consist of a checklist of multiple components of genomic testing to review 
with an individual. These checklists are written in a standard format and include the same 
template with similar scripted information about WGS/WES for everyone whether they 
are referred for WGS/WES or seeking it on their own. This traditional method is 
performed the same way, regardless of the differences between individual situations for 
undergoing WGS/WES, individuals varying education backgrounds, psychosocial 
concerns, values and thoughts about genome sequencing.  
 The consent process, which I am proposing, begins by asking the individual what 
their understanding is of WGS/WES and why they are pursuing sequencing. A consent 
process, which begins with the individual stating their understanding and/or goals for 
undergoing WGS/WES, is more consistent with the original intent of informed consent 
because the content of the subsequent consenting conversation can then be focused on 
what the individual wants, expects and needs to learn about undergoing WGS/WES. The 
process is thereby shaped around individuals’ values, beliefs, and goals, rather than 
determined by a checklist created by experts. Structuring the process in this way allows 
consent to be reflective of the concerns and interests of the specific patient, thereby better 
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respecting her autonomy and individuality. This stands in contrast to traditional protocols 
wherein the checklist of topics to discuss reflects the values and priorities of the experts, 
not those of the patient.  
 
2. Consent process and forms written by experts in genetics  
 Another way in which the consent process proposed in this dissertation is more 
consistent with the original intent of the informed consent obligations is that by asking 
the individual what they understand about the reasons for undergoing WGS/WES, the 
consenter will know what type of information (education) they might need to provide the 
individual about the process of WGS/WES to help them either better understand the 
rational for undergoing sequencing and/or the possible implications of their potential 
results. If the consent process is developed entirely by experts and presented by a 
medically trained person, there is built in bias around the entire consenting process. 
However, if the consenting process is allowed to unfold, as I am proposing, with the 
natural flow of a conversation about WGS/WES focused on the individual’s values about 
WGS, then the individual can make a decision without being influenced by what the 
experts might believe is critical to understand or even critical to considering why they 
might benefit from WGS/WES.  
 The key difference between my proposed protocol and existing protocols is that in 
my protocol, the consent session is focused on the type of information, scientific, 
practical, etc., the individual needs and wants to hear. Existing informed consent 
protocols (including those now being considered for WGS/WES) focus on what types of 
information experts believe individuals need to learn about to better understand the 
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implications for undergoing WGS/WES. It may be the case that much of the time there 
proves to be minimal differences between the type of information individuals feel is 
important to learn, and the information the experts perceive is important, but the ethically 
relevant difference lies in that the individual undergoing sequencing guides the process in 
the former scenario. They express what they do or do not understand about sequencing 
and what type of information they want to discuss. In the latter, content is entirely 
dictated by top down expertise.  
 In my own experiences consenting individuals in this manner, I find that the 
WGS/WES related topics that the individual wants to discuss tend to converge with what 
I feel is important to review, but, importantly, the structure of the discussion and pace of 
presenting new information is determined by the individual. It is through such 
experiences that, as a genetic counselor, I have learned to step back and not force my own 
agenda. The consent process then becomes a conversation, where an individual is 
engaged and this engagement deepens, as they understand the various layers of the 
complexities inherent to WGS/WES. 
 This process, as I describe it here, is what informed consent was created to 
achieve. It will assist the individual to comprehend implications of medical interventions 
of WGS/WES, such that they are intellectually, psychologically and practically as 
prepared as they can be to make informed choices consistent with their own beliefs and 
values. The role of the consenter is still maintained as the expert, but an expert whose job 
it is to guide the individual through the consenting process, while employing “gentle 
paternalism”. “Gentle paternalism” is a term used by a practicing medical oncologist at 
Mayo Clinic, Tom Fitch, M.D., who describes his role in counseling his patients about 
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the implications of a possible therapy to treat cancer (Fitch, 2013). The implication of his 
phrase is that patients are not left on their own to inform physicians what they want, but 
are instead guided by physician’s expertise and experience, to make a decision most 
consistent with their own values.  
 As the informed consent process I describe progresses, individuals will be asked 
to share with the consenter what types of genomic results they do and do not want to 
know. Providing individuals a choice regarding what type of genomic results are 
important to them is a fundamental component of existing informed consent protocols, 
but only in theory and not in practice. Current informed practices do ask individuals to 
select yes or no for whether they would like to learn about genomic results which for the 
most part, are not considered to be related to the specific indication for why there are 
seeking out WGS/WES. For example, if an individual is recommended to undergo WES 
to determine whether his symptoms (a seizure disorder, deafness and congenital cardiac 
anomaly) are all related to an unspecified genetic disorder, he would be given an option 
to learn about genetic diseases not likely to be associated to his symptoms. One example 
is learning whether he is a carrier of an autosomal recessive condition, such as cystic 
fibrosis. Learning about his carrier status for a variety of genetic disorders is not the 
reason in this example for why this individual is pursuing WES, yet the information is 
easily identifiable when he undergoes sequencing. Therefore, current informed consent 
documents ask individuals to check yes or no: “I do or do not want to know about these 
types of conditions.” How a consenter prepares an individual to learn about possibly 
thousands of Mendelian disorders, any of which could potentially be identified with 
sequencing is proving to be an insurmountable hurdle to overcome when considering 
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informed consent protocols for WGS/WES. To address this insurmountable hurdle, 
laboratories performing WGS/WES write consent forms that group diseases together 
based on inheritance pattern (autosomal recessive conditions) or type of diseases (adult 
onset neurological condition for which no treatment is available) and ask individual to 
select yes or no, whether they want to learn about possible genetic risk factors for these 
types of diseases. In some cases, laboratories state which types of diseases they will or 
will not report (Bick et al., 2013). There is no way to realistically describe all the diseases 
that can be detected within each group during an informed consent session, since much of 
this is unknown, plus the amount of information is too much to cover in one session. 
Therefore, this is the solution by the laboratories performing testing for how to address 
this issue in the consent process.  
 The consent process I propose would also discuss the variety of results available 
from WES, but, rather than pick out specific options for individuals to choose from based 
on inheritance patterns or various types of diseases, individuals will be asked what type 
of genetic diseases they might want to know about and which types of diseases they 
might not want to know about based on their own experiences.  A positive family history 
for a particular disease, concerns stemming from previous interactions with individuals 
affected with a particular disease, or any other reason might lead to not wanting results. 
This discussion would occur early on in the consent process after a basic science 
foundation is in place and the individual learns about what types of diseases WGS/WES 
is capable of detecting and which disease WGS/WES is not capable of detecting. When 
the time comes to decide what type of information individuals want to learn about, the 
consenter can frame this discussion around the goals that the individual initially stated at 
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the beginning of the consent process. The difference in this approach when compared to 
existing protocols is that the types of results available for individuals will not be 
preselected by the experts, but again guided by what the individual suggests is important 
to them, within the framework of the diseases WGS/WES are capable of detecting.  
 
3. A consent process that does not engage individuals in conversations about the 
issues inherent to WGS/WES  
 Incorporating a psychological component to the informed consent process as I am 
proposing for WGS/WES, fulfills the ethical obligations of informed consent more 
concretely than current informed consent protocols by creating an opportunity for the 
consenter to naturally delve deeper into a discussion about the implications of results. 
These implications can be medical implications, as well as psychological, psychosocial, 
or financial, and the consequences of learning genomic information for the individual’s 
family members as well as ways in which this type of information might affect his 
relationships. Helping individuals appreciate the consequences of receiving potential 
results from WGS/WES has been a major theme of the traditional informed consent 
protocols created for genetic testing. Yet, it is often not fully explored with individuals 
undergoing genetic testing. Most informed consent protocols list the possible 
psychological, psychosocial and financial, etc., implications in written consent forms 
without engaging individuals in a conversation about these issues, which arguably cannot 
be as effective for assisting individuals in the process of adequately understanding how to 
be psychologically prepared for genomic results revealing a possible risk factor or risk 
factors as the case may be, for any number of unknown diseases.  
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 In addition, because WGS/WES are two technologies that create more uncertainty 
than certainty, it becomes even more important than in the past to take the time to address 
these uncertainties, as they may be the reason WGS/WES leads to potential adverse 
psychological and psychosocial responses. Another fundamental component of 
WGS/WES technologies is that both the experts (scientists and physicians, etc.), are 
struggling with the uncertainties of WGS/WES along side the individuals who are 
undergoing WGS/WES. The uncertainty surrounding what types of results will be 
available after sequencing is completed is in part mitigated by creating structured 
informed consent protocols. In my opinion it is not possible to mitigate implications of 
results that even the experts cannot predict. Instead of worrying about mitigating the 
uncertainty by creating a structure that helps us feel as though we are dealing with them 
in a responsible way, I would suggest, as experts, we acknowledge these uncertainties 
during the consent process and face them along with the individuals undergoing 
sequencing.  
 
4. A consent process incapable of responding to the complexities of WGS/WES 
 The ability to engage individuals in a consent process with multiple methods 
online, in-person and combination of both, lends itself to a more tailored consenting 
experience. By providing genomic education and information about sequencing, in a 
variety of media formats, individuals can choose the modality most consistent with their 
personal learning style. Some would agree with the statement that the better an individual 
understands how undergoing WGS/WES will affect his or her life, the better prepared an 
individual will be for making an informed choice. This statement is not consistent with 
  166 
what frequently occurs in reality. As I unravel the multiple components of the informed 
consent process, the better I understand the fact there are multiple factors, which work 
together to constitute a successful or effective informed consent experience. The 
effectiveness of the process is in reality, truly only determined by the individual who is 
undergoing the process themselves. 
 An inarguable fact, however, is that there is an overwhelming volume of 
information to learn about WGS/WES. By offering several types of consenting methods 
(online and self-guided consenting process, in-person and a combination of both) there is 
opportunity for individuals to set their own pace for learning new information. Also, 
education modules, which are available online, along with electronic versions of an 
interactive format for individuals to learn more about various genetic diseases they might 
be at risk for based on the results from WGS/WES, provides multiple opportunities for 
individuals to review the information on their own, share it with relatives and take the 
time to consider their options. This is another example for how the consent process I 
describe is better suited to fulfill the goal of informed consent because the variety of 
consenting methods provides an environment whereby individuals can optimize their 
chances to be fully informed and engaged in learning about implications from 
WGS/WES. 
 An important nuance I wish to clarify at this point is the consent proposal I 
outline above emphasizes two key elements of informed consent practices necessary to 
fulfill the ethical obligations of informed consent: 1. Elicit what an individual wants or 
does not want to know about genome sequencing and understands about the technology, 
and, 2. Engage the individual in a conversation. I am not proposing that the content of the 
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existing informed consent processes for genetic testing be disregarded. The proposal I 
suggest incorporates the same components of existing informed consent protocols; a 
discussion of the ways in which genome sequencing may or may not affect medical care, 
the limitations of the technology, the possibility of uncertain results, the likelihood that 
the meaning of results will be changed in the future, as scientists develop a better 
understanding of the result, etc. Therefore, the expert’s role, to guide individuals through 
the consent process based on the knowledge established in the profession of genetics, will 
remain in tact. The subtle, but important nuance I wish to highlight is that my proposal 
more effectively incorporates this information into a personalized conversation with the 
individual undergoing genome sequencing, thereby structuring an informed consent 
process around the needs of the individual.   
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CHAPTER 8 
CONCLUSION 
Whole genome and exome sequencing technologies are ripe with promise to personalize 
medical care and improve health outcomes. The potential for what genome sequencing 
promises may never match the real outcomes from genome sequencing. At this point, the 
extent of how genome sequencing will individualize medical care and improve health 
care outcomes is not known. Despite this uncertainty, genome sequencing has already 
made an important imprint onto medical care. The first example of how WGS/WES has 
impacted medical care is in the area of cancer genetics. The field of medical oncology is 
poised to appreciate the benefits of individualizing therapy to prolong a life, or halt 
cancer progression completely. As a result, utilization of genome sequencing is occurring 
in clinical practices, and now laboratories performing the sequencing, physicians working 
with patients and researchers examining issues related to genome sequencing, are 
grappling with real complexities of how to incorporate genome sequencing into medical 
care. The unifying component for WGS/WES that connects all of the complexities of 
genome sequencing is the issue of how to provide informed consent for an individual 
who is interested in undergoing WGS/WES. The consenting process for WGS/WES is 
complicated by the large amount of data generated from sequencing, the uncertainty of 
how to interpret the data, uncertainty for how to apply the data to patient care and how to 
contact individuals over time with updated information about the genomic data.  
Informed consent practices were implemented into medical research and clinical 
care at a time when our society was recovering from the horrifying revelations of the 
medical experiments conducted during WWII. The ethical backlash from these human 
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medical experiments resulted in the creation of the Nuremberg Code in 1947, the first in a 
series of ethical mandates for medical research studies. The ten moral imperatives for 
conducting research studies summarized in the Nuremberg Code were updated in the 
1960s, 70s, 80s and 2002, 2004 and 2008 by the World Medical Association to reflect 
more contemporary research study designs (Mascalzoni et al., 2008). Additional 
guidelines for proper ethical conduct in medical research were released by the U.S. 
government in the late 1970s, with the publication of the Belmont Report. Most recently 
the medical research and clinical communities were reminded of the ethical embodiment 
of informed consent with a reported issued in 1983 by the President’s Commission for the 
Study of Ethical Problems in Medical and Biomedical and Behavioral Research 
(President’s Commission for the Study of Ethical Problems in Medicine and Biomedical 
and Behavioral Research: Making Health Care Decisions, 1982). This report emphasized 
the goal of an “ethically valid” informed consent process. The report reminds medical 
researchers and clinicians that the ethical component to the informed consent process 
consists of a conversation between a patient and physician to encourage an autonomous 
and informed decision-making process (President’s Commission for the Study of Ethical 
Problems in Medicine and Biomedical and Behavioral Research: Making Health Care 
Decisions, 1982). The two major themes identified in all the reports are: 1. To protect the 
autonomy of all individuals participating in a medical research study, and 2. To 
emphasize the voluntary nature of participating in a medical research experiment. 
 Despite these highly visible moral imperatives for conducting ethical medical 
research, numerous medical trials have failed to treat study participants in an ethical 
manner. The most infamous American medical research failures were revealed 
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throughout the 1960s and 1970s. The first published scandal was the case at New York’s 
Jewish Chronic Disease Hospital where two physicians injected cancer cells into patients 
without their knowledge (Stark, 2012). The second widely cited case is the Tuskegee 
Syphilis Study where, between 1932 and 1972, researchers failed to inform men affected 
with syphilis that they were being studied, and further, no treatment was offered to the 
affected men, when treatment became available (Hamilton & Bowers, 2003). These and 
other studies violated the first moral imperative of medical research studies: to protect the 
autonomy of all individuals.  
Ethical failures occur every day in medical research despite the moral obligations 
of the informed consent process described repetitively since the late 1940s. The reason 
for these ethical failures is in large part to be blamed on the ways ethical review has come 
to be institutionalized in medical research practices (Stark, 2012). Medical research 
review boards (IRBs) created to evaluate whether a proposed research project is ethical, 
have not themselves been subject to any review of their process of reviewing studies, or 
about the mechanism through which they make their decisions. The reason the review 
process is not questioned is due to the integration of a practice into our medical research 
community that was assumed to be effective. In reality, IRB practices have never been 
evaluated and in fact may not be effective (Stark, 2012). In addition, once studies are 
approved by the IRBs, the study investigators pledge on good faith they will uphold an 
ethical code of conduct, when again, there is little follow-up to determine if this occurs. 
The way in which the review process for medical research studies occurs has not changed 
over time, in part due to the bureaucratic institutionalization of the ethical component of 
the informed consent process.  
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Informed consent practices in clinical care followed a similar path as the informed 
consent practices in medical research. While the implementation for informed consent 
into clinical care was driven by legal rulings, the ethical obligations of informed consent 
were always considered to be at the core of why informed consent became a mandate in 
clinical care. The Salgo case (Salgo v. Leland Stanford etc. Board of Trustees, 1957) 
introduced the concept of patient autonomy into medical care and encouraged patient 
involvement in health care decisions. The legal incorporation of informed consent into 
clinical care also resulted in the creation of five components of an informed consent 
conversation including a summary of the patient’s diagnosis, recommended treatment 
options, expected outcome of treatment, risks and benefits of various treatment options, 
and any alternative procedures and risks or benefits of these alternative procedures (Plaut, 
1989). The practice of informed consent in clinical care was therefore shaped by a list of 
required elements, with the suggestion that the fulfillment of informed consent also 
includes an ethical responsibility to ensure patients fully understand all possible benefits, 
risks and options available to them. The consent process was designed to occur in a single 
conversation, often times, right before the test is ordered or a procedure or surgery is 
performed. The ethical purpose of informed consent is to protect, empower and respect 
the individual who is faced with a decision surrounding his/her medical care. But again, 
despite the reminders of the ethical nature of a consent process through the report issued 
from the President’s Commission for the Study of Ethical Problems in Medical and 
Biomedical and Behavioral Research, informed consent practices in clinical care have 
failed to fulfill these ethical obligations for the same reason informed consent practices in 
medical research have also failed. 
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As described throughout this dissertation, the ethical obligation of informed 
consent is secondary to the legal obligations of the consent process. This is demonstrated 
by the fact that the evidence that consent is achieved is based on the ability for an 
institution to produce a signed informed consent document. The legal requirement of 
informed consent is based on the need for medical institutions to avoid litigation. The 
emphasis on protecting an institution and physicians over protecting patient rights is also 
demonstrated by the fact that while informed consent continues to be a routine feature in 
clinical medicine, the practice itself is criticized by physicians who do not respect the 
intent of the informed consent process and therefore provide only lip service to the 
process (Lidz, 1983). The practice itself, while arguably ineffective for patients and 
physicians, continues only because it serves to demonstrate informed consent was 
obtained, thereby protecting institutions and physicians. 
The irony of the situation is that informed consent was developed to protect and 
empower patients to make informed decisions, as well as prepare patients for all possible 
outcomes from a medical test or procedure. I have argued that the practice of informed 
consent is no longer primarily driven by an ethical desire to help patients better 
understand options available to them, but rather by a bureaucratic obligation to compete a 
routine step in the process of medical care, a step that is often seen as a nuisance by 
health care workers who are too busy to take the time and review the necessary 
information. The informed consent process today lacks the kind of substantive 
conversation with a patient about implications of a particular medical treatment that the 
process, properly understood, requires.  
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This dissertation has demonstrated that these shortcomings are particularly 
evident-and particularly consequential-in light of new genome sequencing technologies. 
The field of genetics was introduced into clinical medicine in the early 1900s, with the 
advent of heredity clinics. These early heredity clinics openly supported eugenics 
practices, but did not have the ability to confirm a suspected diagnosis of a genetic 
disease. The 1950s, however, brought two pivotal breakthroughs in the understanding of 
hereditary components of disease, with the publication of the physical structure of the 
DNA molecule by Francis Crick and James Watson (Watson & Crick, 1953) and the 
identification of the correct number of chromosomes reported in 1958 by Tijo and Levan 
(Dave & Sanger, 2007). These two scientific discoveries paved the way for prenatal 
testing, which became available in the late 1960s (The NICHD National Registry for 
Amniocentesis Study Group, 1976). Prenatal testing is performed during a pregnancy, to 
diagnose a fetus with a chromosomal alteration or genetic disease. The availability of 
prenatal testing created a new medical test with multiple risk factors requiring couples to 
make difficult decisions about undergoing a test with risks for miscarriage.  
Genetic testing provides medical information that is burdened by the fact that 
learning about a hereditary disorder has consequences to not just the individual suspected 
of being diagnosed with the condition, but this information has consequences to the 
affected individuals’ relatives as well. Couples who have a baby diagnosed with a genetic 
condition may often be informed about the risk to have another affected child while still 
trying to cope with the devastating news about their current baby. Genetic conditions are 
permanent and most genetic diseases have no treatment options. The psychological 
consequences of being diagnosed with a genetic condition are often negative as many 
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individuals who learn about genetic risk factors suffer issues with self-esteem as their 
sense of self is challenged. Others fail to adjust appropriately to the diagnosis of a genetic 
condition (R Klitzman, 2009) (B. Biesecker & Erby, 2008).  
In response to the unique consequences of learning about a genetic disease, as 
well as the difficult decisions surrounding prenatal testing, the profession of genetic 
counseling was created in 1969 (Marks & Richter, 1976). Genetic counselors are trained 
to help individuals understand the implications of a genetic diagnosis, including the 
medical, psychological and familial implications of a disease. Genetic counselors also 
educate individuals on inheritance patterns, testing options, medical management and 
prevention of genetic disease, with the goal of promoting informed choices and 
adaptation to a diagnosis or risk of a diagnosis (Baker et al., 1998). Despite the eugenics 
backdrop from which the field of genetic counseling evolved, the profession has settled 
into a non-directive practice of informed consent, where individuals and couples are 
encouraged to make decisions surrounding genetic testing options consistent with their 
own cultural, religious and personal beliefs (Kessler, 1979).  
 Advances in genetic technology changed the practice of genetics as it became 
possible to diagnose all types of genetic conditions with a variety of inheritance patterns. 
The new genetic tests were always challenging as each test had a different detection rate, 
increasing the complexities associated with explaining genetic tests during an informed 
consent process. Additionally, genetic testing options expanded beyond prenatal testing 
and pediatric practices into predisposition testing (genetic testing for adult onset 
disorders). In response to the complexities of genetic testing, the psychological and 
psychosocial impact of a positive genetic test result, as well as the implications on the 
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family members of an individual undergoing genetic testing, the informed consent 
process for genetic testing was designed to occur in large part, during a genetic 
counseling session. Practice guidelines summarizing the necessary topics to review 
during informed consent sessions before genetic testing were published throughout the 
1990s and thoughtfully addressed all the nuances of both the technical complexities of 
genetic testing as well as the psychological and psychosocial implications of undergoing 
genetic testing.  
 Despite detailed published informed consent practice guidelines for genetic 
testing, and the recommendation that genetic counseling be offered before a genetic test 
is ordered, the informed consent process is still criticized as ineffective. The complex 
nature of genetic testing options, the unfamiliarity of genetic terminology throughout the 
general population, as well as challenges inherent to understanding genetic risk factors, 
are reasons cited for why the informed consent process for genetic testing is not effective. 
Physicians and patients struggle with understanding risk information, and patients 
especially, who are concerned about a possible risk of a genetic disease, have a difficult 
time applying statistical probabilities, to their own situation, while experiencing an 
emotional reaction to learning information about a genetic diagnosis.  
I blame the ineffectiveness of the informed consent practice for genetic testing on 
the fact that, as with other medical tests, a signed informed consent form is all that is 
necessary to provide evidence that informed consent was achieved prior to undergoing 
genetic testing. The fact that a signed informed consent form is evidence for medical 
institutions that informed consent was achieved results in an informed consent process 
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that values the legal obligation over the ethical obligation to fully engage individuals in a 
discussion surrounding the consequences of undergoing genetic testing.  
An even more complex genomic test is now available, genome sequencing 
capable of identifying hundreds to thousands of different genetic diseases and genetic 
variants at one time. The introduction of WGS/WES into clinical care provides an 
opportunity to re-evaluate the informed consent process and consider the direction of 
future informed consent practices. The fact that whole genome sequencing could reveal 
over thousands of different results at one time is one motivation for fine-tuning the 
informed consent process, to create a more flexible process capable of addressing 
multiple results. Reasons to modify the informed consent process to be more flexible at 
managing multiple results reported at once is important, not just for whole genome 
sequencing, but because the informed consent practices developed for genome 
sequencing will likely become the model for how to handle other medical tests that 
produce a lot of data at one time (such as proteomics focusing on the study of the 
interactions of the proteins expressed by our genes). 
Medical professionals and medical researchers interested in developing new 
protocols for the informed consent process for genome sequencing are considering the 
complexities of sequencing and how these complexities challenge existing informed 
consent protocols for genetic testing. The complexities of the genome sequencing 
described in chapters four and seven and include: uncertainty for how to analyze, 
interpret, and manage the large volume of genomic data produced from genome 
sequencing, how or whether to report the numerous variants of unknown clinical 
significance, how to incorporate results from genome sequencing into individual medical 
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records, and how to re-contact individuals with updated genomic information. These 
complexities are well described in the literature, and the researchers, clinicians and 
ethicists who write about them agree that when designing new informed consent 
protocols, these issues need to be considered. What is not described in the literature is a 
real solution for how to address these complexities through the consent process. This 
dissertation addresses both the issue of how to provide informed consent that addresses 
the ethical intent of the consenting experience, as well as describes a model for how to 
implement informed consent into the process of genome sequencing in a way that 
addresses the challenges of the technology. 
A more fundamental motivation for restructuring informed consent practices is to 
re-design the process around the ethical intent of informed consent, rather than the legal 
intent. An ideal informed consent process is one designed around the needs of the patient. 
The fundamental ethical purpose of informed consent is to empower a patient to make a 
fully informed decision. To empower an individual to participate in the decision-making 
process, that person needs to be considered and incorporated into the consent process. 
Current informed consent practices are written by experts, with the same standardized 
form given to every patient or rehearsed list of benefits, limitations and risks from a 
specific test, discussed with every person in a rote exchange. These practices are not 
individualized to address what a patient needs to learn about or discuss. Nor adequate to 
render the patient capable of participating in the decision making process. Unless the 
patient is considered in the process, it’s difficult to address their needs. The fact that the 
existing informed consent protocols do not effectively address the underlying ethical 
purpose of informed consent is an issue that has not yet been adequately confronted in the 
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research studies considering new informed consent practices for WGS/WES. As a result, 
I foresee in the development of informed consent protocols for whole genome and exome 
sequencing the perpetuation of an informed consent process that fails to fulfill the 
underlying ethical obligations of the process. This dissertation has drawn attention to this 
problem, and offered the outlines of a solution.  
The solution I offer to improve informed consent practices and address the 
complexities of genome sequencing is to shape an informed consent process around 
individual goals and understanding of the purpose and implications of undergoing 
sequencing. I introduced four elements of a patient centered informed consent process for 
whole genome and exome sequencing in chapter four. The first element I describe is to 
begin an informed consent process by asking the individual to state their goal for 
undergoing genome sequencing. The stated goal of the individual may not be achievable 
(i.e. learn about all the possible genetic conditions listed in Online Mendelian Inheritance 
in Man (OMIM)), but until the goals of the patient are solicited, the informed consent 
process simply cannot prepare the patient to make an informed decision. The second 
element structures the informed consent session around the individuals stated goal and 
overall understanding of the implications of genome sequencing. For instance, if an 
individual who wants to learn about all possible genetic conditions reported OMIM, it is 
only after learning of this goal that the consenter knows he/she needs to elicit the rational 
for why this individual wants to know about so many conditions. Understanding the goals 
from the individual undergoing WGS/WES provides useful information to the consenter 
for how she might approach the education component of the session. Given the large 
number of conditions that would need to be reviewed in this scenario, asking the 
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individual for further clarification on what types of diseases they are interested in 
learning about and why will give the consenter some clues as to what the individual is 
concerned about and the education can be tailored on helping the individual understand 
the background for whether or not WGS would detect particular conditions.  
The third element is to address the psychological concerns that arise during a 
consent process. The individual in this example who wants to know about every possible 
disease might be worried about a specific condition that affected one or more of his 
relatives. Perhaps he is worried unnecessarily about getting sick and by requesting a 
sophisticated genomic test, he is gathering information about his genome that provides 
him with a sense of control. Whatever the reason, addressing the psychological well 
being of an individual during the informed consent process provides an opportunity for 
health care professionals to tailor the informed consent process around the individuals’ 
experience for what it means to him and his family, to undergo genome sequencing. The 
implications of genome results (many of which are unknown) can therefore, be discussed 
in relation to the individual’s own situation.  
The fourth element of the informed consent process I propose for WGS/WES is to 
provide multiple methods (online, in-person and a combination of both) for undergoing 
informed consent for genome sequencing. The availability of several types of consenting 
interactions is more consistent with an informed consent process that responds to the 
needs of the patient, than current methods that provide the same informed consent form 
for the patient to sign, oftentimes with no additional explanations or opportunities for 
individuals to ask questions or engage in a conversation about the test. An online and in-
person informed consent process also can address multiple learning and communication 
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styles inherent to our population. For a test as complex as genome sequencing, the 
impetus to develop a communication model that is flexible enough to meet both the 
technological challenges of the WGS process, as well as the variety of learning and 
communication styles in our population, is even more important. By offering informed 
consent online, or at least portions of the consent process online, methods are established 
for integrating genome sequencing into an electronic medical world in a way that is 
responsive to patient needs and interests. 
The purpose of proposing an informed consent practice structured around these 
four principles, is to refocus the consent process on what the patient needs to learn about 
in order to better understand the rational for genomic testing and more importantly, be 
able to engage in an informed conversation about the real implications of undergoing 
genomic testing. The reason for designing an informed consent process around these 
principles is to incorporate the ethical component of informed consent into clinical 
practices in a tangible way that might result in improved patient understanding of 
WGS/WES.  
 The steps of the patient-centered informed consent process I describe in chapter 
six, are similar to existing informed consent protocols, but the overall focus of the 
consent process shifts the focus from the need to protect institutions from litigation or 
satisfying a bureaucratic requirement, to protecting patient’s needs first and foremost. 
Existing informed consent protocols incorporate information that experts feel individuals 
need to know to be fully informed of the implications of undergoing WGS/WES. My 
proposal does not reject or even ignore the experts opinions, but renders them subsidiary 
to, and informed by, patients’ goals. For example, the American College of Medical 
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Genetics recommends physician inform their patient about the various complexities of 
WGS/WES; the possible risk, benefits and limitations of undergoing WGS/WES, the 
possibility of finding unexpected genetic alterations during the sequencing process, 
whether and how individuals will be contacted when results are updated, etc. (ACMG 
Board of Directors, 2013). All of these components are included into my proposal, but 
they are shaped around the patient’s goals and understanding of how WGS/WES will 
help them. Therefore, I do not propose eliminating the components of existing informed 
consent protocols. Rather I propose that these components be framed and woven into the 
process differently. The consenter is the expert who maintains control over the consent 
process, but rather than review a list of the issues surrounding the risks, benefits and 
limitations of informed consent, the informed consent process outlined here integrates 
this information into the natural flow of conversation with an individual by grounding it 
in the patient’s own narrative about how genome sequencing can and should affect her 
life.  
 To address the complexities of how to manage large volumes of data produced 
from sequencing as well as how to update individuals when results change from unknown 
to clinically relevant, I described an electronic model for reporting genomic results, 
which also incorporates informed consent into the systems of genome sequencing in 
chapter seven. Recall the systems of WGS are, the patient, the physician, the health care 
environment surrounding the patient (electronic medical records, insurance companies, 
and pharmacy) patient’s family, friends and support groups and research studies. The 
model I propose is designed to facilitate the transfer the patient’s genomic data between 
the systems of WGS. This model is unique from anything I identified in the literature 
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because it is the first example of an informed consent process capable of addressing both 
the complex consenting protocols and the challenges of integrating a patients’ genomic 
results into the medical system.  
Furthermore, by storing the genomic data on a patient portal, this model addresses 
the problem of the uncertainty of the data produced from genome sequencing. Many 
protocols manage uncertainty by determining, with expert opinion, which types of 
genomic results should or should not be released to patients. The American College of 
Medicine Genetics (ACMG) recommends physician should disclose specific types of 
mutations identified in 57 genes related to medically actionable hereditary conditions, 
regardless of whether the individual wants to learn about these results or not (R. Green et 
al., 2013). Other experts advocate the opposite, calling for releasing only those genomic 
results that bear on the clinical purpose of conducting WGS/WES for a given patient, but 
nothing more (Sharp, 2011). This dichotomy reflects an unsettled and underdeveloped 
area in the medical literature for how much emphasis experts place on considering patient 
preferences when making decisions about what information is important to disclose or 
not disclose to a patient.  
Rather than ask the experts to determine which test results ought to be reported, 
my model is to store the data onto the portal, and allow the patient an opportunity to 
determine which results he/she wants to learn about, and when. The consent process I 
describe in chapter six facilitates patient understanding of what type of genomic 
information is, and is not available from sequencing, how the information will change 
over time, and how the results may or may not impact their medical care, and gives the 
patient time to reflect on how he or his family members might respond to learning about 
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genomic risk factors. This process results in creating an environment for an individual to 
make decisions that empower her to use the genomic information in a way that results in 
a positive outcome. By allowing the patient the right to make decisions on her own behalf 
(rather than deferring to expert judgments of what is best) and creating the environment 
through the informed consent process, where she is able to make these decisions, the 
ethical obligations and fundamental purpose of informed consent is thereby achieved. 
To conclude, let us return to Bill and Melinda to see how their experiences would 
have been different if the consent process has followed my proposed model. Bill and 
Melinda decide to undergo WGS and embark on this journey as a couple. Recall that they 
have very different backgrounds in science, different learning styles and different goals 
for undergoing WGS. Bill is a science writer, who has done a fair amount of research on 
the topic of WGS. He works from home and spends a lot of time on a computer. Bill is 
very interested in learning as much as he can about his genome as he is fascinated with 
the implications of learning about one’s genomic information. Bill intellectualizes his 
desire to learn about his genome, and does not associate any negative emotions to the 
possibility he might learn something negative (a deleterious mutation for a hereditary 
disorder) as a result of undergoing genome sequencing.  
He initiates his sequencing by creating a patient portal. He enters the necessary 
demographic information, personal medical history and family history information. When 
prompted to answer why he wishes to undergo whole genome sequencing, he writes; to 
learn about genomic risk factors he might carry for developing prostate cancer; to learn 
about any possible hereditary conditions he might pass to his future children and; to learn 
whether he might be at risk for Huntington’s disease. 
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After his data is uploaded, Bill is offered three types of consenting methods, 
online (self-guided) module, online with the option to undergo a live videoconference or 
Skype interview scheduled at his convenience, or in-person where he can meet with a 
consenter in a medical office close to his home. Bill elects to proceed with the online 
(self-guided) module. He begins the consenting protocol a couple of days after he creates 
his patient portal and finishes the consenting process in just over two hours. During the 
online process, he learns about the technical limitations of genome sequencing. 
Specifically, he learns that genome sequencing cannot detect the triplet repeat for 
Huntington’s disease. More importantly, he learns why he does not need to worry about 
being affected with this genetic condition (because he has no family history of the disease 
and without a family history, he is unlikely to be affected with the condition).  
Bill spends the most time on the education module where he gains a better 
understanding of the manner in which genomic variants determine his risk for common 
diseases like prostate cancer, or heart disease. During the risk assessment portion of his 
consenting process, he is pleased to learn that his risk for prostate cancer, based on his 
family history, is not as high as he was expecting. He is also informed about the 
limitations of prostate cancer screening, which he was not aware of. After spending a 
couple of hours on the module, he pauses the module at the point he is asked to select 
what type of genomic information he is interested in learning. He wants to wait and select 
the types of autosomal recessive conditions offered in the screening section of his 
analysis, until after Melinda undergoes her consenting process, so they can decide 
together what type of genetic conditions they would want to undergo carrier screening 
for. Also, after undergoing the consent process, Bill realizes he needs to secure a life 
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insurance policy before he is tested as well as remember to add Melinda to his benefit 
plan so she has health insurance.  
Melinda’s background in science consists of an introductory biology class she 
completed during her freshman year in college. She is less comfortable with science and 
math and, therefore, was dreading her consenting process for WGS. Melinda is busy with 
many appointments during the day, and decided to schedule her consent session over a 
few days if necessary. She creates her portal on a Saturday afternoon and enters the 
necessary demographic, and personal medical and family history information. When 
prompted to ask why she is interested in undergoing genome sequencing, she states her 
primary motivation is to learn about genetic diseases that she might carry and pass on to 
her children. She also states she wants to know whether her family history of heart 
disease increases her risk for developing heart disease in the future. Not understanding 
what else genome sequencing might tell her, these are the only two goals she lists at the 
beginning of the process. Melinda is asked to select her consenting option and elects to 
undergo online consenting through a Skype interview with a consenter. She schedules a 
day and time to undergo consenting when she is alone in the house and has several 
uninterrupted hours.  
During her first consenting interaction, Melinda is pleased with how much 
information she learns about genome sequencing. She is most appreciative of the fact that 
the consenter asks her to explain why she wants to learn about numerous genetic 
conditions that she and Bill might pass to their future offspring. Melinda has always been 
a worrier, and having an opportunity to ask someone about different genetic diseases and 
how they could affect babies or children, relieves some of her anxiety. In addition, she 
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explains to the consenter that she has always been worried about getting sick and dying 
young because her father died after battling an unexplained illness for many years. She 
was only 18 when he died. The experience of losing her father really affected her to the 
point she is concerned about whether she should have children at all.  
Melinda’s first consenting interaction lasts longer than she anticipated, and after 
discussing her goals for undergoing sequencing with the consenter and working through 
half of the education component of the session, the first session ended. Melinda 
scheduled two more online sessions. The longest session for Melinda was the second 
session when she and the consenter reviewed the possible psychological reactions she 
might have if she learned that she was carrying a hereditary mutation for an untreatable 
adult onset condition. She also learns about the various types of prenatal testing she 
might consider if she and Bill carry a mutation for the same genetic condition. The 
discussion with the consenter about her expected response to learning about hereditary 
disease and the knowledge she gained throughout the consenting process helped her feel 
better prepared to cope with the possibility she and Bill might have a risk to have a child 
affected with a hereditary condition.   
In addition to working with a consenter online, Melinda spends some time on her 
own reviewing the online education module available to her outside of the consenting 
process. Over time she begins to develop a better understanding of the genomic 
terminology surrounding genome sequencing. After her third session, she and Bill talk 
about the types of autosomal recessive genetic diseases they want to be screened for and 
agree they would like to learn about all possible disorders (those that are treatable and 
those that are untreatable). 
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Following this conversation, Bill logs onto his portal and selects his options for 
which types of genetic diseases he wants to learn more about. He elects to learn about 
every type of disease that is detectable. He submits his choices approximately eight 
weeks after he started the consenting process. Bill’s life insurance policy was activated at 
this point and Melinda is now covered under his health insurance plan.  
Melinda also schedules another online consent session where together with the 
consenter, she selects the types of genetic diseases she wants to learn about. She elects 
only to learn about genomic information that might affect her offspring, as well as her 
pharmacogenomics results given her troubled history with anti-depressants. She defers 
learning any information about adult onset conditions or conditions that she might have, 
for which there is no treatment for another time or perhaps never. After the options are 
selected, Bill and Melinda go together into their primary care physician’s office to have 
their blood collected and a sample from each of them is sent to the genomic testing 
laboratory.  
Bill receives an email notifying him his results are ready. He logs into his portal 
once they are available, and reviews his results on his own. His results are not combined 
with Melinda’s carrier test results, because he knew that Melinda would learn her results 
on a different day. Bill learns about his slightly increased risk for prostate cancer, but 
based on his more sophisticated understanding of GWAS he doesn’t feel concerned about 
this risk. Because he is young, he decides to wait until he is older, and the risks are better 
defined, before he shares this information with his physician. He also learns about his 
carrier status for cystic fibrosis, but since Melinda has not yet received her results, he is 
not too concerned about this risk factor. He does however, start educating himself about 
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cystic fibrosis in the event Melinda is also a carrier. Bill’s overall reaction to his results is 
positive and he feels good about his experience. He also elects to be re-contacted 
whenever new information about the variants of unknown clinical significance identified 
in his genome is available. 
Melinda elects to learn about her genomic results during a pre-scheduled Skype 
interview with the same consenter who she worked with before she had her blood sent to 
the laboratory for analysis. The consenter walks her through the carrier screening results 
first, and while she is disappointed by the number of genetic conditions she tests positive 
for, she felt prepared to learn this information and ready to consider prenatal testing if 
Bill is a carrier for one of the same conditions. The comment that the diseases she carries 
are more likely to be identified in individuals who are of Ashkenazi Jewish heritage does 
not surprise her, because she was informed about this possibility during the consent 
process. She decides not to share this information with her family just yet. The 
pharmacogenomics results were very helpful to Melinda as she finally has an answer for 
why she metabolizes medications so poorly and is encouraged that this information might 
help her psychiatrist adjust the medication dose to provide her with more benefit from the 
medication she is taking. Melinda elects to be emailed with any updates pertaining only 
to the genomic information reported to her during this first sequencing run. But she 
understands that if she elects to learn about other disease risk factors in the future, she 
can always re-initiate the consent process at any time.  
 This consent process describes a very different experience than the consenting 
process described in chapter one (reading and signing a written consent form). While the 
informed consent process I propose is not perfect and will have its own technical and 
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practical limitations, the exercise of designing a consent process and model for whole 
genome and exome sequencing, is to illustrate the fact that current informed consent 
practices (requirement of a signed informed consent document) do not fulfill the ethical 
obligations of informed consent; in addition, the informed consent process I describe in 
this dissertation, helps to illustrate the fact that it is possible to design an informed 
consent protocol centered around the needs of a patient while responding to a complex 
medical technology.  
 To counter possible criticism that a patient cannot be expected to know what 
information they need to learn about to be fully informed before undergoing WGS, as I 
demonstrate through Bill and Melinda’s story, individuals do not guide the consent 
process in this manner. The consenter guides individuals through the steps, but the order 
which information is discussed, the pace of the process and degree to which 
psychological issues are addressed, is tailored towards the individual undergoing 
sequencing. Bill and Melinda communicate differently, have different backgrounds in 
science and respond differently to learning about genomic risk factors. The consenting 
process described in chapter six is designed to take these individual differences into 
consideration while learning about genome sequencing. A consent process individualized 
to each person is more fitting for the technology that produces an individualized genomic 
sequence. 
The proposal outlined in this dissertation is not able to address all of the  
complexities of WGS/WES, nor will it likely result in a successful informed consent 
experience for everyone interested in pursuing genome sequencing. This proposal is in 
part an exercise to facilitate conversations about why informed consent is necessary in 
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medical care. This proposal is written to remind all of us working in health care, that 
informed consent, while serving to protect physicians and institutions from litigation was 
really designed to protect individuals from potential resulting harms from undergoing a 
recommended test or treatment. As medicine takes up diagnostic testing that generate 
complex and uncertain pictures of our lives and futures, it is imperative that we recognize 
the failings of the consent process as it stands, and reform our practices accordingly. If 
informed consent practices can be re-structured around the individual undergoing genome 
sequencing, they will be more effective, and will lay an important foundation for patients 
to achieve more successful medial outcomes. This dissertation has sought to interrogate 
these problems, and articulate a pathway for reform.  
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